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Abstract 
A larger percentage of the world’s population is at risk of developing a 
protozoan parasitic infection. Current treatments are failing due to the 
development of anti-parasitic drug resistance and the associated toxicity of 
these treatments. Therefore, research into new drug targets and drugs is 
required. The work presented herein aims to identify new drug leads for the 
treatment of parasitic infections by targeting a membrane-integral 
pyrophosphatase (M-PPase) using a structure-based drug design approach. 
Three approaches were employed to identify novel inhibitors of M-PPase, 
which lead to the identification of three different classes of inhibitors. The first 
approach involved the SPROUT design of a indole based putative inhibitor. 
Due to a number of synthetic difficulties this putative inhibitor could not be 
synthesised. However, simplification of the indole moiety lead to the 
identification of the first inhibitor of a M-PPase that was designed using SBDD. 
The second approach involved the substrate inspired design of a sulfamide 
fragment, which had a moderate activity when biologically evaluated against 
TmPPase. This fragment was designed to mimic phosphate in the hydrolytic 
centre of M-PPase. Expansion of this fragment using SPROUt lead to the 
identification of a second generation sulfamide fragment, which had an 
improved potency. Finally, a heterocyclic fragment library was synthesised 
and biologically evaluated. This library was based upon a heterocyclic 
fragment identified by collaborators using vHTS. This lead to the identification 
of a potent thiazole fragment. However, the binding site of this fragment could 
not be identified so further design could not occur. 
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Chapter 1: Introduction 
1.1 Protozoan Parasitic Infections 
Parasitic infections, such as malaria and toxoplasmosis, are caused by 
protozoan organisms. Protozoa are unicellular eukaryotic organisms and 
their size typically measures between 1-150 µm. [1] They share a number of 
organelles with animal cells and use similar metabolic pathways. In addition, 
they also have a number of unique specialised structures that are not found 
in other eukaryotes, which are required to meet their particular metabolic and 
environmental needs. There are four different groups of protozoa that are 
classified based on their method of locomotion (Table 1): the flagellates, 
which use flagella for locomotion; the amoebae that use pseudopodia; the 
sporozoans, which do not have any obvious means of locomotion; and the 
ciliates that use cilia to achieve locomotion. [1]  
Group Means of Locomotion Example Genus 
The Flagella Flagella Leishmania 
The Amoebae Pseudopodia Entamoeba 
The Sporozoans No obvious means Toxoplasma, 
Plasmodium 
The Ciliates Cilia Balantidium 
Table 1: The classification of protozoa and Genus Examples. [1] 
1.2 Toxoplasmosis 
Toxoplasmosis is a parasitic infection that is caused by Toxoplasma Gondii. 
It is the most widely distributed of all the parasitic infections and infects 
patients on every continent, with the exception of Antarctica. Toxoplasmosis 
is also one of the most prevalent human infections, with an estimated 30-
50% of people worldwide thought to be infected. [2]  
Individuals who have a normal functioning immune system are mainly 
asymptomatic when infected with toxoplasmosis. However, toxoplasmosis 
can be harmful to immunocompromised individuals, such as human 
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immunodeficiency virus (HIV) and chemotherapy patients, and the unborn 
foetus. [3] There are two main clinical manifestations of toxoplasmosis in the 
immunocompromised. Firstly, toxoplasmosis can cause retinal lesions 
leading to a condition called ocular toxoplasmosis and can cause blindness 
if not treated. [4] The other main clinical manifestation is toxoplasmic 
encephalitis (swelling of the brain), which is a leading cause of mortality in 
acquired immune deficiency syndrome (AIDS) patients. [5] There are a 
number of symptoms associated with toxoplasmic encephalitis, such as 
dementia, seizures and headaches. [6]   
The life cycle of T. gondii consists of a sexual phase and an asexual phase. 
[7] The sexual phase occurs in the intestine of felines (defined as the 
definitive host), whilst the asexual phase can occur in any nucleated 
mammalian or avian cell.  
The sexual phase of the life cycle begins when felines ingest prey tissue 
contaminated with T. gondii cysts (Figure 1). Once the cysts enter the feline 
stomach the slowly dividing form of T. gondii, termed bradyzoites, are 
released. Bradyzoites then invade the epithelial cells of the feline small 
intestine, where they differentiate into rapidly dividing tachyzoites as well as 
male and female gametes. These gametes combine to form zygotes that 
develop into millions of oocysts, which contain thousands of sporozoites. The 
formation of these oocysts results in the rupture of the feline intestinal 
epithelial cells, which causes the oocysts to be excreted with the feline 
faeces and ends the sexual phase of the life cycle. [7] 
The asexual phase of the life cycle begins when oocysts are ingested by 
mammals or birds. When the ingested oocysts reach the stomach of the 
mammalian or avian host the sporozites are released and they invade near-
by epithelial cells (Figure 1). Here, they differentiate into the rapidly 
replicating tachyzoites. The tachyzoites then replicate inside the cell until it 
ruptures and they are released into the blood stream, where they can invade 
nearby cells or move to a different part of the organism. This stage of the 
infection is called the acute phase and is responsible for the symptoms 
experienced by immunocompromised patients. The acute phase is followed 
by the chronic phase, where the tachyzoites differentiate into slowly dividing 
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bradyzoites. The bradyzoites form cysts within the hosts’ tissue, mainly in 
the brain and muscle tissue. These tissue cysts can then be transferred back 
to the feline host and thus beginning the protazoic life cycle again. [7] 
 
Figure 1; The lifecycle of T.Gondii. There are two phases to the lifecycle; A sexual phase 
(right) and an asexual phase (left). [8] 
1.2.1 Treatments for Toxoplasmosis 
Current treatments for toxoplasmosis only target the rapidly dividing 
tachyzoites during the acute phase of infection. [9] One of the most widely 
used treatments of toxoplasmosis is a combination of a sulfonamide drug, 
such as sulfadiazine (Compound 1, Figure 2), with pyrimethamine 
(Compound 2, Figure 2). [10] This combination sequentially inhibits 
dihydropterate synthase and dihydropteroate reductase. These enzymes are 
involved in the synthesis of folic acid compounds that are needed for the 
growth and survival of T. gondii. [11] An alternative treatment involves a 
combination of a lincosamide antibiotic, such as clindamycin (Compound 3, 
Figure 2), with pyrimethamine. [12] Clindamycin targets the apicoplast in T. 
gondii, which plays a key role in a number of metabolic processes, such as 




Figure 2; Current treatments for toxoplasmosis include a combination of sulfadiazine (1) 
with Pyrimethamine (2) and a combination of Clindamycin (3) with Pyrimethamine. 
A study involving AIDS patients diagnosed with toxoplasmosis showed that 
there is no statistically significant difference in efficacy between sulfadizene-
pyrimethamine and clindamycin-pyrimethamine combinational therapies. 
There was a complete or partial response in 68% of patients using 
sulfadizene-pyrimethamine, compared with 76% for clindamycin- 
pyrimethamine. [14] 
One of the major disadvantages of both combination therapies is toxicity. A 
study of 115 HIV patients diagnosed with toxoplasmosis encephalitis that 
were using the sulfadizene-pyrimethane combination therapy, found some 
levels of toxicity in 62% of patients. [15] Some of these side effects were 
severe enough that 44% of patients had to change treatment. The major side 
effect of this combination therapy is bone marrow suppression. This can lead 
to a number of complications, such as anaemia and serious infection.  
Therefore, folinic acid is also administered to prevent bone marrow 
suppression. [16] Another side-effect of this combination therapy is caused 
by severe allergic reactions to sulfadizene. [17] In addition, the clindamycin-
pyrithiamine treatment regime has also been found to have similar rates of 
toxicity. [14] Another disadvantage of both these combination therapies is 
that they only target tachyzoites and not bradyzoites, which means that 
patients have to undergo lifelong maintenance therapy to prevent relapse. 
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However, evidence of relapse has been found in patients using both 
treatments for lifelong maintenance therapy. One study found that 11% of 
tested AIDS patients relapsed whilst on the sulfadizene-pyrimethamine 
treatment, whilst 22% of tested patients relapsed on the clindamycin-
pyrimethamine treatment. [14]  
An estimated 10% of patients infected with toxoplasmosis do not respond to 
current treatments. [10] Resistance of T.gondii to current treatments is one 
explanation as to why these patients do not respond to treatment. However, 
it is difficult to accurately quantify drug resistance for toxoplasmosis as T. 
gondii is not routinely isolated from patients. It is also difficult to characterise 
these treatment failures due to a number of issues such as; diagnostic 
limitations, drug intolerance and non-adherence.[14, 18] However, 
sulfadiazine resistance has been found in three different strains of 
toxoplasmosis from across the globe. [19] Resistance of T. gondii to 
clindamycin and pyrithmethamine has not been found in clinical isolates to 
date. 
1.3 Malaria 
Malaria is a major cause of mortality in tropical regions of the world, 
particularly in developing countries. There were 216 million reported cases 
of malaria across the globe in 2016 and 445,000 reported deaths. [20] 
Malaria is caused by protozoa belonging to the Plasmodium genus. While 
there are five species that can cause malaria in humans, the two that pose 
the greatest threat are P. falciparum and P. vivax. P. falciparum is the most 
common cause of malaria infections in sub-Sharan Africa and causes the 
deadliest form of the disease. Whilst infections caused by P. Vivax are not 
as fatal, it is however the most widely distributed of the plasmodium species 
and is the largest cause of malaria infections outside Africa. [20] The 
symptoms of malaria vary depending on the severity of the infection, 
common symptoms include; shaking chills, high fever, headache, nausea 
and vomiting. [21] 
The Plasmodium life cycle consists of an asexual phase, which occurs within 
a mammalian host, and a sexual phase that occurs within a mosquito (Figure 
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3). [22]  The asexual phase of the life cycle begins when Plasmodium 
sporozites from the saliva of an infected mosquito are injected into the 
bloodstream of the mammalian host. The sporozites then migrate to the host 
liver and invade hepatocytes, thus beginning the hepatic stage of the cycle. 
Once the sporozites are taken up by the hepatocytes they differentiate into 
schizonts that contain thousands of merozoites. The hepatocytes then burst 
and release the merozoites into the blood stream where they invade and 
then replicate within red blood cells. This causes the red blood cells to 
rupture and the merozoites can then invade other red blood cells or 
differentiate into gametocytes that will transfer back to the mosquito vector. 
The sexual phase of the life cycle begins within the gut lumen of the 
mosquito, where the male and female gametocytes combine to form a 
zygote. [22] The zygote then undergoes meiosis and becomes an ookinete, 
which then migrates to the midgut wall and transforms into oocysts. After the 
formation of oocysts mitotic divisions occur and sporozoites are formed. 
These sporozoites then travel to the saliva where they can infect a new 
mammalian host and begin the cycle again. 
 
Figure 3: The life cycle of Plasmodium. This life cycle consists of an asexual phase (top) 





1.3.1 Treatments for Malaria 
The World Health Organization (WHO) recommends Artemisinin (Compound 
4, Figure 4) based combination therapies (ACT) for the treatment P. 
falciparum based malaria infections. [20] The mechanism of action of 
artemisinin involves cleavage of the peroxide bond by intraparasitic heme. 
This generates O centred radicals that rearrange to form C centred radicals. 
These radicals then damage nearby cell targets by alkylation. [23] 
Artemisinin is usually given in combination with a drug of another class, such 
as pyrithiamine. For the treatment of P. vivax based malaria infections the 
WHO recommends chloroquine (Compound 5, Figure 4), which is a 
derivative of quinine. [20] It is widely accepted that quinine type drugs 
interfere with the detoxification of heme produced by the degradation of host 
haemoglobin caused by the parasite. [24] Heme is toxic to the parasite and 
is normally converted to the non-toxic hemozoin. Quinine type drugs prevent 
this conversion from occurring and leads to a build-up of heme, which 
ultimately kills the parasite. 
 
Figure 4; The WHO recommends artemisinin (4) based combination therapies for the 
treatment of P. falciparum malaria. Whilst the WHO recommends chloroquine (5) for the 
treatment of P. vivax malaria. 
Drug resistance in malaria is quickly becoming a major problem and there is 
evidence of resistance to all anti-malarial classes currently on the market. 
[25, 26] ACTs are starting to fail rapidly in South-East Asia (SEA), due to the 
emergence of artemisinin-resistant P. falciparum malaria. [26] This is 
worrying as ACTs are the first-line treatments for malaria in SEA. Mutations 
to the kelch13 protein have been found in artemisinin resistant P. falciparum. 
[27] These mutations are thought to mediate artemisinin resistance as some 
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kelch proteins respond to oxidative stress and artemisinin is a pro-oxidant 
drug. Resistance of P. vivax malaria to chloroquines is also becoming a 
major problem since it first appeared in 1989. [28] This resistance is thought 
to be caused by the chloroquine resistance transporter protein (cqrt), which 
is active in chloroquine resistant P. Vivax and P. falciparum but not in wild 
type strains. [29] The cqrt protein is expressed on the membrane of digestive 
vacuoles of the parasite and transports chloroquine out of the digestive 
vacuole, resulting in a lower concentration of chloroquine in the vacuole and 
rendering it less effective. 
1.4 Acidocalcsisomes 
Acidocalcisomes are organelles found in protozoa, such as P. falciparum and 
T. gondii, they are also found in other eukaryotic organisms. [30] The 
acidocalcisomes of protozoan parasites are essential for the normal 
functioning of the cell. They are spherical in shape with average diameters 
between 0.2-0.6 µm. They are highly acidic and contain a high concentration 
of calcium ions, which is why they are termed acidocalcisomes. They also 
contain a high concentration of phosphorous in the form of: phosphate (Pi), 
polyphosphate (PolyP) and pyrophosphosphate (PPi). [30] There are a 
number of phosphatase enzymes within the acidocalcisomes that hydrolyse 
the various forms of phosphates into phosphate ions. There is also a 
vacuolar transporter chaperone (VTC) complex on its membrane that 
converts cystolic phosphate ions into acidocalcisome PolyP. In addition to 
the VTC complex, there are a number of cation pumping and transporting 
proteins on the acidocalcisome membrane, which are essential to the normal 




Figure 5: A schematic representation of the acidocalcisome including the key proteins and 
pumps. Adapted from [30, 31]. 
1.4.1 Functions of Acidocalcisomes in Protozoa 
One of the important functions of the acidocalcisome in protozoan parasites 
is pH regulation; PolyP plays a key role in this function. When the cell is 
exposed to alkaline stress PolyP within the acidocalcisome is hydrolysed, 
which causes the re-acidification of the cell [32]. This is important when the 
parasite enters the host from the vector as mammalian blood is slightly 
alkaline. 
When a protozoan parasite moves to the host from the vector it encounters 
osmotic stress. This is due to the difference in osmotic pressure between the 
host and the vector. The acidocalcisome, together with a contractile vacuole, 
allows the cell to adapt to these changes in osmotic pressure. The levels of 






































1.4.2 Hypo-osmotic Stress 
When the cell is exposed to hypo-osmotic stress the protozoan cell swells 
due to the intake of water caused by a difference in osmotic pressure inside 
and outside of the cell. During times of hypo-osmotic stress there is a 
microtubule and cyclic adenosine monophosphate (cAMP) mediated fusion 
of the acidocalcisome with a contractile vacuole resulting in the translocation 
of an aquaporin (AQP) from the acidocalcisome to the contractile vacuole 
(Figure 6) [34]. This fusion, together with an accumulation of ammonium 
ions, causes the hydrolysis of PolyP. [35, 36] This leads to a reduction in the 
concentration of PolyP in the acidocalcisome. [33] The hydrolysis of PolyP 
results in the transfer of amino acids, Pi, cations (osmolytes) and water 
through the AQP to the contracted vacuole causing it to swell. Water is then 
released to the extracellular medium and the osmolytes are transferred to 
the cytoplasm aiding regulatory volume decrease (RVD) [37]. One key piece 
of evidence for this model is that inhibiting the phosphodiesterase C enzyme, 
which is involved in the modulation of cAMP, also leads to the inhibition of 
RVD. [38] This is due to the termination of the cAMP mediated fusion of the 
acidocalcisome and contractile vacuole. In addition, the fusion of the 






Figure 6: The response of protozoan cells to hypo-osmotic stress. There is a cAMP 
mediated fusion of the acidocalcisome with the contractile vacuole, which aids RVD. 
Adapted from [35] 
1.4.3 Hyper-osmotic Stress 
When the cell is exposed to hyper-osmotic stress the protozoan cell shrinks 
due to the release of water caused by a difference in osmotic pressure inside 
and outside of the cell. The water is released into the extracellular medium 
through the aquaporin of the contractile vacuole, causing the cell to shrink 
(Figure 7). [40] During hyper-osmotic stress the concentration of PolyP in 
the acidocalcisome increases, which complexes to cations in the cystol. [40] 
This counteracts the increase in ionic strength caused by the release of 
water. This model is supported by mutational and inhibitory studies of T. cruzi 
aquaporin (Tcaqp). Inhibition or mutation of Tcaqp results in a decrease in 
cell shrinkage when exposed to hyper-osmotic stress whilst overexpression 
of Tcaqp leads to an increase in intensity of cell shrinkage. [40] The cell then 
undergoes regulatory volume increase (RVI) and the cations return to the 




Figure 7: The response of protozoa to hyperosmotic stress. The acidocalcisome produces 
PolyP to help the cell cope with the increase in ionic strength. Adapted from [35]. 
1.4.4 The Acidocalcisome as a Novel Drug Target for Parasitic 
Infections 
The acidocalcisome plays a key role in the survival of protozoa at times of 
environmental stress. It therefore offers a novel drug target for parasitic 
infections. [30] There are a number of proteins located on the membrane of 
acidocalcisome that offer potential targets for drug design. Research has 
shown that inhibition of the vaculor-type H+ adenosine triphosphatase  (V-
ATPase) results in a less acidic acidocalcisome, which in turn means that 
the acidocalcisome is no longer able to function. [41] Huang et al also 
showed that mutation of the V-ATPase in T.brucei inhibited growth, as the 
acidocalcisome was unable to cope with environmental stress.[42] As 
mentioned earlier, inhibiting phosphodiesterase C prevents cells from 
undergoing RVD during hypo-osmotic stress and causes cell death. [38] 
Showing that enzymes involved in RVD are also targets for drug design. 
Overall, this evidence therefore could suggest that the acidocalcisome is a 
viable drug target for parasitic infections. This project will target the 
acidocalcisome in protozoan parasites through the inhibition of membrane-




1.5 Membrane-Integral Pyrophosphatases (M-PPase) 
M-PPases are located on the surface of membranes and are found in plants, 
protozoa and bacteria [43]. They couple PPi hydrolysis/synthesis to Na+ 
and/or H+ pumping. There are a number of different sub-types of M-PPase 
(Table 2); Na+-pumping K+-dependent, H+-pumping K+-dependent, H+-
pumping K+-independent and Na+/H+-copumping K+-dependent. [44] 
Phylogenetic studies have been carried out on M-PPases and these suggest 
that Na+-pumping M-PPases are likely to be the ancestral proteins, with the 
other M-PPases evolving from Na+-pumping M-PPases later in the 
evolutionary timeline. [45]  M-PPases of protozoa are H+ pumping and are 
responsible, along with V-ATPase, for the acidification of the acidocalcisome. 
[31] 
Type of M-PPase Subtype Example Organisms 
H+-Pumping K+ Dependant Trypanosoma cruzii, 
Vigna radiata 
H+-Pumping K+ Independent Streptomyces coelicolor, 
Plasmodium falciparum 
Na+-Pumping K+ Dependant Thermotoga maritima, 
Clostridium tetani 
Na+ and H+-Pumping K+ Dependant Bacteriodes vulgatus 
Table 2: The different types and sub-types of M-PPases, as well as example organisms 
were they are found. [44] 
There have been a number of reported crystal structures of M-PPases from 
T. maritima (TmPPase) and V. radiata (VrPPase) in various states. The first 
reported structures were of isopentenyl diphosphate (IDP) bound VrPPase 
and VrPPase bound with a single phosphate. VrPPase is an H+-pumping K+-
dependant M-PPase. [46] The second reported structures were of resting 
state TmPPase, IDP bound TmPPase and product bound TmPPase. 
TmPPase is a Na+-pumping K+-dependant M-PPase (Figure 8). [47] These 
crystal structures show M-PPases have a single transmembrane domain and 
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are homodimeric, with each 80 KDa monomer made up 14-17 
transmembrane helices (TM). The two crystal structures are highly 
conserved, showing that the mechanism of hydrolysis is conserved across 
species.  
 
Figure 8: The monomeric structure of TmPPase highlighting the hydrolytic centre. Black 
spheres are M1 and M2. [47] 
The active site of M-PPases are rather unique and are made up of; a 
hydrolytic centre, a coupling funnel, an ion gate and an exit channel. The 
hydrolytic centre and coupling funnel are formed from TMs 5-6, 11-12 and 
15-16, whilst the gate and exit channel are formed from TMs 5-6, 12 and 16. 
[46, 47] 
1.5.1 Hydrolytic Centre 
The hydrolytic centre is located at the surface of the pump and is 
approximately 20 Å above the lipid bilayer. [47] Pyrophosphate binding and 




involved in metal and pyrophosphate binding in the hydrolytic centre are 
highly conserved across different species. [48] In the resting state enzyme 
there are two native Mg2+ cations (termed M1 and M2) that are involved in 
PPi binding and are essential for activity (Figure 9a). [47] In the crystal 
structure of resting state TmPPase M1 and M2 are Ca2+ and Mg2+ 
respectively. M1 is coordinated by three conserved aspartic acid residues, 
whilst M2 is coordinated by two conserved aspartic acid residues. The 
reason Ca2+ is observed in the crystal structure and not Mg2+ is due to the 
crystallisation conditions. [47] 
The hydrolytic centre of IDP bound VrPPase (Figure 9b) and IDP bound 
TmPPase are very similar. [46, 49]  These structures show that when 
substrate binds the volume of the hydrolytic centre is halved, due to the 
contraction of helices 5, 6, 11, 12, 15 and 16. In addition, the hydrolytic centre 
is closed due to the closing of a loop between helices 5-6 over the hydrolytic 
centre.  
Within the hydrolytic centre of IDP bound VrPPase there are five Mg2+ ions 
that are coordinated to both IDP and a number of conserved residues. [46] 
Two of the Mg2+ ions are the native M1 and M2 ions, whilst two of the ions 
(termed M3 and M4) bind with pyrophosphate in the form Mg2IDP. The IDP 
bound TmPPase crystal structure has four Mg2+ ions, showing that the fifth 
ion observed in VrPPase is due to the crystallisation conditions. [49]  
In both IDP bound structures the leaving group phosphate is coordinated to 
a conserved lysine residue, making it a better leaving group. In addition, the 
bottom phosphate group, termed the electrophilic phosphate group, is 
coordinated to a K+ ion. Coordination of the bottom phosphate group to K+ 
increases the electrophilicicity of this group. [46, 49] In K+ independent M-
PPases this electrophilic phosphate group is coordinated by a lysine residue 
instead, which also increases the electrophilicity. [43]  
Positioned underneath the electrophilic phosphate group of both IDP bound 
structures there is a nucleophilic water molecule that is coordinated by two 
conserved aspartic acid residues. In the hydrolytic centre of the resting state 
enzyme one of the aspartic acid residues involved in water binding is 
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coordinated to a lysine residue, meaning the water molecule is only 
coordinated by one aspartic acid residue and is not activated for nucleophilic 
attack. [47] The downwards movement of TM-12 when substrate binds 
displaces the coordination between the aspartic acid and the lysine, which 
allows the aspartic acid to coordinate to the water molecule and activate it 
for nucleophilic attack.  
The hydrolytic centre of product bound TmPPase contains two phosphate 
ions, which are the products of pyrophosphate hydrolysis (Figure 9c), and 
the overall structure is similar to the hydrolytic centre of IDP bound VrPPase 


















          Figure 9a; The hydrolytic centre of resting state Tm-PPase. Green spheres donate metal 
ions. M1 is Mg2+ and M2 is Ca2+. b) The hydrolytic centre of Vr-PPase. Green spheres are 
Mg2+, Purple Sphere is K+, Red Sphere is nucleophilic water and IDP is shown in orange and 
blue. c) The hydrolytic centre of product bound Tm-PPase. Green spheres are Mg2+, purple 




1.5.2 Coupling Funnel 
Below the hydrolytic centre is a coupling funnel that couples pyrophosphate 
hydrolysis to H+/Na+ pumping. [47] This coupling funnel is made up of eight 
conserved residues and is linked to the ion gate via the Asp residue at the 
bottom of the funnel (Figure 10). There are a number of important 
interactions between the different residues within the coupling funnel and 
these form a conformational switch. When substrate binds to the hydrolytic 
centre TMs; 5, 6, 11, 12, 15 and 16 contract. This contraction causes 
conformational changes to the coupling funnel that leads to ion pumping.  
Mutations to any of the conserved residues majorly reduces the pumping 
activity of the M-PPase. [50] 
 
Figure 10; The coupling funnel of Tm-PPase. There are eight conserved residues that make 
a conformation switch that is dependent on substrate binding. The green sphere is M1 of 
the hydrolytic centre, shown for perspective. [47] 
1.5.3 Ion Gate and Exit Channel 
Below the coupling funnel there is an ion gate where Na+/H+ bind. The gate 
of TmPPase, like all Na+ pumping M-PPases, is made up of an ion triplet 
(Figure 11a). [47, 49] This ion triplet is made up of: a conserved aspartic 
acid residue, a conserved lysine residue and a semi-conserved glutamate 
residue. In TmPPase the exact residues are; Asp243, Lys707 and Glu246. 
The Asp243 residue is the last residue of the coupling funnel. When 
substrate binds to TmPPase the salt bridge breaks due to the downwards 
movement of TMs 11-12 and 15-16, which moves Lys707 out of the Na+ 
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binding pocket (Figure 11b). A sodium ion then coordinates to Asp243 and 
Glu246, which is supported by coordination to conserved S298. The ion 
triplet of Na+ pumping M-PPases are also conserved in H+/Na+ M-PPases 
and H+ pumping K+ independent M-PPases. [43, 45]  
In plant K+ dependant H+ MPPases, like VrPPase, the ion triplet is replaced 
with a salt bridge formed between the conserved lysine residue (Lys742) and 
the semi-conserved glutamate residue (E301) (Figure 11c). [46] The 
Glutamate residue is one helix turn lower than that of TmPPase. When 
substrate binds to VrPPase, the glutamate residue becomes protonated and 
is unable to coordinate to the lysine residue and the salt bridge breaks 
(Figure 11d). The lysine residue then coordinates to Asp294 of the coupling 
funnel. It has been suggest that the extra proton of the protonated glutamate 
is the one that is pumped upon substrate binding. [43] Analogous to plant M-
PPases, the gate of Flavobacterium johnsonine type H+ pumping M-PPases 
also consists of an ion pair. In these types of M-PPase the conserved 
glutamate is at an equivalent height to the glutamate in Na+ pumping M-
PPases, but is located on TM5 rather than TM6. [45] 
The positioning of the semi conserved glutamate residue seems to be 
essential for ion specificity. [45-47, 49] The reasoning behind this is the 
presence of an ion triplet that is observed in Na+ pumping M-PPases, this 
ion triplet has an extra formal negative charge compared to the ion doublet 
observed in certain clades of H+ pumping M-PPases. The extra negative 
charge seems to be essential for Na+ binding. As mentioned earlier there are 
certain clades of H+ pumping M-PPases that also have an ion triplet. Here, it 
is assumed that the glutamate residue is in fact protonated and the pumping 
mechanism is similar to the plant and Flavobacterium johnsonine type M-
PPases. Evidence for the importance of the semi conserved glutamate 
residue for pumping has been obtained using mutagenesis studies. [45] 
These studies revealed that mutagenesis of the key Glu residue in 
Flavobacterium johnsonine and Leptospira biflexa (this is similar to plant M-
PPases) type H+-PPases uncouples H+ pumping from PPi hydrolysis, whilst 
mutagenesis of the key Glu residue in Na+-PPases also results in the 














Figure 11; (a) The gate of resting state TmPPase consists on an ion triplet made up of the 
residues D242, K707 and E246. (b) The gate of IDP bound TmPPase. When substrate binds 
K707 moves out of the Na+ binding region, which means a Na+ ion can now bind to 
D243,E246 and S247. Na+ is purple. (c) The gate of resting state VrPPase consists of an 
ion doublet made up of the residues K742 and E301. (d) The gate of IDP bound VrPPase. 
When substrate bind K742 is no longer able to coordinate to the semi-conserved E301 due 
to the protonation of E301. [46, 47, 49] 
The final feature of the active site is an exit channel for either Na+ or H+ ions. 
This exit channel is the least conserved part of the active site and is closed 
in all the crystal structures obtained to date. [46, 47, 49] 
1.6.5 Mechanism of Cation Pumping 
All the crystal structures obtained to date and molecular dynamic studies 
suggest that Na+/H+ pumping is due to pyrophosphate binding to the active 
site rather than its hydrolysis (Figure 8). [46, 47, 49, 51] This binding causes 
the loop between helices five and six to close over the active site. Contraction 
of the coupling funnel then occurs and is caused by the downwards 
movement of TM 5-6, 11-12 and 15-16 toward the centre of the funnel. This 
allows the ion that is to be pumped to bind at the gate. There is then a large 
downward movement of TM 12 and a bending of TM 11 at a hinge, which 





also activates the nucleophilic water. Following release of the ion, the gate 
closes and hydrolysis of PPi occurs. This opens the active site and the 
resultant phosphate ions sequentially leave the active site. 
 
Figure 12; The proposed pumping mechanism of M-PPases. Studies suggest substrate 
binding results in cation pumping and not hydrolysis. Adapted from [47] 
1.5.5 M-PPases as a Novel Drug Target for the Treatment of Parasitic 
infections 
M-PPases are found on the membrane of acidocalcisomes in protozoa and 
they play a key role in its acidification and energisation. [30] Therefore, 
disrupting its function could mean that the acidocalcisome is no longer viable 
and could provide a therapeutic response. Docampo et al mutated a gene 
coding for M-PPase in Trypanosoma brucei and found that the acidity of the 
mutant acidocalcisomes decreased and also contained a lower 
concentration of PolyP. [52] This meant that the mutant T. Brucei were no 
longer able to normalise their intracellular pH on exposure to basic 
conditions, resulting in a slower rate of growth. Liu et al. showed that 
mutation of the gene coding for M-PPase in T. Gondii resulted in a slower 
rate growth both in vivo and in vitro. [53]  They also showed that regulatory 
volume decrease during hypo-osmotic and hyper-osmotic stress is impaired 
in these mutants. Bisphosphonates, which are pyrophosphate analogues 
that inhibit M-PPases, have been shown to inhibit the growth of a number of 
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different protozoa. [54] In these compounds the central oxygen has been 
replaced with a carbon, giving a non-hydrolysable phosphoether bond. The 
central carbon atom can have two other functional groups bonded to it. 
These bisphosphonates have been shown to inhibit the growth of; P. 
falciparum, T. brucei, T. cruzi and Leishmania donovani (Table 3). However 
the mechanism of action is complex and not widely understood as 
bisphosphonates also inhibit the enzyme farnesyl pyrophosphate synthase. 
So, the observed inhibition of growth could be due to inhibition of farnesyl 
pyrophosphate rather than M-PPase (or inhibition of both). M-PPases are 
also not found in mammalian cells, which is also beneficial to drug design. 
Compound Protozoa IC50 
 
P. falciparum 7.7 µm 
 
T. brucei 1.7 um 
 
L. donovani 82.5 µm 
 
T. cruzi 35 µm 
 
T. gondii 23 µm 
Table 3; Examples of Bisphosphonates and their activities against different protozoa [54] 
1.6 Structure Based Drug Design 
In order to develop potential inhibitors of M-PPases, this project will use a 
structure based drug design (SBDD) approach. SBDD uses the three-
dimensional crystal-structure of a protein, as well as various in silico 
techniques to identify potential inhibitors of that protein.[55] There are three 
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main methods of SBDD; substrate-inspired design, virtual high throughput 
screening (V-HTS) and de novo design of inhibitors.[56] Once potential 
inhibitors have been identified using one of the SBBD methods, they are 
synthesised in the laboratory or purchased, if available commercially. This 
allows biological evaluation of the compounds to take place in order to 
establish the level of inhibition against the target enzyme. Once ‘hit’ 
compounds have been identified, optimisation of the compounds can then 
take place, both to improve the level of inhibition and the physicochemical 
properties. Structure activity relationships can also be determined during the 
lead optimisation stage (Figure 13). 
 
 
1.6.1 Substrate-Inspired Design 
Substrate-inspired design uses the crystal structure of the target protein 
bound with a known inhibitor or substrate. Modifications can then be made 
to the inhibitor/substrate with the aim of making a more potent inhibitor.[57] 
An example of how to make an inhibitor more potent is to add additional 
functional groups to increase the number of interactions between the inhibitor 
and target protein. 
One of the computer programmes that can be used for substrate-inspired 
design is called Maestro, which allows the user to visualise the three-

























Figure 13: The Structure based drug design work-flow 
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any interactions between the two. [58] The programme also allows the user 
to make changes to the substrate, giving a new putative inhibitor. The new 
putative inhibitor can then be docked using Glide (grid-based ligand docking 
with energetics), which a programme that is built into Maestro. Glide initially 
uses a series of hierarchal filters that explores the conformational, 
orientational and positional space of the ligand to be docked. This is then 
followed by a rough scoring phase.  Any poses that are unsuitable for binding 
to the active site are discarded. The different binding poses that were not 
discarded are then further refined and the best poses then undergo energy 
minimisation. Finally, each pose is given a score that is based on how the 
designed molecule interacts with the protein.[57]  
One example of the use of Maestro in substrate inspired design was carried 
out by Wang et al, who developed a series of β-glycosidase inhibitors 
(Figure 14).[59] They designed and synthesised a series of gluco-configured 
tetrahydroimidazopyridines (Compound 6, Figure 14). These compounds 
were based on the transition state of the enzyme catalysed reaction 
(Compound 7 & 8, Figure 14). 
 
Figure 14: (6) An example of a tetrahydroimidazopyridine developed by Wang. (7) 
Transition state of β-glycoside hydrolysis bound to β-glycosidase inhibitors. (8) Proposed 
mechanism of inhibition of tetrahydroimidazopyridine. Which mimics the transition state of 




1.6.2 De novo Design 
De novo based design was first developed in the early 1990’s and uses in 
silico methods to design ligands for a particular target site. Since then its use 
has become more widespread this is due to improvements in both computer 
technology and X-ray crystallography.[60] There are a number of steps 
involved in the de novo design process.[57] The first step involves the 
analysis of the target site, which requires the crystal structure of the protein. 
Once the target site has been identified, molecular building blocks obtained 
from a variety of libraries are positioned onto the target site. The building 
blocks are then connected in a variety of ways to generate a number of 
putative inhibitors. These putative inhibitors are then assessed and given a 
score. The user then selects a number of these molecules to synthesise and 
biologically evaluate.  
1.6.2.1 SPROUT 
SPROUT is a de novo design programme that is made up of five different 
modules, each of which has a different function: CANGAROO (cleft analysis 
by geometry based algorithm regardless of the orientation), HIPPO 
(hydrogen bonding interaction site predication as positions with orientations), 
ELEFANT (election of functional groups and anchoring them to target sites), 
SPIDER (structure production with interactive design of results) and 
ALLIGATOR (analyse lots of ligands test and order results) (Figure 13). [61]  
The first module, CANGAROO, defines the receptor site and the ligand cavity 
site. Once potential binding sites have been identified, HIPPO is used to 
identify hydrogen bond donor and acceptor sites, as well as any hydrophobic 
regions. The user then selects some of these sites and then docks small 
fragments onto those selected sites using the ELEFANT module. These 
fragments are then connected together in SPIDER using an inbuilt library of 
‘spacer’ fragments to generate a number of different structures. ALLIGATOR 
then ranks these skeletons according to their binding score. The SPROUT 
score is the sum of the hydrogen bonding interactions, the hydrophobic 
interactions, the Van der Waals interactions and the rotatable bonds of the 
putative inhibitor. The Fishwick group recently applied SPROUT to the 
design of selective inhibitors of Plasmodium Dihydroorotate dehydrogenase, 
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showing that SPROUT can successfully be applied to the design of novel 
inhibitors. [62]   
 
Figure 15: The SPROUT de novo design programme consists of 5 modules that allows the 
design of novel putative inhibitors of a protein using the crystal structure of that protein. 
1.11 Project Aims and Objectives 
The overall objective of the research presented in this thesis was to identify 
novel inhibitors of M-PPases using SBDD. To achieve this objective this 
research had the following aims;  
 To use a combination of de novo design and substrate inspired 
design, along with the crystal structure of TmPPase, to identify novel 
putative inhibitors of TmPPase. 
 To develop robust chemical synthetic routes, using modern synthetic 
techniques, to synthesise any compounds identified during the design 
stage and to synthesis chemical libraries to determine the SAR of any 
active fragments. 
 To biologically evaluate any synthesised compounds against 
TmPPase. 







Chapter Two – De Novo Design of an Inhibitor of TmPPase 
2.1 SPROUT Design of a Novel Putative Inhibitor of TmPPase 
The de novo design programme, SPROUT, was used to develop a putative 
inhibitor of TmPPase and the design process is outlined below. 
Firstly, the resting state crystal structure of TmPPase (PDB: 4AV3) was 
loaded into SPROUT and the CANGAROO module was used to make a 10Å 
cut of the hydrolytic centre (Figure 16). [47] This 10Å cut was then redefined 
as the receptor. [61] 
 
Figure 16: The CANGAROO module of SPROUT was used to make a 10Å cut of the 
hydrolytic centre of TmPPase (PDB:4AV3), which was then redefined as the receptor. [47] 
The HIPPO module was then used to identify potential interaction sites, such 
as hydrogen bond acceptor and donor sites, by analysing the defined 
receptor for hydrophobic and electrostatic forces (Figure 17). HIPPO does 
this by adding a boundary surface to the protein, which is based upon the 
Van der Waals radii of each atom. [61]  A loci is then created around each 
polar atom that defines space where a favourable polar contact may be made 
when a complementary fragment is placed there. These loci are shown as 
coloured spherical sites, where the colour determines the type of contact that 
can be made. The colours are; red for hydrogen bond donors (HBD), blue 
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for hydrogen bond acceptors (HBA) and purple for other contact sites (e.g 
metal ions). Hydrophobic areas are also shown, these areas are green. 
 
Figure 17: HIPPO was used to analyse the defined receptor for potential interaction sites. 
Hydrogen bond acceptor sites are blue, hydrogen bond donor sites are red and hydrophobic 
sites are yellow. [61] 
Fragments, which are located within an in built library, were then docked onto 
two of the previously identified interaction sites using the ELEFANT module 
(Figure 18). The two chosen sites were a hydrogen bond acceptor site of 
Asp-488 and a hydrogen bond donor site of Lys-695. The chosen fragments 
that were docked onto the Lys interaction site included; a carboxylic acid, an 
ester, an alcohol and an amide fragment, whilst an amide and an amine 




Figure 18: The ELEFANT module was used to dock fragments onto the interaction sites of 
Lys and Asp. The two examples shown are a carboxylate docked onto Lys and an amide 
docked onto Asp. [61] 
The fragments were then connected using a number of different spacer 
templates within the SPIDER module to generate > 100,000 structures. The 
spacer templates that were used included; SP3 and SP2 carbon, amide, 
ester, ether, phenyl, cyclohexyl, five membered aromatic rings, indole, five 
membered heterocycles and amine linkages.[61] 
Once the structures were generated they were scored and ranked using 
ALIGATOR, the highest scoring fragment is shown below (Figure 19). The 
fragments were then pruned so only the top 100 scoring fragments remained.  
 
Figure 19: The highest scoring fragment (shown in light blue) generated using SPIDER. [61] 
Further cycles of design then followed that involved expanding the 
fragments, with the aim of making further interactions with the receptor. The 
interaction sites, fragments and spacer templates that were chosen during 
the iterative cycles of design are summarised below (Table 4). [61] 
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Interaction Site Fragment Docked Spacer Templates Used 
Asp-465 Amine, Amide Five membered heterocycle, 
Indole and SP3 Carbon 
Asp-236 Amine, Amide Amide, Ether, SP3 Carbon, and 
Benzene 
Asp-232 Amine, Amide Five membered heterocycle and 
Phenyl 
Table 4: The chosen interaction sites, fragments and spacer templates used during the 
cycles of design. 
At the end of the design process there were 20 structures generated. The 
top ten scoring scaffolds were then docked into the hydrolytic centre of 
TmPPase (PDB: 4AV3) using the Glide docking programme with the Maestro 
suite. [47, 63] The resultant docking poses were identical to the SPROUT 
binding poses, which therefore validated the SPROUT binding poses. Visual 
inspection of these scaffolds was then carried to identify scaffolds that had 
good docking scores and good synthetic accessibility. This lead to the 
identification of compound 9, which had a SPROUT score of -5.90 and was 
selected for further analysis (Figure 20).  
 
Figure 20: Docking pose of SPROUT designed compound 9 visualised in SPROUT and the 
2D representation. The structures highlighted in red for the 2D representation are amino 
acid residues and metal ions of the hydrolytic centre of TmPPase, whilst dashed lines 
represent interactions between 9 and the hydolytic centre. [47, 63] 
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Compound 9 was predicted to coordinate to the Mg2+  of the hydrolytic centre 
via the carbonyl of the primary amide and the hydroxyl group of the chiral 
carbon. In addition, the primary amide was also predicted to form a hydrogen 
bonding interaction with Asp-488. Hydrogen bonding interactions were 
predicted to form between the amide of the glycine moiety with Lys-695 and 
Asp-232. The protonated primary amine group of the glycine moiety was 
predicted to form an ionic interaction with Asp-236. Lastly, the amine of the 
chiral carbon was predicted to form a hydrogen bonding interaction with Asp-
465. 
A number of changes were made to compound 9 to make it more 
synthetically accessible (Figure 21). The chiral carbon of compound 9 bears 
three heteroatoms (including a primary amine and a hydroxyl group), which 
is hydrolytically unstable and undesirable for a potential drug lead. As 
mentioned above, the docking pose of 9 predicts that the hydroxyl group 
coordinates with one of the Mg2+ ions of the hydrolytic centre. In order to 
retain this interaction and increase the hydrolytic stability, the chiral carbon 
was replaced with a carbonyl. This resulted in the generation of an N-acyl 
indole. In addition, the cyclopentadiene was replaced with a phenyl ring to 
make the putative inhibitor more synthetically accessible. These changes 
lead to the identification of compound 10. 
 
Figure 21: A number of changes were made to 9 to make it synthetically accessible, 
this lead to the identification of compound 10. 
Compound 10 was docked into the hydrolytic centre of TmPPase and the 
resultant docking pose was compared to that of compound 9 (Figure 22). 
[63] As predicted the docking poses of both compounds were similar, with 
similar docking scores (-6.78 for 9 and -6.69 for 10), and both are predicted 
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to make similar contacts within the hydrolytic centre. The indole N-acyl 
carbonyl of 10 is predicted to coordinate with one of the Mg2+ ions and there 
is the loss of a contact with Asp-465 that arises from the loss of the chiral 
amine group.  
 
Figure 22: a) The predicted binding pose of compound 10 (green) and compound 9 (blue) 
within the hydrolytic centre of TmPPase (PDB : 4AV3). [47] Predicted interactions are shown 
as dashed black lines. b) The 2-D representation of the docking pose of compound 10. 
Residues of the hydrolytic centre are shown in red and interactions are shown as black 
dashed lines. [64] 
2.2 Retrosynthetic Analysis of Compound 10 
Retrosynthetic analysis of 10 suggested that this target compound could be 
synthesised from the commercially available indole 11, acyl chloride 12, and 
N-Fmoc glycine 13 (Scheme 1). 








2.3 Attempted Synthesis of Compound 10 
The attempted synthesis of the SPROUT designed scaffold 10 is 
summarised below (Scheme 2). 
 
Scheme 2: Attempted synthesis of compound 10. 
The first step of the attempted synthesis of compound 10 involved the N-
acylation of indole 11 with benzoyl chloride 12 in the presence of sodium 
hydride (NaH), which gave indole 14 in good yield. This was followed by the 
reduction of the nitro group of 14 to give the corresponding amine 15, which 
was followed by an 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
mediated amide coupling between amine 15 and fluorenylmethyloxycarbonyl 
(Fmoc) protected glycine (N-Fmoc-Gly-OH) to afford compound 16 in good 
yield. The ester hydrolysis of compound 16 proved to be unsuccessful. Liquid 
chromatography-mass spectrometry (LCMS) analysis revealed that this was 
due to the hydrolysis of the indole N-acyl bond, thus showing that the N-acyl 
bond is base labile (Scheme 3). Hydrolysis of the indole N-acyl bond was 
also observed at low temperatures and when lower equivalents of lithium 




Scheme 3: Hydrolysis of Compound 16. 
2.3.1 Modified Synthetic Route 
To avoid cleavage of the N-acyl bond it was decided to replace the methyl 
ester of 16 with a benzyl ester, which could be cleaved without the use of 
basic conditions. In addition, the protecting group of glycine was changed to 
tert-butyloxycarbonyl (Boc) (N-Boc-Gly-OH) to avoid basic deprotection 
conditions. The modified synthetic route is shown below (Scheme 4).  
Scheme 4: Attempted synthesis of compound 10 using modified synthetic route 
The benzyl ester functionality was introduced to indole 20 through the 
employment of an EDC mediated coupling reaction with benzyl alcohol 
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(BnOH), which proceeded with a good yield. N-Acylation of compound 21 
with acyl chloride 12 gave the corresponding N-acyl indole 22 with an 
improved yield compared to that of the methyl ester 14. Due to the presence 
of the benzyl ester the reduction of the nitro group of 22 was achieved using 
SnCl2 under acidic conditions, rather than by hydrogenation. This was 
followed by the EDC mediated amide coupling of amine 23 with N-Boc-Gly-
OH. Compound 24 was then subjected to hydrogenolysis to afford carboxylic 
acid 25 in moderate yield. The introduction of the desired amide functionality 
proved to be unsuccessful due to aminolysis of the indole N-acyl bond 
(Scheme 5).   
Scheme 5: Aminolysis of compound 25 
During the hydrogenolysis of compound 24 it was observed that if the 
reaction was carried out over a longer period the indole was reduced to the 
corresponding indoline 28. It was proposed that the N-acyl indoline bond of 
28 would be more stable towards aminolysis. Therefore, the desired primary 
amide functionality was targeted using indoline 28 (Scheme 6). Surprisingly, 
the indoline N-acyl bond was also labile towards aminolysis and formation of 
the desired indoline 29 was unsuccessful.   
Scheme 6: Attempted synthesis of compound 29. 
Based on the lability of both the indole and indoline N-acyl bonds to 
ammonia, it was decided to form the triphenymethyl protected amide 31 
(Scheme 7). The protected amide would then be treated with trifluoroacetic 
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acid (TFA) to form the corresponding primary amide. The attempted 
synthesis of the protected amide 31 involved a Bromotri 
pyrrolidinophosphonium hexafluorophosphate (PyBrOP) mediated amide 
coupling between carboxylic acid 24 and triphenylmethyl (Tr) amine. LCMS 
analysis revealed that the formation of the activated ester intermediate 30 
was quantitative, however formation of the desired protected amide 31 was 
unsuccessful. This could be due to steric hindrance caused by the sterically 
bulky activated ester intermediate 30.     
Scheme 7: Failed formation of primary amide 10 via formation of triphenylmethyl protected 
amide 31. 
Due to the synthetic difficulties encountered during the attempted formation 
of the primary amide it was decided that a simple secondary amide would be 
targeted using simple alkyl amines. The formation of methyl amide 32, using 
an EDC mediated amide coupling reaction between methyl amine and acid 
24, was unsuccessful (Scheme 8). However, formation of the corresponding 
nbutyl amide 33 was successful. This amide formation proceeded with a yield 
of 45%. The low yield of this reaction may be due to the steric hindrance 
caused by the sterically bulky activated ester intermediate.  Boc deprotection 
of compound 33 then followed to give compound 34 with a near quantitative 
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yield. The corresponding indoline 35 was also synthesised and comparable 
yields were obtained (Scheme 9). 
Scheme 8: Attempted synthesis of methyl amide 32 and the synthesis of butyl amide 34. 
 
Scheme 9 Synthesis of indoline 35. 
2.4 Biological Evaluation of Compounds 34 and 35 
The biological evaluation of compounds 34 and 35 (as well as all future 
compounds) was carried out by collaborators at the University of Helsinki, 
Finland. The compounds were screened against TmPPase using a 
fluorescence-based activity assay, which measured the formation of 
phosphate produced during the hydrolysis of pyrophosphate (see 








Table 5: Biological evaluation of compounds 34 and 35. % Inhibition values are given as the 
mean standard deviation. NA = Not active. 
Compound 34 inhibited the activity of TmPPase by 13% at a concentration 
of 500 µM, whilst compound 35 was not active at the concentrations used. 
Due to the low activities of both compounds IC50 values were not obtained. 
The low activities observed for these compounds are likely to be caused by 
the presence of the nbutyl amide, which could cause 34 and 35 to adopt a 
less favourable binding pose than was predicted for the primary amide 10. 
Therefore, compound 34 was docked into the hydrolytic centre of TmPPase 
using Glide and the resultant docking pose was compared to the docking 





























Figure 23: a) The predicted docking pose of compound 34 (blue) compared to the predicted 
docking pose of compound 10 (green). Dashed lines represent interactions between the two 
compounds and the hydrolytic centre of TmPPase (PDB:4AV3). [47, 63] b) 2-D 
representation of the predicted docking pose of compound 34. Structures highlighted in red 
are amino acid residiues of the hydrolytic centre. Dashed lines represent interactions 
between 34 and the amino acid residues of the hydrolytic centre. [64] 
The predicted docking pose of compound 34 was found to be significantly 
different than that of compound 10. Compound 34 is also predicted to make 
less contacts with the hydrolytic centre of TmPPase than 10, including one 
less interaction with the Mg2+ ion. This further supports the hypothesis that 
the butyl amide is making a significant contribution to the poor biological 
activity observed for 34.  
2.5 Alternative Structural Isomer 
Due to the synthetic difficulties encountered during the synthesis of the N-
acyl indole 10 it was decided to change the substitution of the indole moiety 
from 1,7- to 3,4- (Compound 36, Figure 24). It was thought the change in 
substitution would lead to an increase in hydrolytic stability.   
 




2.6 Attempted synthesis of Compound 36 
To achieve the desired indole substitution pattern it was planned to use a 
Friedel-Crafts acylation reaction between indole 37 and acyl chloride 12 
(Scheme 10). 
 
Scheme 10: The planned synthesis of indole 38 involved a Friedel-Crafts acylation between 
indole 37 and acyl chloride 12. 
Initially Et2AlCl was used as the Lewis acid for the Friedel-Crafts acylation, 
however no product was observed when the reaction was carried out at both 
RT and under reflux conditions (Scheme 11). [65] The reaction was also 
attempted using AlCl3 as the Lewis acid, which also failed to yield 38. 
 
Scheme 11: Attempted Synthesis of Compound 38 
One possible reason for the lack of reactivity of indole 37 could be due to the 
conjugation of the indole N lone pair with the carbonyl of the ester at the 4- 
position (Scheme 12). This conjugation would mean that the N lone pair is 
unable to attack acylium ion 40 that is generated by the Lewis acid. To test 
this hypothesis a Friedel-Crafts acylation was carried out between indole 41 
and acyl chloride 12, using Et2AlCl as the Lewis acid. This resulted in the 
formation of compound 42 and proceeded with a good yield (Scheme 13), 
further supporting the role of the carbonyl in reducing the reactivity of indole 
37 towards Friedel-Crafts acylation reactions. 
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Scheme 12: Conjugation of the indole nitrogen lone pair of 37 could prevent it from reacting 
with acylium ion 40 to give indole 38. 
 
Scheme 13: The Friedel-Craft acylation between indole 41 and acyl chloride 12 was 
successful, supporting the argument that the presence of a carbonyl at the 4- position affects 
the reacivity of indole towards Friedel-Crafts acylation 
An alternative method to achieve the desired substitution of indole was 
proposed in which the Friedel-Crafts acylation would be carried out using 
bromo indole 43 (Scheme 14). This would then be followed by a bromo-
lithium exchange to give the lithiated indole intermediate 45. Addition of CO2 




Scheme 14: Planned synthesis of indole 46 using Br-Li exchange 
The initial Friedel-Crafts acylation reaction between indole 43 and acyl 
chloride 12 successfully resulted in the formation of compound 44, however 
LCMS analysis revealed that the formation of indole 46 proved to be 
unsuccessful (Scheme 15) and a large number of undesired peaks were 
present.  This may have been due to a number of side reactions occurring 
caused by the high reactivity of the lithiated intermediate 45. 
Scheme 15: Attempted synthesis of compound 46 
Due to the low biological activity of indole 34 and the synthetic difficulties 
encountered during the synthesis of both indole 34 and indoline 35, it was 
decided to abandon the indole skeleton.    
2.7 Simplification of Core 
It was decided to simplify the core by removing the indole moiety to give a 
simple aromatic amide (compound 47, Figure 25). This aromatic amide was 
predicted to be more hydrolytically stable than the corresponding indole N-
acyl bond and would therefore allow the desired primary amide to be 




Figure 25: Simplification of indole 34 to give compound 47. 
2.8 Synthesis of Compound 47 
The synthesis of compound 47 is summarised below (Scheme 16). The first 
step involved a nucleophilic addition elimination reaction between 2-
aminobenzamide 48 and acyl chloride 12, which proceeded in good yield. 
[66] This was followed by the quantitative nitro reduction of compound 49 to 
give the corresponding aniline 50. An EDC mediated amide coupling reaction 
then followed between aniline 50 and Boc-Gly-OH to give intermediate 51 in 
low yield. The low yield obtained from this reaction was due to the low 
solubility of aniline 50. Finally, deprotection of the Boc protecting group by 
the treatment of compound 51 with hydrochloric acid (HCl) resulted in the 
formation of compound 47 in good yield. 






2.9 Biological Evaluation of Compound 47 
Compound 47 was screened against TmPPase to determine the half 
maximal inhibitory concentration (IC50), the results are summarized below 





< 5000 µM 
Table 6: Biological evaluation of compound 47 
Compound 47 was found to be inactive at the concentrations tested. 
Therefore, compound 47 was docked into the hydrolytic centre of TmPPase 
so that alterations could be made in order to improve the potency of the 
compound (Figure 26). [63] Due to the change in geometry arising from the 
removal of the indole moiety the predicted docking pose of compound 47 
was different to that of compound 34. The primary amide group of 47 was 
predicted to make a hydrogen bonding interaction with Asp-202 and also 
coordinate to one of the Mg2+ ions. In addition, the secondary amide of the 
glycine moiety was predicted to form a hydrogen bonding interaction with 
Asp-228. The other secondary amide between both phenyl rings was 
predicted to form one hydrogen bonding interaction with Asp-232. Finally, 
the primary amine was predicted to form an additional hydrogen bonding 




Figure 26: a) Predicted docking pose of simplified SPROUT skeleton 47, dashed lines 
represent the predicted interactions between 47 and the hydrolytic centre of TmPPase 
(PDB: 4AV3). [47, 63] b) The 2D representation of the docking pose. The residues of the 
hydrolytic centre are highlighted in red and dashed lines represent the predicted interactions 
between 47 and the hydrolytic centre. [64] 
It was predicted that replacing the primary amide of compound 47 with a 
carboxylic acid (compound 52, Figure 27) would lead to an improvement in 
activity towards TmPPase. The rationale behind this hypothesis was that the 
carboxylic acid has a formal negative charge, that is absent on the primary 
amide, and this would improve the metal coordination potential of the 
compound.  
 
Figure 27: Replacement of the primary amide on compound 47 with a carboxylic acid to 
generate compound 52 
Compound 52 was docked into the hydrolytic centre of TmPPase and the 
resultant docking pose was compared to that of compound 47. [63] 
Unsurprisingly, both docking poses were almost identical (Figure 28). There 
is a slight difference in orientation of the phenyl ring of 52 that contains the 
carboxylic acid. Here, it is orientated so that the carboxylic acid can 
coordinate to Mg2+ in a bidentate manner. The change in conformation of the 





conformation of the other phenyl ring of 52. The carbonyl of the glycine 
moiety is now predicted to coordinate to the other Mg2+ ion within the 
hydrolytic centre. In addition, the carbonyl of the amide between the two 
aromatic rings is now predicted to make a hydrogen bonding interaction with 
Lys-664. The final difference in the docking pose of compound 52 is that the 
primary amine is predicted to make a hydrogen bonding interaction with the 
hydroxyl group of Thr-225, in addition to Asp-228. 
 
Figure 28: a) The docking pose of compound 52 (in blue) compared to that of compound 
47 (green). The dashed lines represent interactions between the hydrolytic centre of 
TmPPase (PDB: 4AV3) and 47 and 52. [47, 63] b) the 2-D representation of the docking of 
52. The structures in red are the residues of the hydrolytic centre, whilst the dashed lines 
represent interactions between 52 and the hydrolytic centre. [64] 
2.10 Synthesis of Compound 52 
The synthesis of compound 52 is summarised below (Scheme 17). Firstly, 
acyl chloride 12 was coupled with aniline 53 to give compound 54 in good 
yield. [66] This was followed by the quantitative reduction of the nitro group 
of 54 using zinc and ammonium chloride to yield the corresponding aniline 
55. An EDC mediated coupling reaction between 55 and Boc-Gly-OH 
resulted in the formation of compound 56, which proceeded with excellent 
yield. Deprotection of the Boc group, followed by the hydrolysis of the ester 




Scheme 17: Synthesis of compound 52 
2.11 Biological Evaluation of Compound 52 
Compound 52 was screened against TmPPase and the IC50 was compared 










Table 7: Biological evaluation of compound 52 and compound 47 
The IC50 of compound 52 was improved when compared with compound 47, 
if the docking studies are accurate this could be due to the stronger 
coordination of the carboxylic acid of 52 with Mg2+. 
-47- 
 
2.12 SAR Exploration of Compound 52 
A library of compounds based on compound 52 was synthesised, using the 
same route as Scheme 17, and screened against TmPPase in order to 

















3665 ± 974 µM 
Table 8: Biological results for compounds 52-59, which were screened against TmPPase 
The methyl ester 57 showed lower activity against TmPPase than the 
corresponding acid, suggesting that the negative charge of the carboxylate 
of compound 52 is important for activity. This is unsurprising considering that 
the carboxylate of 52 is predicated to coordinate with a positively charged 
Mg2+. Compound 58, which does not contain the glycine primary amine, has 
a much higher IC50 than that of compound 52. This suggests that the primary 
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amine is essential for potency and the loss of activity observed could be 
caused by the loss of the hydrogen bonding interactions that the amine is 
predicted to make with Thr-225 and Asp-228 mentioned above. The amide 
of the glycine moiety also seems to be important for activity, which can be 
seen from the drop in activity observed between compound 58 and 
compound 59. Loss of the amide carbonyl could result in the loss of the 
hydrogen bonding interaction that it was predicted to make with Asn-229. 
2.13 Analysis of Compound 52 for Lead Likeness using LLAMA 
An important factor to consider during the early stages of drug development 
is the lead-likeness of a compound. Lead-likeness is a qualitative guide for 
identifying compounds that will likely deliver lead compounds further down 
the drug discovery pipeline. [67] 
The Lead-Likeness and Molecular Analysis (LLAMA) programme determines 
the lead-likeness of a compound by analysing some of its key predicted 
properties. [68] The first of these properties is the predicted partition 
coefficient (ALogP), which is a measure of the predicted lipophilicity of a 
compound. The lipophilicity of a compound is important because it 
determines properties such as solubility, drug availability and off target 
effects. [69] To be considered lead-like by LLAMA the ALogP must be 
between -1 and 3. In addition, the relative molecular mass (RMM) of the 
compound must be between than 200 and 350 da. If a compound has an 
ALogP and RMM that is within these ranges then it is said to occupy lead-
like space. There are also a number of other properties that LLAMA uses to 
determine if a compound is lead-like. The heavy atom count must be 
between 17 and 27 and the compound must have <3 aromatic rings. 
Furthermore, the compound must not possess any ‘bad’ functional groups 
(e.g NO2). These bad functional groups are known to be toxic, the nitro group 
for example is metabolised to give toxic metabolites. 
When the LLAMA programme analyses a compound it assigns a “lead-
likness” penalty for properties that are not lead-like. [68] The output score of 
each compound therefore determines how much the compound deviates 
from lead-like space. A score of 0 means it does not deviate from lead-like 
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space, which means that all the properties fall within the accepted ranges 
discussed above.  Whilst, higher scores mean that the compound moves 
further away from lead like space. 
Compound 52 was analysed using LLAMA and the results are shown as both 
a lead-likeness plot (Figure 29) and in tabulated form below (Table 9). 
Overall 52 had a lead-likeness penalty of 0 and a plot of the AlogP against 
RMM indicates that it occupies lead-like space. The AlogP of 52 is predicted 
to be 0.03, meaning that is well within the acceptable range for AlogP. In 
addition, there are 23 heavy atoms (with two aromatic rings) and no 
unfavourable functional groups. This indicates that compound 52 occupies 
lead-like space and is worth developing further. 
 
Figure 29: Lead-likeness plot of predicted AlogP vs relative molecular mass of compound 












Property  Value Lead-Likeness Penalty 
AlogP 0.03 0 
No. of Heavy Atoms 23 0 
No. of Aromatic Groups 2 0 
RMM 313.08 0 
No. of ‘Bad’ functional 
groups 
0 0 
Table 9: LLAMA predicted properties of compound 52 and their associated lead-likeness 
penalty. Compound 52 has an overall lead-likeness penalty of 0. [68] 
2.14 SPROUT Expansion of Compound 52 
SPROUT was used to expand compound 52, with the aim of making a more 
potent inhibitor. [61] This resulted in the generation of compound 60, the 
predicted docking pose for compound 60 is shown below (Figure 30). The 
‘pre-expanded’ portion of compound 60 has an identical docking pose to 
compound 52, whilst the primary amine of the benzylamine moiety is 
predicted to make an additional hydrogen bonding interaction with Glu-667.   
 
Figure 30: a) Predicted docking pose of the SPROUT expanded compound 60 visualised 
in PyMol highlighting the benzylamine functionality added using SPROUT. Dashed lines 
represent interactions between 60 and the hydrolytic centre of TmPPase. b) The 2-D  
representation, the new benzylamine moiety is highlighted in blue. The structures in red are 
the residues of the hydrolytic centre, whilst the dashed lines represent interactions between 




2.15 Retrosynthetic Analysis of Compound 60 
Structure 60 was subjected to a retrosynthetic analysis. It was thought that 
60 could be accessed from the commercially available starting materials 
shown below (Scheme 18).  
Scheme 18: Retrosynthetic analysis of compound 60, which identified 53, 61, 62 and 63 as 
starting materials 
2.16 Synthesis of Compound 60 
The initial attempted synthesis of compound 65 is shown below (Scheme 
19). An amide coupling reaction between aniline 53 and Boc-Gly-OH resulted 
in the generation of compound 64 in good yield. Hydrolysis of the methyl 




Scheme 19: Attempted synthesis of compound 65. 
An alternative synthetic route was then devised in order to synthesise 
compound 60 (Scheme 20). The first step in the modified synthetic route 
involved the protection of aniline 66 using di-tert-butyl dicarbonate (Boc2O). 
Intermediate 67 was then coupled with aniline 53 using an EDC mediated 
amide coupling reaction and resulted in the formation of compound 68, which 
proceeded with a moderate yield. Compound 68 was then treated with HCl 
to form aniline 69, which then underwent an EDC mediated amide coupling 
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reaction with Boc-Gly-OH to give intermediate 70 in good yield. Boronic acid 
63 and intermediate 70 were then coupled using standard Suzuki coupling 
conditions. [70] Due to the basicity of the Suzuki conditions the methyl ester 
of compound 70 hydrolysed during the Suzuki reaction to give the 
corresponding acid, which was treated with HCl to give the desired 
compound 60. 
Scheme 20: Synthesis of compound 60 
2.16 Biological Evaluation of Compound 60 
Compound 60 was screened against TmPPase to determine the IC50, the 












550 ± 94 µM 
Table 10: Biological evaluation of compound 60 
The SPROUT expanded compound 60 had an IC50 value of 550 µM. This 
was considerably higher than that of compound 52, which had an IC50 value 
of 179 µM. The observed reduction in potency could be caused by the 
increased size of 60. As mentioned earlier (Section 1.5.1), when the 
substrate binds to M-PPases the hydrolytic centre closes and there is a 
reduction in its volume. This reduced volume could mean that 60 adopts a 
sub-optimal binding pose that was not predicted by SPROUT. These results 
therefore suggest that smaller modifications of compound 52 are needed to 
increase potency. 
2.18 Conclusions 
The de novo design programme SPROUT was used to develop an indole-
based putative inhibitor of TmPPase (compound 10, Figure 31), which was 
designed to bind to the hydrolytic centre. A number of synthetic difficulties 
were encountered during the synthesis of 10 that were caused by the lability 
of the indole N-acyl bond. Therefore, the n-butyl amide 34 was targeted 
instead. Compound 34, as well as the corresponding indoline 35, were 




Figure 31: The SPROUT designed putative inhibitor 10 could not be synthesised, so the 
corresponding butyl amide 34 was targeted instead. It was found that 34 had a very low 
potency against TmPPase. 
Indole 10 was then simplified to compound 47, this was due to both the 
synthetic difficulties encountered during the synthesis of indole 10 and its low 
activity (Figure 32). Compound 47 was found to be inactive against 
TmPPase at the concentrations tested. In order to make a more potent 
inhibitor the primary amide of 47 was replaced with a carboxylic acid 
(compound 52, Figure 32). It was thought that the carboxylate would be a 
better metal-coordinating group to Mg2+ than the amide. Compound 52 had 
an IC50 of 179 µM against TmPPase and is the first example of an inhibitor 
of an M-PPase using SBDD. A small library of compounds based on 
compound 52 was also synthesised to determine the SAR of 52. All 
compounds tested were less active than 52, suggesting that the key 
functionalities of 52 are important for activity. 
Figure 32: Simplification of 10 resulted in the generation of compound 47, which was 
inactive against TmPPase. Replacing the amide of 47 with a carboxylic acid lead to the 
identification of 52, which had an IC50 of 179 µM. This is first example of an inhibitor of a M-
PPase designed using SBDD. 
Compound 52 was then expanded using SPROUT to generate of compound 
60 (Figure 33), which was synthesised in six steps. The IC50 value of 
compound 60 was 550 µM, which was higher than compound 52 and 
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therefore less potent. One possible explanation of this lower activity is due 
to the large size of compound 60. This large size could mean that compound 
60 occupies a sub-optimal binding pose within the closed hydrolytic centre 
of TmPPase.  
 
Figure 33: SPROUT expansion of 52 lead to the identification of compound 60, which had 























Chapter 3: Substrate-Inspired Design of a Novel Phosphate 
Mimetic 
3.1 De novo Design of a Novel Sulfamide Fragment. 
The de novo design programme SPROUT was used to develop a novel 
sulfamide fragment that was designed to mimic phosphate in the hydrolytic 
centre of TmPPase (compound 71, Figure 34). [47, 61] The design process 
initially involved docking a sulfonamide group onto one of the Mg2+ ions of 
the hydrolytic centre, which mimics the coordination of a phosphate ion. In 
addition, a carboxylic acid group was docked onto the other Mg2+ ion. Linking 
the sulfonamide and carboxylic acid groups with phenyl rings resulted in the 
generation of compound 71, which is a novel sulfamide fragment.  
    
Figure 34: a) Predicted docking pose of SPROUT designed sulfamide fragment 71, 
visualised using PyMol. Dashed lines represent interactions between sulfamide 71 and the 
hydrolytic centre of TmPPase. [47, 61]  b) The 2D representation The Mg2+ ions and amino 
acid residues of the hydrolytic centre are highlighted in red. [64] 
3.2 Retrosynthetic Analysis of SPROUT Designed Sulfamide 
Fragment 
Retrosynthetic analysis of 71 revealed that it could be synthesised using the 
commercially available; aniline 72, chlorosulfonic acid 73 and methyl 4-




Scheme 21: Retrosynthetic analysis of sulfamide 71. 
3.3 Synthesis of Sulfamide Fragment 71 
The initial synthesis of sulfamide 71 is summarised below (Scheme 22). 
 
Scheme 22: Attempted synthesis of sulfamide 71. 
Formation of sulfamic acid 75 was achieved using the reported method of 
treating aniline 72 with chlorosulfonic acid, which proceeded with a moderate 
yield of 64 %. [71]  The next stage in the planned synthetic route was the 
chlorination of 75 using PCl5. [71] However, LC-MS and nuclear magnetic 
resonance spectroscopy (NMR) analysis showed that formation of sulfamoyl 
chloride 76 was unsuccessful. This was due to the substitution of toluene 
(the reaction solvent) with 75 to give the undesired sulfonic acid 78 (Scheme 
23). Chlorination of 78 then resulted in the formation of sulfonyl chloride 79. 
 
Scheme 23: Substitution between toluene and sulfamic acid 75 resulted in the formation of 
sulfonic acid 78. 
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This observation was confirmed by coupling the resultant sulfonyl chloride 
79 with 74, which resulted in the formation of sulfonamide 80 (Scheme 24). 
 
Scheme 24: Formation of undesired sulfonamide 80. 
3.3.1 Optimisation of Chlorination Step and Synthesis of Sulfamide 
Fragment 71 
To avoid the substitution of sulfamic acid with toluene, alternative solvents 
were explored for the chlorination reaction. Both chloroform and 
dichloromethane (DCM) were initially tested and both led to the successful 
formation of sulfamoyl chloride 76 (Scheme 25) and no side-products were 
observed. The yield for the chlorination reaction was 10% when DCM was 
used and 15% when chloroform was used. Heating the reaction mixture lead 
to an increase in yield for both chloroform (30%) and DCM (15%), the 
remainder of the material in both reactions was 75.  Due to the higher yield 
obtained, chloroform was chosen as the solvent for the chlorination reaction. 
 
Scheme 25: Chlorination of 75. No side products were observed when DCM or chloroform 
were used as the solvent. Refluxing the reaction mixture in chloroform gave the highest yield 
of 30%. 
It was thought that the yield of the chlorination reaction could be further 
improved by using the sodium salt of 75. The desired sodium sulfamate 82 
was obtained through the treatment of aniline 72 with chlorosulfonic acid in 
the presence of triethylamine (TEA) (Scheme 26). [72] This lead to the 
generation of the generation of the TEA salt 81, which was then treated with 




Scheme 26: Formation of sodium sulfamate 82. 
Chlorination of sodium sulfamate 82 resulted in the formation of sulfamoyl 
chloride 76 with an improved yield of ~50 % (Scheme 27). 
 
Scheme 27: Formation of sulfamoyl chloride 76 using sodium sulfamate 82 
The desired sulfamide fragment was then obtained by coupling sulfonyl 
chloride 82 with aniline 74 (Scheme 28), which proceeded with a moderate 
yield of 61%. The overall yield obtained for the formation of 77 starting from 
aniline was 29%. Finally, ester hydrolysis of 77 gave the desired carboxylic 
acid 71 with near quantitative yield. 
 
Scheme 28: Synthesis of SPROUT designed sulfamide fragment 71 was achieved through 
the coupling of sulfanoyl chloride 82 and aniline 74, followed by ester hydrolysis. 
3.3.2 Alternative Synthesis of 71 
Due to the low overall yield of 77, alternative routes for the synthesis of 
sulfamides were explored. One alternative route involves using a Buchwald-
Hartwig coupling reaction to couple a primary sulfamide with an aryl bromide, 





Scheme 29: Buchwald coupling of a primary sulfamide with an aryl/vinyl bromide. R = alkyl, 
aryl or vinyl R'=aryl or vinyl 
The planned Buchwald-Hartwig coupling reaction to produce 77 is outlined 
below (Scheme 30). Initially, aniline 74 would be converted to the primary 
sulfamide 86. This would then be followed by the Buchwald-coupling reaction 
between 86 and bromobenzene to give sulfamide 77. [74] 
 
Scheme 30: Modified synthetic route of sulfamide 77 involving the formation of primary 
sulfamide 86, which would then be coupled with PhBr using the Buchwald reaction 
There are a number of different reported methods of forming primary 
sulfamides. One method involves the addition of a large excess sulfamide 
(H2NSO2NH2) to an aniline 87 and is carried out at high temperatures 
(Scheme 31). [75] An alternative method involves the formation of the Boc-
protected sulfamide 89, which is then deprotected to give the desired primary 
sulfamide 88 (Scheme 31). [76] The Boc-protected sulfamide is formed by 
the reaction of an aniline with Boc-sulfonyl chloride, which in turn is formed 
by the addition of chlorosulfonyl isocyanate (ClSO2NCO) to tBuOH. 
 
Scheme 31: Possible route towards primary sulfamides. [75, 76] 
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Initial attempts toward the synthesis of primary sulfamide 86 involved the 
addition of sulfamide to 74 (Scheme 32), which lead to the formation of 86 
with a poor yield of 15%.  
 
Scheme 32: Synthesis of 86 was achieved by heating aniline 74 with a large excess of 
sulfamide. 
Due to the low yield obtained for this reaction it was decided to attempt to 
target the primary sulfamide using the second method discussed above 
(Scheme 33). Firstly, Boc-sulfamoyl chloride was formed in situ by the 
addition of chlorosulfonyl chloride to tBuOH. This was followed by the 
addition of 74, which lead to the formation of intermediate 90 in good yield. 
Deprotection of 90 under acidic conditions then followed, which lead to the 
formation of 86 in near quantitative yield. The overall yield for this method 
was 81% and no purification steps were needed. Therefore, this method was 
chosen for the formation of primary sulfamides.  
 
Scheme 33: The second synthesis of primary sulfamide 86. Initially, the Boc protected 
sulfamide 90 was formed. This was followed by Boc deprotection to the corresponding 
primary sulfamide with an excellent yield. 
Primary sulfamide 86 and bromobenzene then underwent a Buchwald-
Hartwig coupling reaction, which lead to the formation of sulfamide 77 with a 
high yield of 75% (Scheme 34). [74] The overall yield for the formation of 
sulfamide 77, starting from aniline 74, was 61%. This was much higher than 
the yield obtained for the previous sulfamide synthesis discussed. Therefore, 






Scheme 34: Buchwald-coupling between 86 and bromobenzene lead to the formation of 77 
in good yield. 
3.4 Biological Evaluation of Compound 71 
Compound 71 was screened against TmPPase to determine the % inhibition 
at a concentration of 100 µM and the IC50 value (Table 11). 




26 ± 7 % 
 
 
1353 ± 173 µM 
Table 11: Biological Evaluation of Compound 71. Results are shown as % inhibition and an 
IC50 and Ligand efficiencies. 
The SPROUT designed sulfamide fragment inhibited the activity of TmPPase 
by 26% at a concentration of 100 µM and had an IC50 value of 1353 µM. 
3.5 pKa of Sulfamides 
The sulfamide functionality is acidic and will deprotonate under basic 
conditions to generate the corresponding conjugate base 92 (Figure 35). 
[77] 
 
Figure 35: The sulfamide functionality 91 is acidic and can undergo deprotonation to give 
the corresponding conjugate base 92. [77] 
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As discussed above, the sulfamide of 71 was predicted to coordinate to one 
of the Mg2+ ions of the hydrolytic centre of TmPPase. It was therefore 
hypothesised that the conjugate base of 71 would have a stronger interaction 
with Mg2+, due to the formal negative charge. Consequently, if the pKa of the 
sulfamide is decreased it would be expected that there would be a greater 
proportion of the conjugate base and this would lead to an increase in 
potency (Figure 36). Contrary to this, an increase in pKa would be expected 
to lead to a decrease in potency. 
 
Figure 36: It was predicted that if the pKa of the sulfamide of 71 was lower, the proportion 
of conjugate base 93 would be higher and the potency would increase. Whilst, an increase 
in pKa would cause the proportion of 93 to be lower and this would lead to a decrease in 
potency. 
3.6 Synthesis of SAR Library 
A library of sulfamide fragments were synthesised using the synthetic route 
shown in Scheme 35. [74] This was done to determine both the structure 
activity relationships of 71 and to determine if the pKa of the sulfamide had 
an effect on the potency of the compounds against TmPPase. 
Scheme 35: Synthesis of sulfamide fragment library. Conditions for a = Pd/C, H2, MeOH, 
RT. 
During the synthesis of the fragment library it was found that if the aryl ring 
of the primary sulfamide contained a strongly electron withdrawing group, it 
would not undergo the desired Buchwald reaction (Scheme 36). The 
electron withdrawing group will make the aromatic ring less electron rich, 
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which in turn will make the primary sulfamide group less electron rich. This 
could mean that the primary sulfamide is unable to coordinate to the Pd 
catalyst and could account for the failure of the coupling reaction. 
 
Scheme 36: The Buchwald reaction to form sulfamides was unsuccessful when the aryl ring 
of the primary sulfamide contained a strongly electron withdrawing group. 
3.7 Biological Evaluation of Sulfamide Fragment Library 
Sulfamide fragments 104-108 were biologically evaluated against TmPPase 
and their IC50 values were determined (Table 12). In addition, MarvinSketch 
was used to predict the sulfamide pKa values of each of the fragments to 
establish any link between pKa and potency of the sulfamide fragments. All 
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Table 12: Biological evaluation and pKa predicted pKa of sulfamide fragments 74-108. 




Compound 77, which had ester in place of the carboxylic acid, had a lower 
pKa than 71 and was found not be active at the concentrations tested. This 
shows that the negative charge of the acid is essential for the activity of 
sulfamide 71. As mentioned above, the carboxylic acid of 71 was predicted 
to coordinate to one of the Mg2+ ions within the hydrolytic centre. Therefore, 
the formal negative charge of the acid may be essential for coordination. 
Compound 107, which contained a m-NO2 group on the left-hand aryl ring, 
had an IC50 of 989 µM and is more potent than 71. In addition, the sulfamide 
group of 107 had a predicted pKa of 8.88. The nitro group of 107 will make 
the corresponding aryl ring more electron deficient, which in turn makes the 
sulfamide group more electron deficient and therefore accounts for the 
decrease in the predicted pKa. The decrease in pKa could mean that 
deprotonation of the sulfamide occurs more readily and a higher percentage 
of 107 will exist as the conjugate base, accounting for the greater potency.  
The addition of a p-NO2 (compound 105) on the left-hand aryl ring resulted 
in a further decrease in the predicted pKa compared to both 71 and 107. 
However, 105 was not active against TmPPase. The decreased pKa is 
caused by the conjugation of the sulfamide with the nitro group. This 
conjugation means that the conjugate base of 105 is more stable due to the 
resonance of the negative charge (Figure 37). This resonance could also 
mean that the conjugate base is unable to coordinate to the Mg2+ and it is 
therefore inactive against TmPPase. In addition, the addition of the p-NO2 
could result in a steric clash with other residues of the hydrolytic centre 
causing 105 to adopt an unfavourable binding pose. 
 
Figure 37: The negative charge resonance of the conjugate base 109 increases the pKa of 
the sulfamide. This could suggest that the resonance form 110 is unable to coordinate to 
the Mg2+ of the hydrolytic centre and could account for the poor activity of 105. 
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When an electron donating NH2 group is present on the left-hand aromatic 
ring of the sulfamide fragment (Compound 108) the pKa is predicted to be 
higher than that of all the previous fragments. In addition, 108 was found to 
be inactive against TmPPase. The increased pKa could mean that less of 
108 will exist as the conjugate base and hence the coordination to Mg2+ will 
be weak, resulting in the observed lack of activity towards TmPPase. 
Similarly, 104 also had an increased predicted pKa and was inactive against 
TmPPase. In this case the electron donating group (methoxy) is present on 
the same aryl ring as the carboxylic acid. 
The addition of a carboxylic acid group to the left-hand aromatic ring in the 
para- position had no effect on the predicted pKa of the sulfamide and was 
found to be inactive against TmPPase (compound 106). One possible 
explanation for the loss of activity can be obtained by examining the 
predicted docking pose of 71. [63] This showed that there was an aspartic 
acid residue located close to the para position of the second aromatic ring 
(Figure 38). The addition of the para-carboxylic acid group would therefore 
lead to a repulsive interaction with aspartic acid residue and could force 106 
to adopt an unfavourable binding pose. 
 
Figure 38: The predicted docking pose of the parent sulfamide fragment 71, highlight the 





3.8 Suitability of Sulfamides for Hit-to-Lead Development 
Sulfamide fragment 71 was analysed using LLAMA to determine if it 
occupied lead-like space (Section 2.13). [68] The predicted AlogP of 71 was 
2.17, which is within the acceptable AlogP range. Furthermore, a plot of the 
predicted AlogP vs RMM showed that 71 occupies lead like space, with no 
lead-likeness penalties (Figure 39).  
 
Figure 39: Plot of the predicted AlogP vs RMM of compound 71. The plot indicates that 71 
occupies lead-like space. 
Extensive studies into the pharmokinetic properties of sulfamide compounds 
has been conducted by Aoki et al. [79] They studied a series of sulfamide 
compounds that inhibit both Raf and mitogen-activated protein kinase 
(Figure 40). They showed that these sulfamide compounds undergo 
demethylation in the presence of mouse and human liver microsomes. 
However, they also found that the aromatic-sulfamide bond is metabolically 
stable in the presence of liver microsomes and do not hydrolyse to toxic 
anilines. In addition, all sulfamides tested had low clearances and high bio 





Figure 40: Aoki et al found that the aromatic-sulfamide bond of a series of Raf/mek inhibitors 
based on 111 were metabolically stable, whilst the methyl group of the sulfamide 
functionality underwent demethylation in the presence of liver microsomes 
Both the LLAMA analysis and the metabolic stability of aromatic sulfamides 
suggest that sulfamide fragment 71 is worth exploring further. 
3.9 SPROUT Design of a Second-Generation Sulfamide 
Fragment 
SPROUT was used to expand the parent sulfamide fragment 71, with the 
aim of producing a more potent inhibitor. [61] The design process involved 
docking a primary amine and amide fragment to the Val-408 residue of the 
hydrolytic centre of TmPPase. To connect 74 with the docked amine and 
amide fragments a number of spacer templates were selected including; 
alkyl, phenyl, amide, and ether groups. This resulted in the generation of the 
second generation sulfamide fragment 112, which had a para- substituted 
benzylamine moiety in place of the phenyl ring of 71 (Figure 41). The primary 
amine of 112 was predicted to make hydrogen bonding interactions with Ala-
402, Thr-410 and Val-408. There is a slight change in the conformation of 
the predicted binding pose of 112 compared to that of 71. The carboxylic acid 
of 112 was predicted to coordinate to one of the Mg2+ in a bidentate manner 
and the sulfamide N-H of the benzyl amine was predicted to make a 
hydrogen bonding interaction with Asp-228. Compound 112 had a SPROUT 
score of -5.11 and was therefore predicted to be more potent than 71, which 





Figure 41: a) Predicted docking pose of SPROUT designed sulfamide fragment 112 
visualised in PyMol, dashed lines represent interactions between 112 and the hydrolytic 
centre of TmPPase. [47, 61, 63] b) 2D representation of the docking pose. Residues of the 
hydrolytic centre are shown in red. 
3.10 Synthesis of Second Generation Sulfamide Fragment 
112 
The second generation sulfamide fragment was synthesised using a 
Buchwald-Hartwig coupling reaction between primary sulfamide 86 and 113 
to give intermediate 114, which proceeded with a moderate yield of 61% 
(Scheme 37). [74] Ester hydrolysis and Boc-deprotection of 114 lead to the 
formation of 112 in near quantitative yield.  
 
Scheme 37: Synthesis of second generation sulfamide fragment 112 
3.11 Biological Evaluation of Compound 112 
The second generation sulfamide fragment 112 was biologically evaluated 
against TmPPase and the IC50 value was determined and compared to that 






716 ± 64 µM 
 
 
1353 ± 173 µM 
Table 13: Biological evaluation of the second generation sulfamide fragment 112. The IC50 
of 112 was also compared to that of 71. 
Sulfamide 112 had an IC50 value of 716 µM against TmPPase and was more 
potent than the parent sulfamide fragment 71. This suggests that the primary 
amine of 112 is making additional interactions with the hydrolytic centre of 
TmPPase, as was predicted by the SPROUT design. 
3.12 Attempted Synthesis of an Electron Deficient Derivative 
of 115 
It was hypothesised that the addition of a strongly electron-withdrawing NO2 
group to 112 would lead to an increase in activity, due to the decreased pKa 
of the sulfamide moiety. Therefore, sulfamide 115 was identified as a key 
compound for synthesis (Figure 42).  
 
Figure 42: The addition of an electron-withdrawing NO2 group to the second generation 
sulfamide fragment lead to the identification of sulfamide 115. 
The attempted formation of 115, summarised below (Scheme 38), involved 
the Buchwald-Hartwig coupling of primary sulfamide 86 with 116. This would 
give intermediate 117, which would be followed by the conversion of the 
nitrile group of 117 to the corresponding Boc-protected amine 118. Boc-
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deprotection and ester hydrolysis would have then lead to the formation of 
the desired sulfamide fragment 115. 
 
Scheme 38: Synthetic strategy for the formation of sulfamide fragment 115. 
LCMS analysis revealed that the formation of 117 was unsuccessful due to 
the rapid debromination of 116 (Scheme 39 and Scheme 40). The 
debromination is likely to have occurred due to the presence of two strongly 
electron withdrawing groups on aryl bromide 116, thus making a highly 
electron deficient aryl bromide. 
 
Scheme 39: LCMS analysis revealed that the formation of sulfamide 117 was unsuccessful 
 
Scheme 40: Debromination of 116 to give 119. This was likely caused by the presence of 
two strongly electron withdrawing groups on 116. 
One alternative route towards 118 involves the conversion of the nitrile group 
of 116 to the Boc-protected amine 120 (Scheme 41). This would make the 
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resultant aryl bromide 120 more electron rich and will reduce the rate of 
debromination and allow the Buchwald coupling reaction between 120 and 
86 to occur. 
 
Scheme 41: Proposed alternative synthesis of 118. 
3.13 Conclusions 
The de novo design programme SPROUT was used to design the novel 
sulfamide fragment 71, which was designed to mimic phosphate and bind to 
the hydrolytic centre of TmPPase (Figure 43). 
 
Figure 43: SPROUT designed sulfamide fragment 71, which was designed to mimic 
phosphate and bind to the hydrolytic centre of TmPPase 
The initial synthesis of 71 involved the formation of sodium sulfamate 82, 
which was then chlorinated to give sulfamoyl chloride 76 (Scheme 42). This 
was followed by the coupling of 76 with aniline 74 to give 77 with a poor 




Scheme 42: The initial synthesis of 71. The insertion of the sulfamide moiety proceeded 
with a poor overall yield of 29%. 
Due to the low yield of the previously used strategy for the formation of 
sulfamide 77, an alternative strategy was explored. This strategy involved 
the formation of primary sulfamide 86, which was then coupled with 
phenylbromide using a Buchwald-Hartwig coupling reaction to give 77 
(Scheme 43). The overall yield for this strategy was 61%. Therefore, this 
strategy was selected for the future synthesis of sulfamides. 
 
Scheme 43: Buchwald-coupling between 86 and bromobenzene lead to the formation of 77 
in good yield. 
Sulfamide 71 was biologically evaluated against TmPPase and was found to 
have an IC50 value of 1353 µM. The corresponding ester 77 was also tested 
and was found to be inactive against TmPPase. This supported the binding 
pose that was predicted by SPROUT and highlights the importance of the 
formal negative charge of the acid. 
It was hypothesised that decreasing the pKa of the sulfamide moiety would 
lead to an increase in potency against TmPPase, due to the increased 
proportion of the conjugate base 93 (Figure 44). To test this hypothesis a 




Figure 44: It was hypothesized that lowering the pKa of the sulfamide of 71 would lead to 
an increase in potency due to the increased coordination potential of 93. 
Compounds 104-107 were biologically evaluated against TmPPase. It was 
found that decreasing the pKa of the sulfamide moiety (compound 107) lead 
to an increase in potency, whilst an increase in the pKa  (compounds 104 
and 108) lead to the loss of activity.  One exception to the trend was 
compound 105, which contained a para- NO2 group on the second aromatic 
ring. This was predicted to have the lowest pKa of the series, but it was 
inactive against TmPPase. It was thought that this was due to the 
conjugation of the lone pair of electrons of its conjugate base with the nitro 
group. This would mean that the lone pair is unable to coordinate to the Mg2+ 
ion of the hydrolytic centre. 
 
Figure 45: Biological of evaluation of 104-108 suggested that the pKa of the sulfamide 
moiety is important for activity against TmPPase. 
LLAMA analysis of the original sulfamide fragment 71 revealed that it 
occupies lead-like space and had a lead-likeness penalty score of 0 (Figure 
39). In addition, Aoki et al showed that sulfamides have favourable properties 
and that aromatic-sulfamide bonds are not metabolically labile. This 
suggested that 71 was worth exploring further.  
SPROUT was then used to expand the initial sulfamide fragment 71, which 




Figure 46: The second generation sulfamide fragment 112, which contained a benzylamine 
moiety on the left hand aromatic ring. 
The second generation inhibitor 112 was synthesised according to the 
scheme shown below (Scheme 44) and was then biologically evaluated 
against TmPPase. The IC50 was found to be 716 µM, which means that it is 
more potent than the original sulfamide fragment 71.  
  
















Chapter Four - Heterocyclic Fragment Series 
4.1 Previous vHTS Campaign 
A virtual-highthroughput screening (vHTS) campaign has previously been 
conducted by collaborators at the University of Helsinki. [80] This involved 
docking small molecule fragments, from an in-house virtual library, into the 
hydrolytic centre of TmPPase using Glide.  The compounds that gave the 
highest docking scores were then biologically evaluated against TmPPase.  
This lead to the identification of isoxazole 121 (Figure 47), which inhibited 
the activity of TmPPase by 30% at a concentration of 500 µM. An IC50 value 
could not be obtained at the concentrations tested.  
 
Figure 47: A fragment screening campaign carried out by collaborators lead to the 
identification of Isoxazole 121, which inhibited the activity of TmPPase by 30% at a 
concentration of 500 µM.  
To determine if the activity of 121 could be improved with alternative 
heterocycles, a number of heterocyclic fragments were targeted (Table 14). 
These fragments were to be docked into the hydrolytic centre of TmPPase 
and biologically evaluated against TmPPase. If the biological results 
supported the docking models the de novo design programme SPROUT 












Table 14: A number of different heterocyclic fragments were targeted for synthesis and 
biological evaluation. 
4.2 Docking of Heterocyclic Fragments 121-126 
The heterocyclic fragments 121-126 were docked into the hydrolytic centre 
of TmPPase (PDB: 4AV3) using Glide. [47, 63] Overall, the predicted binding 
poses and docking scores (Table 15) were similar for each of the fragments, 
with only minor differences observed. This suggests that the fragments 
would bind to the hydrolytic centre of TmPPase in a similar manner and have 
































Table 15: The Glide docking scores of heterocyclic fragments 121-126 
Firstly, the predicted binding poses of oxazole125 and thiazole 123 are 
shown below (Figure 48). The carboxylic acid groups of both 125 and 123 
were predicted to coordinate to the same Mg2+ ion of the hydrolytic centre in 
a bidentate manner. In addition, the phenyl rings of both 125 and 123 were 
predicted to form π-cation stacking interactions with the other Mg2+ ion. 
Finally, the heterocyclic nitrogen of 123 was predicted to form a hydrogen 
bonding interaction with Lys-199. Whilst, the heterocyclic nitrogen of 125 was 







Figure 48: a) The predicted docking poses of thiazole 123 and oxazole 125 within the 
hydrolytic centre of TmPPase, visualised in PyMol (PDB: 4AV3). Dashed lines represent 
interactions between the fragments and the hydrolytic centre. [47, 63] b) The 2D 
representations of the docking poses of 123 and 125. The residues of the hydrolytic centre 
are shown in red. 
The predicted binding poses of thiazole 124 and oxazole 126 are shown 
below (Figure 49). The carboxylic acid groups of both 124 and 126 were 
predicted to make a monodentate interaction with one of the Mg2+ ions, as 
well as a hydrogen bonding interaction with Lys-664. In addition, the phenyl 
ring of 124 was predicted to form a π-cation stacking interaction with the 









Figure 49: a) The predicted docking poses of thiazole 124 and oxazole 126 within the 
hydrolytic centre of TmPPase, visualised in PyMol (PDB: 4AV3). The dashed lines represent 
the predicted interactions between the fragments and the hydrolytic centre. [47, 63] b) The 
2D representation of the predicted docking poses of 124 and 126. The residue of the 
hydrolytic centre are shown in red.  
Finally, the predicted binding poses of thiophene 122 and isoxazole 121 are 
shown below (Figure 50). The carboxylic acid groups of both 122 and 121 
were predicted to coordinate with one of the Mg2+ ions of the hydrolytic centre 
in a bidentate fashion. A π-cation stacking interaction was also predicted 
between the phenyl ring of 122 and the other Mg2+ ion. Whilst, the 
heterocyclic nitrogen of 121 was predicted to make a hydrogen bonding 








Figure 50: a) The predicted docking poses of thiophene 122 and oxazole 121 within the 
hydrolytic centre of TmPPase, visualised in PyMol (PDB: 4AV3). Dashed lines represent 
interactions between the fragments and the hydrolytic centre. [47, 63] b) The 2D 
representation of the docking posed of 122 and 121. The residues of the hydrolytic centre 
are shown in red. 
4.3 Synthesis of Hererocyclic Fragments 
4.3.1 Synthesis of Thiophene 122 and Thiazole 124 
Thiophene 122 and thiazole 124 were synthesised according to the scheme 
outlined below (Scheme 45). Initially, a Suzuki coupling reaction between 
the appropriate heterocyclic bromide (127 and 128) and phenylboronic acid 
lead to the formation of intermediates 129 and 130. [70] Ester hydrolysis of 
both 129 and 130 lead to the formation of the desired compounds 122 and 
124 with near quantitative yields. 
 
Scheme 45: Synthesis of thiophene 122 and thiazole 124 
 
4.3.2 Synthesis of Thiazole 123 and Oxazole 125 
The synthesis of both thiazole 123 and oxazole 125 involved the cyclisation 
of intermediate 133, which was obtained through the coupling of 2-
aminoacetophenone 131 with ethylcholorooxoacetate 132 (Scheme 46). 
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Heating intermediate 133 in the presence of phosphoryl chloride lead to the 
formation of oxazole 135, whilst heating 133 in the presence of phosphorous 
pentasulfide lead to the formation of thiazole 134. [81, 82] Both the 
cyclization reactions had moderate yields of 34% and 46% respectively. 
Ester hydrolysis of both 134 and 135 lead to the formation of 123 and 125 in 
near quantitative yields.   
 
Scheme 46: Synthesis of thiazole 123 and oxazole 125 
4.3.3 Synthesis of Oxazole 126 
The synthetic strategy that was used to target oxazole 126 is summarised 
below (Scheme 47). [83] Firstly, benzoyl chloride 136 was coupled with 
amine 137 to give intermediate 138 with a moderate yield of 77%. The 
cyclisation of 138, which involved heating 138 in the presence of N-
bromosuccinimide (NBS) and K2CO3, was unsuccessful. LCMS and NMR 
analysis revealed a complex mixture and that there was no formation of 139. 
One possible reason for this was the thermal decomposition of intermediate 
138. The reaction was therefore repeated at room temperature (RT) and 
used recrystallized NBS. However, the same complex mixture was observed 
by LCMS analysis.   
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Scheme 47: Attempted synthesis of oxazole 139. The cyclisation of intermediate 138 was 
unsuccessful, which may have been caused by the decomposition of 138.  
It was hypothesised that if intermediate 138 was replaced with the 
unsaturated derivative 140 (Figure 51), then the cyclisation would be more 
favourable. 
 
Figure 51: Intermediate 140 was predicted to undergo the desired cyclisation reaction more 
readily than the saturated intermediate 138. 
Intermediate 140 was formed through the Pd(OAc)2 catalysed coupling of 
benzamide 141 with methyl acrylate 142 (Scheme 48). [84] This was 
followed by the cyclisation of 140 using [bis(trifluoroacetoxy)iodo]benzene 
(PIFA), which lead to the formation of 139 with a moderate yield of 53%. 
Finally, ester hydrolysis of 139 lead to the formation of the desired oxazole 
126 in near quantitative yield. 
Scheme 48: Synthesis of oxazole 126 
4.4 Biological evaluation of Heterocyclic Fragments 
Heterocycles 122-126 were biologically evaluated against TmPPase and 
their IC50 values were determined (Table 16). 
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22 ± 24 µM 
 
 
2025 ± 550 µM 
 
 




Table 16: Biological evaluation of heterocycles 121-126 against TmPPase.  
Thiazole 124 had an IC50 of 22 µM and was more potent than 123, which had 
an IC50 of 789 uM. A similar pattern was observed between oxazoles 126 
and 125. Oxazole 126 had the highest potency with an IC50 of 2025 µM, 
whilst 125 was not active at the concentrations tested. In addition, thiophene 
122 was not active at the concentrations tested. These results suggest that 
the presence of a heterocyclic nitrogen is essential for activity and the 
preferred position of this nitrogen is adjacent to the phenyl ring. When the 
nitrogen is in this position it could be close enough to an amino acid residue 
that it can partake in a hydrogen bonding interaction. Conversely, when the 
nitrogen is adjacent the carboxylic acid it is unable to partake in a hydrogen 
bonding interaction. This is the contrary to what was predicted by the docking 
studies, which predicted hydrogen bonding interactions between the 
heterocyclic nitrogen of 123 and 125 with Lys-664 and Lys-199 respectively. 
Whilst, the heterocyclic nitrogen of 124 and 126 were not predicted to make 
any interactions. 
Both thiazole 124 and oxazole 126 were more potent than isoxazole 121, 
which has an oxygen atom adjacent to the phenyl ring. It has been observed 
that heterocyclic oxygen atoms are poor HBAs, this therefore means that any 
hydrogen bonding interactions it partakes in are much weaker than those of 
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the corresponding nitrogen atoms of 124 and 126 and could account for the 
poor potency of 121.  
Comparing the IC50 values of thiazole 124 with oxazole 126 and 123 with 
125 suggests that thiazoles are preferred over oxazoles. There are a number 
of potential reasons for this. Firstly, the thiazole nitrogen is more basic than 
the oxazole nitrogen and a number of studies suggest that the thiazole 
nitrogen is a more effective HBA. [85, 86] Therefore, the thiazole nitrogen 
could be forming a stronger HB interaction with an amino acid residue of 
TmPPase. Finally, the thiazole ring has more aromatic character than the 
oxazole ring. This would be beneficial to the activity if the heterocycle was 
involved in a π-stacking interaction. [87] 
Overall, the results suggest that the heterocycles are not binding as was 
predicted by the docking studies. This means that they could be binding to a 
different part of the hydrolytic centre or they are binding to an allosteric site. 
Therefore, a co-crystal structure of 124 and TmPPase is needed before 
SPROUT can be used to expand the fragment. Work is currently ongoing to 
obtain this crystal structure. 
4.4.1 Biological Evaluation of Methyl Ester 130 
The methyl ester of 124 (compound 130, Table 17) was biologically 
evaluated against TmPPase and the IC50 value was determined and 








Table 17: Biological evaluation of methyl ester 130. The IC50 value was compared to that 
of the corresponding acid 124 
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It was found that methyl ester `130 was not active at the concentrations 
tested, suggesting that the carboxylic acid is essential for activity.  
4.5 Ligand Efficiencies of Active Fragments 
The ligand efficiency is defined as the binding affinity per heavy atom of a 
ligand that is binding to a particular protein. The determination of the ligand 
efficiency of a fragment is often used to determine if a fragment is worth 
further development. [88] 
The equation used to determine the ligand efficiency is shown below 
(Equation 1). [89] The closer the calculated ligand efficiency of a compound 
is to 1, the more efficiently that compound binds to the protein. Generally, if 
a compound has a calculated ligand efficiency of <0.2 it is considered poor, 
if it is between 0.2-0.4 it is considered moderate and if it is >0.4 it is 
considered good.  
𝐿𝐸 = 1.4(− log10 𝐼𝐶50)/𝑁 
Equation 1: The equation used to determine the ligand efficiency (LE) of a fragment. N = 
No. of heavy atoms. 
Highlighted below are the ligand efficiencies of the three active heterocylic 
fragments 123, 124 and 126 (Table 18). Unsurprisingly, 124 was found to 
have an excellent ligand efficiency of 0.47. This suggests that 124 is worth 






















Table 18: Calculated ligand efficiencies of 123, 124 and 126. LE was calculated using 
equation 1. 
4.6 Conclusions 
A small library of heterocyclic fragments were synthesised and biologically 
evaluated against TmPPase. These fragments were based on isoxazole 
121, which was identified by collaborators using vHTS. The results indicated 
that; the heterocycle, the presence of a hetrocyclic nitrogen and the position 
of the nitrogen are important for biological activity.  The most active fragment 
was thiazole 124 that had an IC50 of 22 µM (Figure 51), which also had an 
excellent ligand efficiency of 0.47. 
 
Figure 51: The most active fragment was thiazole 124. 
Each of the fragments were docked into the hydrolytic centre of TmPPase. 
Overall, the observed trends for the predicted docking scores and predicted 
docking poses did not follow the trends for the biological results. This 
suggests that the fragments are either binding to the hydrolytic centre in a 
different manner than was predicted by the docking models, or they are 
binding to an allosteric site. Therefore, SPROUT could not be used to 
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develop a second generation inhibitor. However, the excellent ligand 
efficiency of 124 suggests that it is worth exploring further. Therefore, work 
is currently ongoing to obtain a crystal structure of TmPPase with 124 bound. 

























Chapter 5 - Conclusions and Future Work 
The aim of this study was to identify small molecule inhibitors of a M-PPase 
using structure based drug design. Three approaches were employed to 
achieve this aim, which are evaluated below.  
5.1 Series 1 
The first approach involved the SPROUT design of putative inhibitor 10 
(Sections 2.1 and 2.2) (Figure 52). A number of synthetic challenges were 
encountered during the synthesis of 10, which were caused by the lability of 
the indole N-acyl bond (Schemes 2-4). Therefore, the nbutyl amide 34 was 
targeted instead (Figure 52). It was found that 34 was not active when 
biologically evaluated against TmPPase, this was likely caused by the bulky 
nature of the butyl group (Table 4).  
 
Figure 52: Putative inhibitor 10 was designed using SPROUT. The synthesis of 10 was 
unsuccessful due to the lability of the indole N-acyl bond. Due to the lack of synthetic 
accessibility of 10, butyl amide 34 was targeted and found not to be active against TmPPase. 
The poor potency and synthetic accessibility of 34 lead to the replacement 
of the indole moiety of 34 with a simple carboxamide, resulting in the 
identification of 47 (Section 2.7) (Figure 53). Whilst 47 was synthetically 
more accessible than 34, it also showed poor potency against TmPPase 
(Table 5). Examination of the predicted binding pose of 47 showed that the 
primary amide of 47 was predicted to coordinate to one of the Mg2+ ions of 
the hydrolytic centre (Section 2.9) (Figure 26). Therefore, the amide was 
replaced with a carboxylic acid (compound 52, Figure 53). It was 
hypothesised that the carboxylic acid would increase the strength of the 
coordination with Mg2+ ion, which in turn would lead to an increase in 
potency. The IC50 value of 52 was found to be 179 µM and is the first example 
-91- 
 
of an inhibitor of an M-PPase using SBDD (Table 6). Finally, SAR analysis 
of 52 supported the predicted binding pose as removal of key binding 
functionalities lead to decreases in activity (Table 7). Expansion of 52 using 
SPROUT failed to lead to an increase in potency, which may have been 
caused by the large size of the second generation compound 60 (Section 
2.13) (Table 9) (Figure 53). This observation will be used to guide future 
design. 
 
Figure 53: The simplified core 47 was inactive against TmPPase. Replacement of the amide 
of 47 with a carboxylic acid lead to the identification of 52, which had an IC50 of 179 µM 
against TmPPase and is the first inhibitor of a TmPPase designed using SBDD. SPROUT 
expansion of 52 lead to the identification of 60, which was less potent than 52. 
5.2 Series 2 
The second approach involved the SPROUT aided design of the novel 
sulfamide fragment 71 (Section 3.1) (Figure 54), which was designed to 
mimic phosphate within the hydrolytic centre of TmPPase. This fragment was 
found to have a moderate potency against TmPPase, with an IC50 value of 
1353 µM (Table 10). An efficient synthetic route towards 71 was also 
developed, involving a Buchwald-Hartwig coupling of the appropriate primary 
sulfamide with the appropriate aryl bromide (Scheme 34, Section 3.5). This 
route allowed the synthesis of a small library of sulfamide fragments 
(Scheme 35). The most potent fragment in this series was 107, which had 
an IC50 value of 989 µM (Table 11). This suggests that the presence of 





Figure 54: Sulfamide 71 was designed to mimic phosphate within the hydrolytic centre of 
TmPPase and it was found to have a moderate IC50 of 1353 µM. Fragment 107 was the 
most potent fragment in a series of sulfamide fragments, which may be due to the decreased 
pKa of the sulfamide moiety. 
Expansion of 71 using SPROUT lead to the identification of the second 
generation fragment 112 (Section 3.10) (Figure 55), which had an improved 
IC50 value of 716 µM (Table 12). The moderate potency of 112, its synthetic 
accessibility and the favourable predicted properties of the sulfamide 
functionality suggest that it is a suitable candidate for hit-to-lead progression. 
 
Figure 55: Expansion of the original fragment lead to the identification of 112, which was 
more potent than 71. 
5.3 Series 3 
Finally, a library of heterocyclic fragments were synthesised and biologically 
evaluated against TmPPase (Section 4.1-4.4). These fragments were based 
on the isoxazole fragment 121 (Figure 56), which was identified by 
collaborators during a vHTS campaign. Each of the fragments within the 
series, including isoxazole 121, was docked into the hydrolytic centre of 
TmPPase (Section 4.2). The docking poses and docking scores were similar 
for each of the fragments. However, the fragments had a wide variety of 
potencies when tested against TmPPase. The most active fragment was 
thiazole 124 (Figure 56)(Table 15). This fragment had an IC50 value of 22 
µM and had an excellent ligand efficiency. The biological results suggested 
that the fragments could be binding to the hydrolytic centre in a different 
manner to what was predicted by the docking studies, or they are binding to 
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an allosteric site. Due to the unknown binding mode of these fragments, 
SPROUT could not be used to guide further design. Therefore, work is 
currently ongoing to crystallise these fragments with TmPPase. However, 
thiazole 124 is a good candidate to take forward for further design due to its 
excellent activity and ligand efficiency. 
 
Figure 56: A number of heterocyclic fragments that were based on isoxazole 121 were 
synthesised and biologically evaluated against TmPPase. The most active fragment was 
thiazole 124. 
5.4 Overall Conclusions 
There are currently a number of problems associated with current treatments 
of parasitic infections, including resistance and negative side-effects. 
Therefore, research into new treatments and new drug targets is required. 
This thesis has presented three series’ of novel M-PPase inhibitors that are 
suitable candidates for hit-to-lead progression and could ultimately provide a 
good starting point for the development of the first anti-parasitic drug that 
targets a M-PPase. In addition, two of the series’ presented herein are the 
first examples of M-PPase inhibitors designed using SBDD and suggests 
that SBDD can be applied to the discovery of novel M-PPase inhibitors.  
5.5 Future Work for Series 1 
In the short term it is planned to get a better understanding of the SAR of 
compound 52. This will be achieved by exploring three different regions of 
52 (Figure 57). Firstly, the carboxylate of 52 will be substituted with different 
metal binding groups e.g hydroxamic acid. In addition, the effect of changing 
the substitution pattern of both aromatic rings will be explored. Finally, the 




Figure 57: Further SAR analysis of compound 52 is planned. Alternative metal binding 
groups, shown in red, will be explored. In addition, SAR of the glycine moiety will also be 
explored, shown in blue. Finally, differing substitution patterns of both aromatic rings 
(circled) will also be explored. 
It has been widely reported that amides derived from anilines are 
metabolically labile. Therefore, the aromatic amide of 52 (highlighted below, 
Figure 58) will need to be replaced with a more metabolically stable group. 
One potential candidate is a sulfamide group (compound 141), which has 
been shown to be metabolically stable. 
 
Figure 58: The metabolically labile amide of 52 will be replaced with a sulfamide (compound 
141), with the aim of making a more metabolically stable compound 
The longer term goal is to improve the potency of 52. To achieve this further 
cycles of SPROUT aided design will be used. As discussed above, large 
expansions are not tolerated so the best approach will be to make smaller 
sequential expansions. It is hoped that this approach will eventually lead to 






5.6 Future Work of Series 2 
One of the short term aims of this series is to synthesis sulfamide 115 using 
the modified synthetic route discussed in Section 3.13 (Figure 59). It is 
hypothesised that this fragment will be more potent than the parent fragment 
112 due to the decreased pKa of the sulfamide moiety.  
 
Figure 59: Sulfamide 115 will be targeted. It is hypothesised that the decreased pKa of the 
sulfamide moiety will lead to an increase in potency. 
An additional aim is to further explore the SAR of 112 (Figure 60). This will 
include; exploring the effect of changing the substitution pattern of both the 
aromatic rings; changing the size and type of aromatic rings and exploring 
other metal binding moieties in place of the sulfamide (such as urea). The 
use of alternative electron withdrawing groups that decrease the pKa of the 
sulfamide moiety will also be explored. One example is CF3, which is a 
strongly electron withdrawing group that doesn’t have the toxicity associated 
with NO2. 
  
Figure 60: SAR analysis of 112 will involve exploring other metal binding groups in place of 
sulfamide, these are highlighted in red. Electron withdrawing groups on the benzylamine 
moiety will also be explored, these are highlighted in blue. Finally, different aromatic groups 
and substitution patterns will be explored 
In the longer term further cycles of SPROUT aided design will occur, with the 
aim of increasing the potency of fragment 112. The designed compounds will 
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continue to be synthesised using the synthetic strategy discussed above. It 
is hoped that this will allow the quick progression of this series and will lead 
to the identification of a more potent inhibitor. 
5.6 Future Work of Series 3 
Work is currently ongoing to obtain a crystal structure of TmPPase bound 
with thiazole 124 (Figure 61). This will confirm the binding site of 124, which 
will mean that SPROUT could then be used to expand 124 to further increase 
potency. Due to the simplistic nature of 124 and its synthetic accessibility, 
further derivatives can be easily accessed. 
 
Figure 61: Work is ongoing to obtain a crystal structure of 124 bound to TmPPase. This will 
















Chapter 6 - Experimental Section 
6.1 Experimental for High-Throughput TmPPase activity 
assay [90] 
6.1.1 Preparation of Solutions 
Solution A: Ascorbic acid (0.3 g, 1.70 mmol) was dissolved in ice cold 0.5 M 
HCl (10 mL) and the solution was kept at 0 °C. Solution B: Ammonium 
heptamolybdate (70 mg, 0.06 mmol) was dissolved in ice cold, fresh double 
distilled water (1 mL) and the solution was kept at 0 °C. Preparation of 
Solution C: To 10 mL of solution A was added solution B (1 mL).  
Preparation of sodium arsenite solution: Sodium arsenite (5 g, 38.49 mmol), 
trisodium citrate dihydrate (5 g, 17.00 mmol) and ice cold acetic acid (5 mL, 
87.43 mmol) was dissolved in water (245 mL).  
Preparation of RX mixture: To a solution of water (280 mL) was added 1M 
Tris-HCl pH 8.0 (300 mL), 40 mM aqueous MgCl2 (300 mL), 1M aqueous KCl 
(500 mL) and 1M aqueous NaCl (100mL).  
Preparation of TmPPase Solution: To a solution of 20% DDM (22.5 µL) was 
added 30 mg mL-1 soybean lecithin (40 µL). The mixture was then heated to 
55 °C for 15 min before being cooled to ambient temperature. Buffer (36.5 
µL) (20 mM MES pH 6, 3.5% glycerol, 2 mM DTT, 0.5% NM) was added and 
the resultant solution was stirred for 5 min before 13 mg mL-1 TmPPase (1.5 
µL) was added. 20 µL of the resulting solution was dissolved in the previously 
prepared RX mixture (1480 µL) to produce the desired TmPPase solution. 
Preparation of Compound Solution: A 25 nM stock solution of each 
compound in DMSO was prepared before being diluted with water to various 
concentrations 
6.1.2 Assay 
200 µL tube strips (8 tubes per strip) were used for the assay. To each tube 
was added 25 µL of compound solution followed by 15 µL of TmPPase 
solution. The tube strips were then sealed and incubated at 71 °C for 5 min. 
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Following this, 2 mM Na2PPi solution (10 µL) was added to each tube and 
the tubes were resealed and incubated at 71 °C for a further 5 min. The tubes 
were then cooled to 0 °C for a period of 10 mins (after 8 min the tubes were 
centrifuged and any water drops under the seal were decanted off). Solution 
C (60 µL) was then added to each tube and the tubes were again cooled to 
0 °C for 10 min. Sodium arsenite solution (90 µL) was then added to each 
tube and the tubes were stored at ambient temperature for 1 h. Each tube 
was then emptied into a clear, PS Micro Plate 96 Well and the absorbance 
was measured at 860 nm using a MultiSkan Go. 
6.2 Computational Methods 
All computational aspects of this research was carried out on a LINUX 
computer using the CentOS operating system. 
6.2.1 In silico Docking Using Glide 
The Glide docking programme within the Maestro suite was used for the 
docking studies mentioned throughout this work. All docking procedures 
used the resting-state crystal structure of TmPPase (PDB: 4AV3), which was 
obtained from the RSCB PDB databank. All compounds and ligands were 
energy minimised using the ligand preparation tool of Maestro prior to 
docking. This used the OPLS3 force field and charges were assigned to 
ionisable groups using a pH range of 5.0-9.0. 
The crystal structure of TmPPase was prepared using the protein 
preparation tool within Maestro, which included the assignment of 
protonation and deprotonation sites of amino acid residues at a pH of 7.4 
and removal of water molecules. On completion, all recommended changes 
to the crystal structure were accepted. The prepared protein was then energy 
minimised using the OPLS3 force field. This was followed by the generation 
of a Glide grid, which was a 10x10x10 box around the hydrolytic centre of 
the TmPPase crystal structure. The centroid of this box was the two Mg2+ 
ions of the hydrolytic centre. 
The minimised compounds were then docked into the previously defined 
Glide grid using the Glide docking programme of Maestro, the standard 
-99- 
 
precision settings were used. For each round of docking 5 poses were 
generated and each generated pose was subjected to post-docking 
minimisation. Each of the docking poses were then inspected by eye. 
The resultant docking poses were then loaded into PyMol to visualise the 
predicted contacts. A screen capture of the docking poses was taken from 
PyMol and used for the docking images reported in this thesis. TmPPase 
was shown as a surface and the ligands were shown as sticks. 
6.2.2 SPROUT 
Prior to carrying out SPROUT design, the TmPPase crystal structure that 
was used (PDB: 4AV3) was minimised within Maestro using the methodology 
described above. The minimised crystal structure was exported as a PDB 
file and imported into SPROUT. 
The PDB crystal structure was initially loaded into CANGAROO and the 
receptor and cavity site were defined using a 10Å cut of the hydrolytic centre. 
This cut was made by selecting the two Mg2+ ions of the hydrolytic centre 
and selecting the residues within a 10Å radius. The hydrogen bond acceptor 
and donor sites, along with any hydrophobic sites, were then explored using 
HIPPO. The ELEFANT module was then used to dock fragments onto these 
sites using fragments within SPROUTs built-in fragment library. The first 
round of design only involved docking to two sites. These fragments were 
then connected using SPIDER and used the spacer templates within an in-
built library to generate a number of fragments. The fragments were scored 
and the top 10% were pruned using the ALLIGATOR module. The process 
was repeated and with each cycle of design one further binding site was 
chosen to expand to.  
At the end of the design process the top 10 scoring ligands were selected for 
further analysis. These selected ligands were docked into the hydrolytic 
centre of TmPPase using Maestro and the methodology described above to 
improve the confidence of the proposed docking pose predicted by 
SPROUT. The re-docked compounds were then visually inspected and the 
most synthetically accessible compounds with the highest docking scores 
were chosen to synthesise. 
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6.3 General Experimental Information and Instrumentation 
All reactions, unless otherwise stated, were carried out under an inert 
nitrogen atmosphere with anhydrous solvents and using a magnetic stirrer 
with a stirrer-hotplate. All reagents were obtained from commercial sources 
and were used without further purification. Anhydrous solvents were 
obtained from a PureSolv MD6 solvent purifications system. Thin layer 
chromatography (TLC) was performed on aluminium pre-coated silica gel 
plates (254 µm) supplied by Merck chemicals and visualised by UV-light (254 
nm). Solvents were removed under reduced pressure using a Buchi rotary 
evaporator and a high vacuum pump was used for the removal of residual 
solvent. Silica flash chromatography was preformed using Geduran silica gel 
60. Reverse phase column chromatography was performed on a Biotage® 
Isolera Four with a Biotage® Ultra C18 12 g column (mobile phase: 0.1% 
formic acid in water + 0.1% formic acid in acetonitrile). Normal phase 
automated column chromatography was carried out using a Biotage® Isolera 
Four with Thomson pre-packed silica cartridges (various sizes) at various 
flow rates. 
LCMS analysis was performed on a Bruker Daltronics instrument running on 
a gradient of increasing acetonitrile in water containing 0.1% formic acid on 
a 50 × 20 mm C18 reverse phase column. Runs were conducted using a flow 
rate of 1 mL per min and samples dissolved in MeOH. High-resolution mass 
spectrometry was carried out using a Bruker MaXis Impact Time of Flight 
spectrometer using electron spray ionisation, with samples dissolved in 
MeOH. The reported masses correct to four decimal places.  Unless stated 
otherwise, Proton and Carbon NMR spectra were recorded at 400 and 500 
MHz (at room temperature) on a Bruker Advance 400 or 500 Fourier 
Transform spectrometer. Samples were dissolved in CDCl3, DMSO-d6 or 
CD3OD. Chemical shifts are reported in ppm. Multiplicities are reported with 
coupling constants and are given to the nearest 0.1 Hz. The following 
abbreviations were used when displaying NMR data; s = singlet, d = doublet, 
t = triplet, q = quartet, sxt = sextet, dd = doublet of doublets, ddd = doublets 
of doublets of doublets, m = multiplet and app = apparent. Where needed, 
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two-dimensional correlation spectroscopy (2D-COSY), heteronuclear single 
quantum coherence spectroscopy (HSQC) and distortionless enhancement 
by polarisation transfer (DEPT) were used to aid assignment. IR spectra 
were recorded in solid phase on a Bruker Alpha Platinum ATR FTIR 
spectrometer with vibrational frequencies given in cm-1. Analytical high 
performance liquid chromatography (HPLC) was conducted on an Aglient 
1290 infinity series equipped with a UV detector and a Hyperclone C18 
reverse phase column eluting with an increasing MeCN-Water gradient and 
0.1% TFA over a run time of 5 minutes and a flow rate of 0.5 mL min-1. HPLC 
analysis was conducted on compounds that were biologically evaluated only 
and samples were dissolved in MeOH. Melting points were measured on a 
Stuart SMP30 for crystalline solids only. 
6.3.1 Compound Numbering for NMR 
Listed below (Table 19) are the numbering systems used for the NMR 













6.3.1.1 Assignment of NMR Spectra 
The NMR Spectra of each compound reported in this thesis were assigned 
using the methodology described below, using compound 34 as an example. 
Firstly, an easily identifiable signal was chosen to start the assignment. In  
the case of 34 this signal was an apparent singlet at 8.16 ppm (see appendix 
for spectrum), which was assigned to 2’’-H (Figure 62). The COSY spectrum  
of 34 showed that the signal for 2”-H coupled to two protons. One of these 
protons had a signal at 7.93 ppm, whilst the other had a signal at 7.52 ppm. 
Therefore, the signal at 7.93 ppm was assigned to 4’’-H as it was ortho- to a 
carbonyl and would be the most de-shielded. Thus, the signal at 7.52 ppm 
was assigned to 6’’-H. In addition, both the signals at 7.93 ppm and 7.52 ppm 
were found to couple to a triplet at 7.56 ppm that was assigned to 5’’-H. One 
other triplet was observed at 7.33 ppm, which was assigned to 5-H of the 
indole. This was found to couple to signals at 7.78 ppm and 7.40 ppm, which 
were assigned to 6-H and 4-H respectively. 6-H was the most de-shielded 
as it was ortho- to a carbonyl. The two final aromatic protons were assigned 
as 2-H (at 7.46 ppm) and 3-H (at 6.78 ppm), these were simple to assign as 
2-H is next to the electron withdrawing N of the indole. The aliphatic protons 
were also assigned using the COSY spectrum. The CH2 of the Gly only 
coupled to one of the N-H signals, whilst all of the protons of the butyl group 
coupled with the aliphatic protons they were adjacent to. 
 
Figure 62: The numbering system used in the reporting of the NMR spectra of 34. 
The 1H NMR spectral assignments were then used to assign the 13C 
spectrum using HSQC and DEPT experiments. 




6.3.2 Synthesis of Series One Compounds 
Synthesis of methyl 1-[(3-nitrophenyl)methyl]-1H-Indole-7-carboxylate 
(14) 
To a stirred solution of methyl indole-7-
carboxylate (1.00 g, 5.70 mmol) in THF (30 mL) 
was added NaH (0.342 g, 14.25 mmol) portion 
wise at 0 ºC. The reaction mixture was then 
stirred at 0 ºC for 15 mins and then at rt for a further 15 mins. 3-Nitrobenzoyl 
chloride (1.58 g, 8.55 mmol) was then added and the reaction mixture was 
then stirred at RT overnight. The reaction mixture was then quenched with 
water (20 ml) and extracted with EtOAc (3 x 25 mL). The organic layers were 
then combined, dried with MgSO4, filtered and the solvent removed to yield 
a crude yellow oil. The yellow oil was purified using column chromatography 
(20% EtOAc-Petroleum Ether) to afford the title compound as a colourless 
solid (1.33 g, 72%). Rf 0.71 (30% EtOAc-Petroleum Ether). δH (500 MHz, 
DMSO) 8.59 (app d, 1H, J = 8.3 Hz, 6’’-H), 8.56 (app s, 1H, 2’’-H), 8.30 (app 
d, 1H, J = 8.3 Hz, 4’’-H), 7.94-7.92 (m, 2H, 6-H and 5’’-H), 7.65 (app d, 1H, 
J = 7.0 Hz,  4-H), 7.60 (app d, 1H, J = 3.6 Hz, 2-H), 7.46 (app t, 1H, J = 7.0 
Hz,  5-H), 6.90 (app d, 1H, J = 3.6 Hz, 3-H), 3.69 (s, 3H, CH3). δC (500 MHz, 
DMSO) 166.8 (C=O), 166.3 (C=O), 148.0 (1’’-C), 135.8 (3’’-C), 135.7 (4’’-C), 
134.0 (7’-C), 132.2 (3’-C), 132.0 (5’’-C), 130.9 (2-C) 130.0 (6’’-C), 127.8 (6-
C), 125.0 (4-C), 124.3 (5-C), 123.6 (2’’-C), 120.6 (7-C), 109.6 (3-C), 52.4 
(OCH3). νmax/cm-1 (ATR); 3084, 1720, 1693, 1532, 1422, 1277. m/z (ESI) 









Synthesis of methyl 1-[(3-aminophenyl)methyl]-1H-Indole-7-
carboxylate (15) 
To a stirred solution of SnCl2 (0.235 g, 1.24 
mmol) in EtOH was added concentrated HCl 
(4.5 mL) at RT. The resultant cloudy solution 
was then heated to 65 ºC and stirred for 15 
mins. To this solution was added methyl 1-[(3-nitrophenyl)methyl]-1H-Indole-
7-carboxylate 14 (0.100 g, 0.31 mmol). The reaction mixture was then stirred 
at 65 ºC for 45 mins and then cooled to rt. The reaction mixture was then 
neutralised using 2M NaOH and the resultant solution was extracted with 
EtOAc (3 x 15 mL). The combined organic layers were then washed with 
brine (30 mL), dried over MgSO4, filtered and the solvent removed to give a 
yellow residue. The residue was taken up in EtOAc (20 mL) and washed with 
a further amount of brine (20 mL). The organic layer was again dried over 
MgSO4, filtered and the solvent removed to give the title compound as a 
yellow solid. (0.074 g, 81%) Rf 0.58 (30% EtOAc-Petroleum Ether). δH (500 
MHz, DMSO) 7.90 (app d, 1H, J = 7.8 Hz,  6-H), 7.59 (app d, 1H, J = 7.8 Hz, 
4-H) 7.48 (app d, 1H, J = 3.6 Hz,  2-H), 7.39 (m, 1H, 5-H), 7.25 (m, 1H, 5’’-
H), 6.95 (s, 1H, 2’’-H), 6.92-6.90 (m, 2H, 4’’-H and 6’’-H), 6.80 (app d, 1H, J 
= 3.6 Hz,  3-H), 5.53 (s, 3H, CH3). δC (500 MHz, DMSO) 169.3 (C=O), 167.4 
(C=O), 149.7 (1’’-C), 133.5 (7’-C),132.5 (3’’-C), 132.4 (3’-C), 130.7 (2-C), 
129.9 (5’’-C), 125.2 (6-C), 125.0 (4-C), 123.5 (5-C), 121.0 (7-C), 119.1 (6’’-
C), 117.4 (4’’-C), 114.9 (2’’-C), 107.5 (3-C), 52.1 (CH3). νmax/cm-1 (ATR); 
3464, 3358, 1707, 1693, 1421, 1339. m/z (ESI) (100%, MH+); (Found MNa+, 








Synthesis of methyl 1-{3-[2-({[(9H-fluoren-9-
yl)methoxy]carbonyl}amino)acetamido]benzoyl}-1H-indole-7-
carboxylate (16) 
To a stirred solution of methyl 1-[(3- 
aminophenyl)methyl ] – 1 H - Indole-7-carboxylate 
15 (0.500 g, 1.70 mmol) in DCM (15 mL) was 
added; Fmoc-Gly-OH (0.607 g, 2.04 mmol), 
EDC.HCl (0.391 g, 7.04 mmol) and DMAP (0.025 
g, 0.2 mmol) at RT. The reaction mixture was then 
stirred for 12 hours at RT and then diluted with 
DCM (15 mL). The resultant solution was then washed with water (15 mL) 
and brine (15 mL), dried over MgSO4, filtered and the solvent removed to 
give a crude yellow oil. The crude product was then purified using column 
chromatography (20% EtOAc-Petroleum Ether) to give the title compound as 
a crystalline colourless solid. (0.618 g, 63%) m.p 126-128 ºC. Rf 0.34 (2% 
MeOH-DCM).  δH (500 MHz, DMSO) 10.31 (s, 1H, NH amide) 8.21 (s, 1H, 
2’’-H), 7.88-7.95 (m, 4H, 3-H Fmoc, 6-H and 4’’-H), 7.74 (app d, 2H, J = 7.4 
Hz, 6-H Fmoc), 7.67 (app t, 1H, J = 6.1 Hz, Fmoc-NH), 7.61 (m, 2H, 4-H and 
6’’-H), 7.55 (m, 1H, 5’’-H), 7.52, (d, 1H, J = 3.6 Hz, 2-H) 7.42 (m, 3H, 5-H and 
5-H Fmoc), 7.32 (dd, 2H, J = 10.7, 4.2, 4-H Fmoc), 6.84, (d, 1H, J = 3.6 Hz, 
3-H), 5.52 (s, 3H, OCH3), 4.32 (m, 2H, CH2 Fmoc), 4.25 (m, 1H, CH Fmoc), 
3.84 (d, 2H, J = 6.1Hz, CH2 Glycine). δC (500 MHz, DMSO) 169.2 (C=O), 
168.4 (C=O), 166.9 (C=O), 156.4 (C=O), 143.8 (1-C Fmoc), 140.7 (2-C 
Fmoc), 139.4 (1’’-C), 133.0 (7’-C), 132.1 (3’’-C), 132.0 (3’-C), 130.1 (2-C), 
129.6 (4’’-C), 127.6 (4-C Fmoc), 127.0 (5-C Fmoc), 125.2 (6-C Fmoc), 124.9 
(6-C), 124.7 (4-C), 124.5 (5’’-C), 123.7 (5-C), 123.2 (6’’-C), 121.3 (7-C) 120.4 
(2’’-C ), 120.1 (4-C Fmoc), 107.4 (3-C), 65.7 (CH2 Fmoc), 51.7 (CH3), 46.5 
(CH Fmoc), 44.0 (CH2 Gly). νmax/cm-1 (ATR); 1686, 1534, 1433, 1417, 1318, 






Synthesis of benzyl indole-7-carboxylate (21) 
To a stirred solution of indole-7-carboxylic acid (0.300 
g, 1.86 mmol) in DCM (15 mL) was added; benzyl 
alcohol (0.39 mL, 3.72mmol), EDC.HCl (0.713g, 3.72 
mmol) and DMAP (0.454 g, 3.72 mmol) at RT. The 
reaction mixture was then stirred for 12 hours at RT. 
The reaction mixture was then diluted with DCM (15 
mL). The resultant solution was then washed with water (3 x 15 mL) and 
brine (15 mL). The organic layer was then dried over MgSO4, filtered and the 
solvent removed to give a crude yellow oil. The crude product was then 
purified using column chromatography (2% MeOH- DCM) to give the title 
compound as a colourless oil (0.317g, 68%). Rf 0.92 (2% MeOH-DCM). δH 
(500 MHz, DMSO) 9.87 (bs, 1H, NH), 7.89 (app d, 1H, J = 7.60 Hz, 6-H), 
7.83-7.81 (dd, 1H, J = 7.60 Hz, 4-H), 7.51 (app d, 2H, J = 7.36 Hz, 2’’’-H), 
7.44-7.41 (m, 3H, 2-H and 3’’’-H), 7.36-7.34 (m, 1H, 4’’’-H), 7.13 (app t, 1H, 
J = 7.60 Hz, 5-H), 6.59-6.58 (m, 1H, 3-H), 5.47 (s, 2H, OCH2). δC (500 MHz, 
DMSO) 166.4 (C=O), 137.1 (7’-C), 136.6 (1’’’-C), 130.0 (3’-C), 129.0 (3’’’-C), 
128.5 (4’’’-C), 128.4 (2’’’-C), 127.6 (2-C), 126.8 (6-C), 124.2 (4-C), 119.0 (5-
C), 112.8 (7-C), 102.2 (3-C), 66.1 (OCH2) νmax/cm-1 (ATR); 3416, 1689, 1586, 
1486, 1338, 1266 m/z (ESI) (100%, MH+); (Found MH+, 252.1022. 
C16H13NO2 requires MH+, 252.1019). 
Synthesis of benzyl 1-[(3-nitrophenyl)methyl]-1H-indole-7-carboxylate 
(22) 
To a stirred solution of benzyl indole-7-
carboxylate 21 (0.300g, 1.19 mmol) in THF 
(10 mL) was added NaH (0.071 g, 2.98 
mmol) portion wise at 0 ºC. The reaction 
mixture was then stirred at 0ºC for 15 
minutes. The reaction mixture was then 
warmed to RT and stirred at that temperature for 15 minutes. 3-nitrobenzoyl 
chloride (0.331 g, 1.79 mmol) was then added and the resultant solution was 
then stirred at RT for 18 hours. The reaction mixture was then quenched with 
water (10 mL) and the resultant solution was extracted with EtOAc (3 x 25 
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mL). The organic layers were then combined, washed with brine (20 mL), 
dried over MgSO4, filtered and the solvent removed to yield a crude yellow 
oil. The crude product was purified by column chromatography (20% EtOAc-
Petroleum ether) to afford the title compound as a crystalline yellow solid 
(0.390 g, 81%). Rf 0.69 (20% EtOAc-Petroleum ether). m.p 83.8-84.5ºC. δH 
(500 MHz, DMSO) 8.56 (ddd, 1H, J = 8.3, 2.2, 0.9 Hz, 6’’-H), 8.25 (app s, 
1H, 2’’-H), 8.15 (dd, 1H, J =8.3, 2.2 Hz, 4’’-H) 7.94 (dd, 1H, J = 7.7, 1.0 Hz, 
6-H), 7.86 (app t, 1H, J = 8.3 Hz, 5’’-H), 7.71 (m, 1H, 4-H), 7.52 (app d, 1H, 
J = 3.7 Hz, 2-H), 7.46 (app t, 1H, J = 7.7 Hz, 5-H), 7.06-7.17 (m, 5H, 2’’’-H, 
3’’’-H and 4’’’-H), 6.86 (app d, 1H, J = 3.7 Hz, 3-H ), 5.12 (s, 2H, OCH2). δC 
(500 MHz, DMSO) 166.8 (C=O), 166.8 (C=O), 148.18 (1’’-C) 136.4 (3’’-C), 
135.5 (7’-C), 134.3 (4’’-C), 132.8 (1’’’-C) 132.4 (3’-C), 131.3 (5’’-C), 130.5 (2-
C), 129.0 (2’’’-C), 128.5 (3’’’-C), 128.4 (4’’’-C), 128.1 (6’’-C), 125.8 (4-C), 
125.6 (6-C), 124.7 (2’’-C), 124.3 (5-C), 121.04 (7-C), 108.7 (3-C), 67.1 
(OCH2). νmax/cm-1 (ATR); 3113, 1710, 1597, 1422, 1315, 1276. m/z (ESI) 
(100%, MNa+); (Found MNa+, 423.0984. C23H16N2O5 requires MNa+, 
423.0957).  
Synthesis of benzyl 1-[(3-aminophenyl)methyl]-1H-indole-7-
carboxylate (23) 
To a solution of SnCl2 (0.659 g, 3.48 
mmol) in EtOH (23 mL) was added 
concentrated HCl (4.5 mL). The resultant 
solution was then heated to 65ºC for 15 
mins. To this solution was added benzyl 
1-[(3-nitrophenyl)methyl]-1H-indole-7-
carboxylate 22 (0.348 g, 0.87 mmol). The 
reaction mixture was then stirred at 65 ºC for 45 mins and then cooled to rt. 
The solution was then neutralised using 4M NaOH. The resultant solution 
was extracted with EtOAc (3 x 15 mL). The organic layers were then 
combined, washed with brine (20 mL), dried over MgSO4, filtered and the 
solvent removed to give a yellow residue. The residue was taken up in EtOAc 
(15 mL) and was washed with a further amount of brine (20 mL). The organic 
layer was again dried over MgSO4, filtered and the solvent removed to afford 
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the title compound as a yellow oil (0.189 g, 68%). Rf 0.54 (50% EtOAc-Petrol) 
δH (500 MHz, DMSO) 7.91 (dd, 1H, J = 7.8, 1.1 Hz 6-H), 7.63 (dd, 1H, J = 
7.6, 1.1 Hz,4-H), 7.51 (app d, 1H, J = 3.7 Hz, 2-H), 7.41 (m, 1H, 5-H) 7.22-
7.40 (m, 6H, 2’’’-H, 3’’’-H, 4’’’-H and 5’’-H) 7.06 (app s, 1H, 2’’-H) 6.91 (m, 
2H, 4’’-H and 6’’-H)  6.82 (app d, 1H, J = 3.7 Hz, 3-H), 5.53 (bs, 2H, NH2), 
5.14 (s, 2H, OCH2). δC (500 MHz, DMSO) 169.2 (C=O), 166.9 (C=O), 146.7 
(1’’-C), 135.8 (7’-C), 133.5 (3’’-C), 132.5 (1’’’-C) 132.3 (3’-C) 130.7 (2-C), 
129.84 (5’’-C), 128.9 (2’’’-C), 128.7 (3’’’-C), 128.5 (4’’’-C), 125.3 (6-C), 125.2 
(4-C), 123.6 (5-C), 121.1 (7-C), 119.1 (6’’-C), 117.6 (4’’-C), 115.1 (2’’-C), 
107.6 (3-C), 66.8 (OCH2). νmax/cm-1 (ATR); 3417, 3033, 1692, 1336, 
1316,1272. m/z (ESI) (100%, MH+); (Found MH+, 371.1399. C23H18N2O3 
requires MH+, 371.1390). 
Synthesis of benzyl 1-[3-(2-{tert-butoxy)carbonyl] 
amino}acetamido)benzoyl]-1H-indole-7-carboxylate (24) 
To a stirred solution of benzyl 1-[(3-
aminophenyl)methyl]-1H-indole-7-carboxylate 
23 (0.725 g, 1.95 mmol) in DCM (20 mL) was 
added; Boc-Gly-OH (0.410 g, 2.34 mmol), 
EDC.HCl (0.449 g, 2.34 mmol) and DMAP 
(0.030g, 0.2 mmol) at RT. The reaction 
mixture was them stirred at RT for 12 hours. 
The reaction mixture was then diluted with DCM (20 mL). The resultant 
solution was then washed with water (2 x 20 mL) and brine (2 x 20mL). The 
organic layer was then dried over MgSO4, filtered and the solvent removed 
to give a crude colourless solid. The crude solid was purified by column 
chromatography (2% MeOH-DCM) to give the title compound as yellow solid 
(1.03 g, 73%). Rf 0.41 (2% MeOH-DCM). δH (500 MHz, DMSO), 10.21 (s, 
1H, amide NH), 8.10 (app s, 1H, 2’’-H), 7.91-7.93 (m, 2H, 6-H and 4’’-H), 
7.65 (app d, 1H, J = 7.8 Hz, 4-H), 7.54-7.52 (m, 1H, 5’’-H), 7.49 (d, 1H, J = 
3.8 Hz, 2-H), 7.47-7.44 (m, 1H, 6’’-H), 7.43 (app t, 1H, J = 7.8 Hz, 5-H), 7.21-
7.22 (m, 1H, 4’’’-H), 7.17-7.18 (m, 4H, 2’’’-H and 3’’’-H), 7.10 (t, 1H, J = 6.1 
Hz, Gly-NH), 6.83 (d, 1H, J = 3.8 Hz, 3-H), 5.11 (s, 2H, OCH2), 3.75 (d, 2H, 
J = 6.1 Hz, Gly-CH2), 1.40 (s, 9H, Boc-CH3). δC (500 MHz, DMSO) 169.2 
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(C=O), 168.5 (C=O), 166.9 (C=O), 156.4 (C=O), 139.9 (1’’-C), 135.6 (7’-C), 
133.3 (3’’-C), 132.5 (1’’’-C), 132.4 (3’-C), 130.6 (5’’-C), 130.0 (2-C), 128.8 
(2’’’-C), 128.7 (3’’’-C), 128.5 (4’’’-C), 125.4 (6-C and 4’’-C), 125.0 (4-C), 124.1 
(6’’-C), 123.9 (5-C), 121.0 (7-C), 120.6 (2’’-C), 108.0 (3-C), 78.6 (C-Boc), 
66.9 (OCH2), 44.3 (Gly-CH2), 28.7 (Boc-CH3) vmax / cm-1 (solid): 3354, 1709, 
1687, 1590, 1533, 1271; m/z (ESI) (100%, MNa+); (Found MH+, 550.1952. 




To a stirred solution of benzyl 1-[3-(2-{tert-
butoxy)carbonyl] amino}acetamido)benzoyl]-1H-
indole-7-carboxylate 24 (0.527 g, 1.00 mmol) in 
MeOH (20 mL) was added 10% Pd/C (0.150 g). 
The resultant slurry was then stirred at RT under 
an atmosphere of hydrogen (1 atmosphere) for 12 
mins. The reaction mixture was then diluted with 
MeOH (20 mL) and the resultant solution was filtered through Celite. The 
filtrate was collected and the solvent was removed to give a crude purple 
solid. The crude solid was then purified by reverse phase ACC (gradient 0-
60% MeCN-H2O in 0.1 % formic acid) to give the title compound as a 
colourless crystalline solid (0.179 g, 41%). Rf 0.24 (2% MeOH-DCM). m.p 
187-191 ºC. δH (500 MHz, DMSO), 10.35 (s, 1H, amide NH), 8.18 (app s, 
1H, 2’’-H), 7.94 (app d, 1H, J = 8.0 Hz, 4’’-H), 7.89 (dd, 1H, J = 7.8 and 0.9 
Hz, 6-H), 7.64 (dd, 1H, J = 7.8 Hz and 0.9 Hz, 4-H) 7.56 (app t, 1H, J = 8.0 
Hz, 5’’-H), 7.50 (m, 2H, 6’’-H and 2-H), 7.40 (app t, 1H, J = 7.8 Hz, 5-H), 7.09 
(t, 1H, J = 6.1 Hz, Gly N-H), 6.81 (d, 1H, J = 3.63 Hz, 3-H), 3.74 (d, 2H, J = 
6.1 Hz, Gly-CH2), 1.39 (s, 9H, Boc-CH3). δC (500 MHz, DMSO)169.2 (C=O), 
168.4 (C=O), 168.2 (C=O), 156.4 (C=O), 139.4 (1’’-C), 133.7 (7’-C), 132.9 
(3’’-C), 132.4 (3’-C), 130.8 (5’’-C), 130.4 (2-C), 125.2 (4-C), 125.0 (6’’-C), 
124.9 (6-C), 124.1 (4’’-C), 123.4 (5-C), 122.0 (7-C), 120.6 (2’’-C), 107.5 (3-
C), 78.6 (Boc-C), 44.3 (Gly-CH2), 28.6 (Boc-CH3). vmax / cm-1 (solid): 3344, 
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1683, 1645, 1542, 1477, 1368, 1215. m/z (ESI) (100%, M-H); (Found M-H, 
436.1513. C23H23N3O6 requires M-H, 436.1509). 
Synthesis of 1-[3-(2-{[(tert-
butoxy)carbonyl]amino}acetamido)benzoyl]-2,3-dihydro-1H-indole-7-
carboxylic acid (28) 
To a stirred solution of benzyl 1-[3-(2-{tert-
butoxy)carbonyl] amino}acetamido)benzoyl]-1H-
indole-7-carboxylate 24 (0.549 g, 1.00 mmol) in 
MeOH (20 mL) was added 10% Pd/C (0.150 g). The 
resultant slurry was then stirred at RT under an 
atmosphere of hydrogen (1 atmosphere) for 12 
hours. A further amount of 10% Pd/C (0.050 g) was 
then added and the reaction mixture was stirred under an atmosphere of 
hydrogen (1 atmosphere) for a further 2 hours. The reaction mixture was 
then filtered through Celite, the filtrate was collected and the solvent removed 
to give a crude yellow solid. The crude solid was then purified by reverse 
phase ACC (gradient 0-30% MeCN-H2O in 0.1 % formic acid) to give the title 
compound as a colourless solid (0.404 g, 92%). Rf 0.20 (2% MeOH-DCM). 
δH (500 MHz, DMSO), 10.15 (s, 1H, amide N-H), 7.94 (app s, 1H, 2’’-H), 7.78 
(app d, 1H, J = 8.1 Hz, 4’’-H), 7.47-7.42 (m, 3H, 6-H, 6’’-H and 5’’-H), 7.34 
(app d, 1H, J = 7.5 Hz, 4-H), 7.15 (app t, 1H, J = 7.5 Hz, 5-H), 7.09 (t, 1H, J 
= 6.0 Hz, Gly Boc-NH), 4.08 (t, 2H, J = 7.8 Hz, 2-H), 3.74 (d, 2H, J = 6.0 Hz, 
Gly-CH2), 3.07 (t, 2H, J = 7.8 Hz, 3-H), 1.40 (s, 9H, Boc-CH3). Exchangeable 
proton for acid not observed.  δC (500 MHz, DMSO) 169.3 (C=O), 169.1 
(C=O), 168.1 (C=O), 156.5 (C=O), 141.0 (7’-C), 139.5 (1’’-C), 136.7 (4-C), 
135.8 (3’’-C), 129.4 (6-C), 127.9 (3’-C), 126.9 (5’’-C) 127.5 (4’’-C), 124.6 (5-
C), 123.3 (6’’-C), 122.0 (2’’-C), 119.2 (7-C), 78.5 (Boc-C), 53.2 (2-C), 44.3 
(Gly-CH2), 29.4 (3-C), 28.3 (Boc-CH3) νmax/cm-1 (ATR); 3304, 2975, 1688, 
1608, 1368, 1160. (ESI) (100%, M-H); (Found M-H, 438.1668. C23H25N3O6 







Synthesis of tert-butyl N-[({3-[7-(butylcarbamoyl)-1H-indole-1-
carbonyl]phenyl}carbamoyl)methyl]carbamate (33) 
To a stirred solution of 1-[3-(2-{[(tert-
butoxy)carbonyl]amino}acetamido)benzoyl]-1H-
indole-7-carboxylic acid 25 (0.725 g, 1.95 mmol) 
in DCM (20 mL) was added; butylamine (0.23 
mL, 2.34 mmol), EDC.HCl (0.449 g, 2.34 mmol) 
and DMAP (0.030g, 0.2 mmol) at RT. The 
reaction mixture was them stirred at RT for 3 
hours. The reaction mixture was then diluted with DCM (20 mL) and the 
resultant solution was then washed with water (2 x 20 mL) and brine (2 x 
20mL). The organic layer was then dried over MgSO4, filtered and the solvent 
removed to give a crude colourless solid. The crude solid was purified by 
column chromatography (2% MeOH-DCM) to afford the title compound as 
colourless solid (0.441 g, 46%). Rf 0.37 (2% MeOH-DCM). δH (500 MHz, 
DMSO), 10.22 (s, 1H, amide NH), 8.35 (t, 1H, J = 5.6 Hz, butyl amide NH), 
8.11 (app s, 1H, 2’’-H), 7.91 (app d, 1H, J = 8.0 Hz, 4’’-H), 7.77 (dd, 1H, 7.6 
Hz and 1.6 Hz, 6-H), 7.52 (app t, 1H, J = 8.0 Hz, 5’’-H), 7.47-7.43 (m, 2H, 6’’-
H and 2-H), 7.39-7.37 (m, 1H, 4-H), 7.33 (app t, 1H, J = 7.6 Hz, 5-H), 7.09 
(t, 1H, J = 6.1 Hz, Boc-NH), 6.77 (d, 1H, J = 3.6 Hz, 3-H), 3.74 (d, 2H, J = 
6.1 Hz, Gly-CH2), 3.08 (q, 2H, J = 6.6 Hz, butyl amide CH2NH), 1.39 (m, 11H, 
Boc-CH3 and butyl amide CH2CH2NH2), 1.28 (sxt, 2H, J = 7.4 Hz butyl amide 
CH3CH2) 0.83 (t, 3H, J = 7.4 Hz, butyl amide CH3) δC (500 MHz, DMSO) 
169.1 (C=O), 167.8 (C=O), 167.6 (C=O), 156.4 (C=O), 139.8 (1’’-C), 134.0 
(7’’-C), 132.4 (3’’-C), 132.1 (3’-C), 129.9 (5’’-C), 129.7 (2-C), 125.9 (4-C), 
125.1 (6’’-C), 123.8 (6-C), 123.6 (4’’-C), 123.1 (5-C), 120.7 (7-C), 120.1 (2’’-
C), 107.1 (3-C), 78.6 (Boc-C), 44.3 (Gly-CH2), 39.0 (Butyl amide 
CH2NH2),31.6 (Butyl amide CH2CH2NH2), 28.6 (Boc-CH3), 20.2 (Butyl amide 
CH3CH2), 14.2 (Butyl amide CH3). vmax / cm-1 (solid): 3271, 2931, 1688, 1529, 
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1280, 1189.  m/z (ESI) (100%, MNa+); (Found MNa+, 515.2270. C27H32N4O5 
requires MNa+, 515.2270).  
Synthesis of 3-{3-[7-(butylcarbamoyl)-1H-indole-1-carbonyl]phenyl}-2-
oxopropan-1-aminium chloride (34) 
To a RBF charged with tert-butyl N-[({3-[7-
(butylcarbamoyl)-1H-indole-1-carbonyl]phenyl} 
carbamoyl)methyl]carbamate 33 (0.330 g, 0.67 
mmol) was added 4M HCl in dioxane (5 mL) at RT. 
The reaction mixture was then stirred at RT for 2 
hours. The resultant ppt was then collected by 
vacuum filtration and was washed with DCM (5 
mL) to afford the title compound as a colourless solid (0.280 g, 98%). Rf 0.10 
(10% methanolic ammonia-DCM). m.p >250 ºC δH (500 MHz, DMSO), 11.13 
(s, 1H, amide NH), 8.39 (t, 1H, J = 6.0 Hz, butyl amide NH), 8.32 (bm, 3H, 
NH3+), 8.16-8.15 (m, 1H, 2’’-H), 7.93-7.92 (m, 1H, 4’’-H), 7.78-7.76 (m, 1H, 
6-H), 7.56 (app t, 1H, J = 7.9 Hz, 5’’-H), 7.52-7.50 (m, 1H, 6’’-H), 7.46 (d, 1H, 
J = 3.6 Hz, 2-H), 7.40-7.38 (m, 1H, 4-H), 7.33 (app t, 1H, J = 7.6 Hz, 5-H), 
6.78 (d, 1H, J = 3.6 Hz, 3-H), 3.83 (q, 2H, J = 5.7 Hz, Gly-CH2), 3.08 (q, 2H, 
J = 6.0 Hz, butyl amide CH2NH), 1.41 (p, 2H J = 6.0 Hz, butyl amide 
CH2CH2NH2) 1.29 (sxt, 2H, J = 6.5 Hz butyl amide CH3CH2), 0.83 (t, 3H, J = 
6.5 Hz, butyl amide CH3). δC (500 MHz, DMSO) 167.6 (C=O), 167.6 (C=O), 
165.7 (C=O), 139.2 (1’’-C), 134.2 (7’-C), 132.4 (3’’-C), 132.1 (3’-C), 130.0 
(5’’-C), 129.9 (2-C), 125.9 (4-C), 125.8 (6’’-C), 124.0 (6-C), 123.7 (4’’-C), 
123.2 (5-C), 123.1 (7-C), 120.8 (2’’-C), 107.3 (3-C), 41.5 (Gly-CH2), 39.0 
(Butyl amide CH2NH2), 31.6 (Butyl amide CH2CH2NH2), 20.1 (Butyl amide 
CH3CH2), 14.2 (Butyl amide CH3) vmax / cm-1 (solid): 2930, 1693, 1555, 1414, 
1397, 1372 m/z (ESI) (100%, MNa+); (Found MNa+, 415.1736. C22H24N4O3 








Synthesis of tert-butyl N-[({3-[7-(butylcarbamoyl)-2,3-dihydro-1H-
indole-1-carbonyl]phenyl}carbamoyl)methyl]carbamate  
To a stirred solution of 1-[3-(2-{[(tert-
butoxy)carbonyl]amino}acetamido)benzoyl]-2,3-
dihydro-1H-indole-7-carboxylic acid 28 (0.725 g, 
1.95 mmol) in DMF (9 mL) was added; butylamine 
(0.23 mL, 2.34 mmol), EDC.HCl (0.449 g, 2.34 
mmol) and DMAP (0.030g, 0.2 mmol) at RT. The 
reaction mixture was them stirred at RT for 12 
hours. A further amount of n-BuNH2 (0.12 mL, 1.17 mmol) and the reaction 
mixture was then stirred at 80 ºC for 2 hours. The reaction mixture was then 
cooled to RT and then diluted with water (20 mL). The resultant solution was 
then extracted with EtOAc (3 x 20 mL). The organic layers were then 
combined and washed with water (2 x 20 mL) and brine (2 x 20mL). The 
organic layer was then dried over MgSO4, filtered and the solvent removed 
to give a crude colourless solid. The crude solid was recrystallized from DCM 
to give the title compound as a colourless crystalline solid (0.539 g, 56%). 
m.p 160-165 ºC. Rf 0.30 (2% MeOH-DCM). δH (500 MHz, DMSO), 10.13 (s, 
1H, amide NH), 7.94-7.91 (m, 2H, 2’’-H and butyl amide NH), 7.74 (app d, 
1H, J = 7.9 Hz, 4’’-H), 7.48-7.36 (m, 3-H, 6-H, 6’’-H and 5’’-H), 7.29 (app d, 
1H, J = 7.5 Hz, 4-H), 7.18-7.06 (m, 2H, 5-H and Gly NH), 4.06 (t, 2H, J = 7.7 
Hz, 2-H), 3.74 (d, 2H, J = 5.8 Hz, Gly CH2), 3.05-3.02 (m, 4H, 3-H and butyl 
amide CH2NH), 1.37-1.25 (m, 11H, Boc-CH3 and butyl amide CH2CH2NH), 
1.20 (sxt, 2H, J = 7.3 Hz, butyl amide CH3CH2CH2), 0.73 (t, 3H, J = 7.3 Hz, 
butyl amide CH3). δC (500 MHz, DMSO) 169.0 (C=O). 168.8 (C=O), 167.0 
(C=O), 156.4 (C=O), 140.1 (7’-C), 139.5 (1’’-C), 136.9 (4-C), 135.5 (3’’-C), 
129.0 (6-C), 128.1 (3’-C), 126.7 (4’’-C), 126.4 (5’’-C), 124.5 (5-C), 123.4 (6’’-
C), 121.9 (2’’-C), 119.5 (7-C), 78.5 (Boc C), 53.1 (2-C), 44.3 (Gly CH2), 39.0 
(Butyl amide CH2NH), 31.7 (butyl amide CH2CH2NH), 29.5 (3-C), 28.7 (Boc 
CH3), 20.2 (butyl amide CH3CH2CH2) 14.3 (butyl amide CH3). νmax/cm-1 
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(ATR); 3296, 1634, 1543, 1440, 1380, 1208.  m/z. (ESI) (100%, MNa+); 
(Found MNa+, 517.2433. C27H34N4O5 requires MNa+, 517.2421) 
Synthesis of ({3-[7-(butylcarbamoyl)-2,3-dihydro-1H-indole-1-
carbonyl]phenyl}carbamoyl)methanaminium chloride (35) 
To a solution of tert-butyl N-[({3-[7-
(butylcarbamoyl)-2,3-dihydro-1H-indole-1- 
carbonyl]phenyl}carbamoyl)methyl]carbamate  
(0.330 g, 0.67 mmol) in dioxane (5 mL) was 
added 4M HCl in dioxane (5 mL) at RT. The 
reaction mixture was then stirred at 50 ºC for 2 
hours. The reaction mixture was then cooled to 
RT. The resultant ppt was then collected by vacuum filtration and was 
washed with DCM to afford the title compound as a colourless solid (0.285 
g, 99%). Rf 0.10 (10% methanolic ammonia-DCM). m.p >250 ºC δH (500 
MHz, DMSO), 11.00 (s, 1H, amide NH), 8.31 (bs, 3H, NH3+), 7.95 (m, 2H, 
2’’-H and butyl amide NH), 7.78 (app d, 1H, J = 7.7 Hz, 4’’-H), 7.41-7.30 (m, 
3H, 6-H, 6’’-H and 5’’-H), 7.21 (app d, 1H, J = 7.5 Hz, 4-H), 7.13 (app t, 1H, 
7.5 Hz, 5-H), 4.07-4.05 (m, 2H, 2-H), 3.83-3.81 (m, 2H, Gly CH2), 3.04-3.02 
(m, 4H, 3-H and butyl amide CH2NH), 1.32-1.28 (m, 2H, butyl amide 
CH2CH2NH), 1.23-1.17 (m, 2H, butyl amide CH3CH2CH2). 0.72-0.70 (m, 3H, 
butyl amide CH3). δC (500 MHz, DMSO) 168.6 (C=O), 167.2 (C=O), 165.4 
(C=O), 140.1 (7’-C), 138.8 (1’’-C), 137.0 (4-C), 135.5 (3’’-C), 129.3 (6-C), 
128.1 (3’-C), 126.7 (4’’-C), 126.4 (5’’-C), 124.6 (5-C), 123.7 (6’’-C), 122.0 (2’’-
C), 119.5 (7-C), 53.0 (2-C), 46.6 (Gly CH2), 39.0 (butyl amide CH2NH), 31.7 
(butyl amide CH2CH2NH), 29.1 (3-C), 20.2 (butyl amide CH3CH2CH2), 14.1 
(butyl amide CH3) νmax/cm-1 (ATR); 2957, 1695, 1632, 1585, 1556, 1487, 
1433. m/z. (ESI) (100%, MNa+); (Found MNa+, 417.1893. C22H26N4O3 






Synthesis of 3-[(3-nitrophenyl)carbonyl]-1H-Indole (42) 
 To a solution of Indole (0.500 g, 4.34 mmol) in 
DCM (19 mL) was added Et2AlCl (1M in hexane, 
6.6 mL, 6.60 mmol) dropwise at -78 ºC. The 
reaction mixture was then stirred at -78 ºC for 15 
mins. To this solution was added 3-nitrobenzoyl 
chloride (1.20 g, 6.51 mmol) in DCM (15 mL). The reaction mixture was then 
warmed to 0 ºC and stirred at that temperature for three hours. The reaction 
mixture was then quenched with pH 7 buffer solution (20 mL). The resultant 
ppt was filtered and washed with water (10 mL). The crude product was 
purified using column chromatography (2% MeOH/DCM) to give the title 
compound as a yellow crystalline solid (0.335g, 29%), m.p. 217-218 ºC, δH 
(500 MHz, DMSO); 12.24 (s, 1H, NH), 8.50 (app s, 1H, 2’’-H), 8.45 (m, 1H, 
6’’-H), 8.28 (app d, 1H, J = 7.1 Hz, 4-H), 8.23 (dd, 1H, J = 7.6 Hz, 0.9 Hz, 4’’-
H), 8.10 (s, 1H, 2-H) 7.84 (app t, 1H, J = 7.6 Hz, 5’’-H), 7.56 (dd, 1H, J = 6.7, 
1.6 Hz,  7-H), 7.30 (m, 2H, 5-H and 6-H), δC (500 MHz, DMSO); 187.4 (C=O), 
147.7 (1’’-C), 141.6 (7’-C), 136.8 (2-C), 136.7 (3’’-H) 134.6 (4-C), 133.2 (4’’-
H) 130.3 (5’’-C), 126.1 (3’-C), 125.5 (6’’-C), 123.5 (6-C ), 123.0 (5-C), 121.4 
(2’’-C), 114.6 (3-C), 112.5 (7-C); νmax/cm-1 (ATR); 3114, 1596, 1530, 1514, 
1424;  m/z (ESI) (100%, MH+); (Found MH+, 267.0764. C15H10N2O3 requires 
MH+, 267. 0764). 
Synthesis of 2-(3-nitrobenzamido)benzamide (49) 
To a stirred solution of methyl 2-
aminobenzamide (0.450g, 3.31 mmol) in THF 
(20 mL) was added Et3N (0.7 mL, 4.97 mmol) 
and 3-nitrobenzoyl chloride (0.614 g, 3.31 
mmol) at RT. The reaction mixture was then stirred at RT for 12 hours and 
the resultant ppt was collected by vacuum filtration and the solid was washed 
with water (10 mL) and DCM (10 mL). The crude solid was then recrystallized 
from EtOH to afford the title compound as a colourless solid (0.774 g, 82%). 
m.p 178-180 ºC. Rf 0.46 (10% MeOH-DCM). δH (500 MHz, DMSO) 13.31 (s, 
1H, amide NH), 8.73-8.72 (m, 1H, 2’-H), 8.69-8.67 (m, 1H, 3-H), 8.51 (bs, 
1H, amide NH), 8.49-8.46 (m, 1H, 6’-H), 8.36-8.35 (m, 1H, 3’H), 7.98 (bs, 
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1H, amide NH), 7.97-7.95 (dd, 1H, J = 1.4, 7.9 Hz, 6-H), 7.90 (app t, 1H, J = 
8.0 Hz, 5’-H), 7.63-7.59 (m, 1H, 4-H), 7.25-7.21 (m, 1H, 5-H) δC (500 MHz, 
DMSO) 171.6 (C=O), 162.7 (C=O), 148.6 (1’-C), 140.2 (1-C), 136.5 (3’-C), 
133.6 (4’-C), 133.2 (4-C), 131.2 (5’-C), 129.3 (6-C), 127.0 (6’-C), 123.7 (5-
C), 122.2 (2’-C), 120.7 (3-C), 119.9 (2-C) vmax / cm-1 (solid): 3414, 3152, 
1678, 1511, 1312. m/z (ESI); (100%, MH+); (Found MH+, 308.0647. 
C14H11N3O4 requires MNa+, 308.0647).  
Synthesis of 2-(3-aminobenzamido)benzamide (50) 
To a solution of 2-(3-nitrobenzamido)benzamide 49 
(0.285 g, 1 mmol) in MeOH (20 mL) was added 10% 
Pd/C (0.150 g). The resultant slurry was then stirred 
at RT under an atmosphere of hydrogen (1 
atmosphere) for 12 hours. The reaction mixture was 
then filtered through Celite and the solvent removed to give a crude purple 
solid. The crude solid was then recrystallized from ethanol to afford the title 
compound as a colourless solid (0.228 g, 89%). m.p 194-195 ºC. Rf 0.21 
(10% MeOH-DCM). δH (500 MHz, DMSO), 12.78 (s, 1H, amide NH), 8.70 
(app d, 1H, J = 8.3 Hz, 3-H), 8.41 (bs, 1H, primary amide NH), 7.89 (dd, 1H, 
8.3 and 1.3 Hz, 6-H), 7.80 (bs, 1H, primary amide NH), 7.57-7.54 (m, 1H, 4-
H), 7.20-7.14 (m, 3H, 5-H, 5’-H and 2’-H), 7.05 (app d, 1H, J = 7.6 Hz, 4’-H), 
6.79-6.77 (m, 1H, 6’-H), 5.41 (bs, 2H, aniline-NH2). δC (500 MHz, DMSO) 
171.6 (C=O), 165.7 (C=O), 149.8 (1’-C), 140.7 (1-C), 136.0 (3’-C), 132.9 (4-
C), 129.7 (5’-C), 129.2 (6-C), 122.8 (5-C), 120.5 (3-C), 119.6 (2-C), 117.7 
(6’-C), 114.0 (4’-C), 113.0 (2’-C) νmax/cm-1 (ATR); 3215, 2601, 1581, 1521, 
1395, 1313. m/z (ESI); (100%, MH+); (Found MH+, 256.1077. C14H13N3O2 








Synthesis of tert-butyl N-[({3-[(2-
carbamoylphenyl)carbamoyl]phenyl}carbamoyl)methyl]carbonate (51) 
To a stirred solution of 2-(3-
aminobenzamido)benzamide 50 (0.214 
g, 0.84 mmol) in DMF (10 mL) was 
added; Boc-Gly-OH (0.178 g, 1.01 
mmol), EDC.HCl (0.194 g, 1.01 mmol) 
and DMAP (0.010g, 0.08 mmol) at RT. 
The reaction mixture was them stirred at 100 ºC for 12 hours. A further 
amount of EDC.HCl (0.097 g, 0.05 mmol) and Boc-Gly-OH (0.089 g, 0.05 
mmol) was added and the reaction mixture was stirred at 100ºC for a further 
3 hours. The reaction mixture was then cooled to RT and then diluted with 
DCM (20 mL). The resultant solution was then washed with water (2 x 20 
mL) and brine (2 x 20mL). The organic layer was then dried over MgSO4, 
filtered and the solvent removed to give a crude colourless solid. The crude 
solid was then recrystallized from ethanol to afford the title compound as a 
colourless solid (0.156 g, 45%). m.p 198-206 ºC. Rf 0.15 (10% MeOH-DCM). 
δH (500 MHz, DMSO), 12.93 (s, 1H, amide NH), 10.20 (s, 1H, amide NH), 
8.70 (app d, 1H, J = 8.3 Hz, 3-H), 8.42 (bs, 1H, primary amide N-H), 8.20 
(app s, 1H, 2’-H, 7.91-7.85 (m, 3H, 6-H, 4’-H and primary amide N-H), 7.60-
7.59 (m, 2H, 4-H and 6’-H), 7.51 (app t, 1H, J = 7.86, 5’-H), 7.19 (app t, 1H, 
J = 8.1 Hz, 5-H), 7.08 (t, 1H, J = 5.83, Boc-NH), 3.76 (d, 2H, J = 5.83, Gly-
CH2) 1.45 (s, 9H, Boc-CH3) δC (500 MHz, DMSO) 171.9 (C=O), 169.0 
(C=O), 164.8 (C=O), 156.4 (C=O), 140.5 (1’-C), 140.1 (1-C), 135.8 (3’-C), 
133.1 (4-C), 129.8 (5’-C), 129.2 (6-C), 123.2 (5-H), 122.9 (4’-C), 121.5 (6’-
C), 120.6 (3-C), 119.6 (2-C), 118.6 (2’-C), 78.6 (Boc-C), 46.2 (Gly-CH2), 28.5 
(Boc-CH3). νmax/cm-1 (ATR); 3195, 1662, 1543, 1520, 1297  m/z (EI): (Found 









To a stirred solution of tert-butyl N-[({3-[(2-
carbamoylphenyl)carbamoyl]phenyl} 
carbamoyl)methyl]carbonate 51 (0.200 g, 
0.84 mmol) in DCM (2 mL) was added 4M 
HCl in dioxane (2 mL) at RT. The resultant 
reaction mixture was then heated at reflux 
for 1 hour. The reaction mixture was then cooled to RT and the resultant ppt 
was collected by vacuum filtration and washed with DCM (10mL) to afford 
the title compound as colourless crystalline solid (0.280 g, 96%). Rf 0.16 
(10% methanolic ammonia-DCM). m.p >250 ºC. δH (500 MHz, DMSO), 12.97 
(s, 1H, amide NH), 11.02 (s, 1H, amide NH), 8.70 (dd, 1H, J = 8.4 Hz and 
0.97 Hz, 3-H), 8.47 (bs, 1H, primary amide N-H), 8.32 (bs, 3H, NH3+) 8.25 
(app s, 1H, 2’-H), 7.93  (dd, 1H, J = 7.86 Hz and 1.35 Hz, 6-H), 7.89-7.87 (m, 
1H, 4’-H),  7.83 (bs, 1H, primary amide N-H), 7.65-7.64 (m, 1H, 6’H) 7.60-
7.55 (m, 2H, 4-H and 5’-H), 7.12-7.18 (m, 1H, 5-H), 3.84 (d, 2H, J = 5.48, 
Gly-CH2)  δC (500 MHz, DMSO) 171.5 (C=O), 165.6 (C=O), 164.6 (C=O), 
140.5 (1’-C), 139.4 (1-C), 136.0 (3’-C), 133.0 (4-C), 130.0 (5’-C), 129.3 (6-
C), 123.2 (5-H), 123.0 (4’-C), 122.2 (6’-C), 120.6 (3-C), 119.6 (2-C), 118.7 
(2’-C), 66.8 (Gly CH2). νmax/cm-1 (ATR); 3190, 2892, 1692, 1590, 1524, 1474.  
m/z (EI): (Found M+Na, 335.1115 C16H16N4O3 requires M+Na, 335.1115) 
HPLC (RT: 1.45 min(98 % relative area)). 
Synthesis of methyl 2-(3-nitrobenzamido)benzoate (54)  
To a stirred solution of methyl 2-aminobenzoate 
(0.500g, 3.31 mmol) in THF (20 mL) was added 
Et3N (0.7 mL, 4.97 mmol) and 3-nitrobenzoyl 
chloride (0.614 g, 3.31 mmol) at RT. The reaction 
mixture was then stirred at RT for 12 hours. The 
reaction mixture was then diluted with EtOAc (25 
mL). The resultant solution was then washed with water (2 x 25 mL) and 
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brine (25 mL). The organic layer was then dried over MgSO4, filtered and the 
solvent removed to give a crude yellow solid. The crude solid was 
recrystallized from EtOAc to afford the title compound as a colourless solid 
(0.854 g, 86%). Rf 0.85 (20% EtOAc-Petrol). m.p 85-87 ºC δH (500 MHz, 
DMSO), 11.60 (s, 1H, amide NH), 8.80-8.79 (m, 1H, 2’-H) 8.56-8.53 (ddd, 
1H, J = 8.1, 2.3 and 1.0 Hz, 6’-H), 8.45-8.40 (m, 2H, 4’-H and 6-H), 8.06-8.04 
(dd, 1H, J = 1.6, 7.9 Hz, 3-H), 7.99 (app t, 1H, J = 8.1 Hz, 5’-H), 7.78-7.76 
(m, 1H, 5-H), 7.38-7.35 (m, 1H, 4-H), 3.94 (s, 3H, OCH3). δC (500 MHz, 
DMSO) 168.2 (C=O), 163.2 (C=O), 148.5 (1’-C), 139.5 (1-C), 136.3 (3’-C), 
134.5 (5-C), 133.8 (4’-C), 131.2 (3-C), 131.1 (5’-C), 127.1 (6’-C), 124.7 (4-
C), 122.6 (2’-C), 122.5 (6-C), 119.6 (2-C), 53.1 (OCH3). vmax / cm-1 (solid): 
3248, 1693, 1671, 1526, 1304. m/z. (ESI) (100%, MH+); (Found MH+, 
301.1168. C15H12N2O5 requires MH+, 301.1160).  
Synthesis of methyl 2-(3-aminobenzamido)benzoate (55)  
To a stirred solution of methyl 2-(3-
nitrobenzamido)benzoate 54 (0.330 g, 1.10 mmol) 
in MeOH (20 mL) was added zinc powder (0.719 g, 
11.00 mmol) at 0 ºC. Ammonium chloride (11.00 
mmol) was then added portionwise over a period of 
5 minutes. The reaction mixture was then warmed 
to RT and stirred at that temperature for 1 hour. The reaction mixture was 
then filtered through Celite. The filtrate was then collected and the solvent 
removed to give a crude residue. The crude residue was then taken up in 
EtOAc (30 mL). The resultant solution was washed with water (20 mL) and 
brine (20 mL). The organic layer was dried over MgSO4, filtered and the 
solvent removed to afford the title compound as a yellow solid (0.226 g, 
76%). Rf 0.64 (20% EtOAc-Petrol). δH (500 MHz, DMSO), 11.60 (s, 1H, 
amide NH), 8.68-8.67 (dd, 1H, J = 8.54, 1.02 Hz, 3-H), 8.09-8.07 (m, 1H, 6-
H), 7.75-7.71 (m, 1H, 4-H), 7.29-7.24 (m, 2H, 5-H and 5’-H), 7.22-7.21 (m, 
1H, 2’-H), 7.13-7.12 (m, 1H, 4’-H), 6.87-6.83 (m, 1H, 6’-H), 5.50 (bs, 2H, 
NH2), 3.95 (s, 3H, OCH3). δC (500 MHz, DMSO) 168.6 (C=O), 166.00 (C=O), 
149.8 (1’-C), 141.2 (1-C), 135.7 (3’-C), 134.9 (5-C), 131.2 (3-C), 129.8 (5’-
C), 123.5 (4-C), 120.9 (6-C), 117.9 (6’-C), 116.7 (2-C), 114.0 (4’-C), 113.0 
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(2’-C), 53.1 (OCH3) vmax / cm-1 (solid): 3470, 1667, 1631, 1601, 1301. m/z 
(ESI) (100%, MNa+); (Found MNa+, 293.1221. C15H14N2O3 requires MNa+, 
293.1220).  
Synthesis of methyl 2-[3{[(tert-
butoxy)carbonyl]amino}acetamido)benzamide] benzoate (56)   
To a stirred solution of methyl 2-(3-
aminobenzamido)benzoate 55 (0.283 g, 
1.05 mmol) in DCM (20 mL) was added; 
Boc-Gly-OH (0.193 g, 1.01 mmol), 
EDC.HCl (0.211 g, 1.10 mmol) and 
DMAP (0.012 g, 0.10 mmol) at RT. The 
reaction mixture was them stirred at RT for 12 hours. The reaction mixture 
was then diluted with DCM (20 mL). The resultant solution was then washed 
with water (2 x 20 mL) and brine (2 x 20mL). The organic layer was then 
dried over MgSO4, filtered and the solvent removed to give a crude 
colourless solid. The crude solid was then recrystallized from ethanol to 
afford the title compound as a colourless solid (0.331 g, 74%). Rf 0.51 (2% 
MeOH-DCM). m.p 133-138 ºC.  δH (500 MHz, DMSO), 11.57 (s, 1H, amide 
NH), 10.21 (s, 1H, amide NH), 8.56 (app d, 1H, J = 7.7 Hz, 3-H), 8.22 (app 
s, 1H, 2’-H), 8.01 (app d, 1H, J = 7.7 Hz, 6-H), 7.86 (app d, 1H, J = 7.4 Hz, 
4’-H), 7.70 (app t, 1H, J = 7.7 Hz, 4-H), 7.63 (app d, 1H, J = 7.4 Hz, 6’-H), 
7.55 (app t, 1H, J = 7.4 Hz, 5’-H), 7.26 (app t, 1H, J = 7.7 Hz, 4-H), 7.10 (m, 
1H, Boc-NH), 3.90 (s, 3H, OCH3), 3.76 (d, 2H, J = 5.5 Hz, Gly-CH2), 1.41 (s, 
9H, Boc-CH3). δC (500 MHz, DMSO) 169.1 (C=O), 168.5 (C=O), 165.2 
(C=O), 140.6 (1-C), 140.1 (1’-C), 135.5 (4-C), 134.8 (3’-C), 131.2 (6-C), 
129.9 (5’-C), 123.9 (5-C), 123.0 (4’-C), 121.6 (6’-C), 121.4 (3-C), 118.7 (2’-
C), 117.6 (2-C), 78.6 (Boc-C), 53.1 (O-CH3), 44.3 (Gly-CH2), 28.6 (Boc-CH3); 
vmax / cm-1 (solid): 3423, 1692, 1671, 1556, 1274; m/z (EI): (Found MNa+, 







um           trifluoroacetate (57) 
To a stirred solution of methyl 2-
[3{[(tert-butoxy)carbonyl]amino} 
acetamido)benzamide] benzoate 
56 (0.214 g, 0.50 mmol) in DCM (2 
mL) was added TFA (2 mL) at RT. 
The resultant reaction mixture was 
then stirred at RT for 1 hour. The solvent was then removed to give a crude 
colourless solid. The crude solid was then triturated with DCM (5 mL) to 
afford the title compound as a colourless amorphous solid (0.211 g, 96%). 
Rf 0.47 (10% Methanolic ammonia-DCM). m.p >250 ºC. δH (500 MHz, 
DMSO) 11.59 (s, 1H, amide NH), 10.72 (s, 1H, amide NH) 8.56-8.54 (dd, 1H, 
J = 8.14, 1.14 Hz, 3-H), 8.21-8.20 (m, 1H, 2’-H), 8.17 (bs, 3H, NH3+), 8.02-
8.01 (dd, 1H, J = 8.14, 1.14 Hz, 6-H), 7.85-7.83 (dd, 1H, J = 7.99, 1.14 Hz, 
4’-H), 7.71-7.67 (m, 2H, 4-H and 6’-H), 7.59 (app t, 1H, J = 7.99 Hz, 5’-H), 
7.27-7.24 (m, 1H, 5-H), 3.88 (s, 3H, OCH3), 3.84 (d, 2H, J = 5.33, Gly-CH2) 
δC (500 MHz, DMSO) 168.5 (C=O), 165.7 (C=O), 165.0 (C=O), 159.2-158.3 
(q, TFA C=O), 140.6 (1-C), 139.3 (1’-C), 135.8 (4-C), 134.9 (3’-C), 131.2 (6-
C), 130.2 (5’-C), 124.0 (5-C), 123.1 (4’-C), 122.3 (6’-C), 121.4 (3-C), 120.1-
113.1 (q, TFA CF3), 118.7 (2’-C), 117.8 (2-C), 53.2 (OCH3), 41.6 (Gly CH2); 
vmax / cm-1 (solid): 3128, 1781, 1680, 1586, 1173;) m/z (EI): (Found MNa+, 
350.1485 C17H17N3O4 requires MNa+, 350.1479). HPLC (RT: 1.77 min(100 











To a stirred solution of [(3-{[2-
(methoxycarbonyl)phenyl]carbamoyl} 
phenyl)carbamoyl]methanaminium           
trifluoroacetate 57 (0.200 g, 0.45 mmol) 
in MeOH (2 mL) and H2O (2 mL) was 
added LiOH·H2O (0.084 g, 2.00 mmol)  at 
RT. The resultant reaction mixture was then stirred at RT for 12 hours. The 
reaction mixture was then concentrated and acidified with 2M HCl. The 
resultant precipitate was then collected by vacuum filtration and washed with 
H2O (5 mL) and DCM (5 mL) to afford the title compound as a colourless 
solid (0.157 g, 95%). Rf 0.05 (10% methanolic ammonia-DCM). m.p >250 
ºC. δH (500 MHz, DMSO) 12.19 (s, 1H, amide NH), 11.12 (s, 1H, amide NH), 
8.71 (app d, 1H, J = 8.3 Hz, 3-H), 8.37 (bs, 3H, primary amine 3 x N-H), 8.31-
8.30 (m, 1H, 2’-H), 8.07 (dd, 1H, J = 8.0 and 1.7 Hz, 6-H), 7.88-7.87 (m, 1H, 
4’-H), 7.70-7.66 (m, 2H, 4-H and 6’-H), 7.58 (app t, 1H, J = 7.9 Hz, 5’-H), 
7.24-7.21 (m, 1H, 5-H), 3.85-3.84 (m, 2H, Gly-CH2). δC (500 MHz, DMSO) 
170.1 (C=O), 165.6 (C=O), 164.4 (C=O), 141.5 (1-C), 139.5 (1’-C), 135.0 (4-
C), 134.9 (3’-C), 131.8 (6-C), 130.1 (5’-C), 123.5 (5-C), 123.1 (4’-C), 122.2 
(6’-C), 120.4 (3-C), 118.7 (2’-C), 117.0 (2-C), 41.5 (Gly-CH2). vmax / cm-1 
(solid): 2958, 1677, 1586, 1528, 1477, 1445 m/z (EI): (Found M-H, 312.0987 












Synthesis of methyl 2-(3-propanamidobenzamido)benzoate  
To a stirred solution of methyl 2-(3-
aminobenzamido)benzoate 55 (0.230 g, 0.84 
mmol) in DCM (20 mL) was added; propionic 
acid (0.076 mL, 1.01 mmol), EDC.HCl (0.194 
g, 1.01 mmol) and DMAP (0.010g, 0.08 mmol) 
at RT. The reaction mixture was them stirred 
at RT for 12 hours. The reaction mixture was then diluted with DCM (20 mL). 
The resultant solution was then washed with water (2 x 20 mL) and brine (2 
x 20mL). The organic layer was then dried over MgSO4, filtered and the 
solvent removed to give a crude colourless solid. The crude solid was then 
recrystallized from DCM to afford the title compound as a colourless 
amorphous solid (0.189 g, 69%). Rf 0.66 (2% MeOH-DCM). δH (500 MHz, 
DMSO) 11.57 (s, 1H, amide NH), 10.14 (s, 1H, amide NH), 8.56 (app d, 1H, 
J = 8.0 Hz, 3-H), 8.22 (s, 1H, 2’-H), 8.02 (dd, 1H, J = 8.0, 1.5 Hz, 6-H), 7.89-
7.88 (m, 1H, 4’H), 7.71-7.67 (m, 1H, 4-H), 7.61-7.59 (m, 1H, 6’-H), 7.52 (app 
t, 1H, J = 7.90 Hz, 5’-H), 7.27-7.24 (m, 1H, 5-H), 3.90 (s, 3H, OCH3), 2.37 (q, 
2H, J = 7.5 Hz, propyl-CH2), 1.11 (t, 3H, J = 7.5 Hz, propyl-CH3). δC (500 
MHz, DMSO) 172.8 (C=O), 168.5 (C=O), 165.2 (C=O), 140.7 (C-1), 140.5 
(1’-C), 135.5 (4-C), 134.8 (3’-C), 131.2 (6-C), 129.8 (5’-C), 123.9 (5-C), 122.9 
(4’-C), 121.3 (6’-C), 121.2 (3-C), 118.6 (2’-C), 117.5 (2-C), 53.1 (O-CH3), 
30.0 (propyl-CH2), 10.0 (propyl-CH3). νmax/cm-1 (ATR); 3255, 1697, 1587, 
1536, 1488, 1235  m/z (ESI) (100%, M+Na); (Found M+Na, 349.1168. 









Synthesis of 2-(3-propanamidobenzamido)benzoic acid 58   
To a stirred solution of methyl 2-(3-
propanamidobenzamido)benzoate 
(0.137 g, 0.42 mmol) in MeOH (2 mL) 
and H2O (2 mL) was added LiOH·H2O 
(0.084 g, 2.00 mmol)  at RT. The resultant reaction mixture was then stirred 
at 64 ºC for 12 hours. The reaction mixture was then cooled to RT, 
concentrated in vacuuo and acidified with 2M HCl. The resultant precipitate 
was then collected by vacuum filtration and the solid was washed with H2O 
(5 mL) and DCM (5 mL) to afford the title compound as a colourless solid 
(0.119 g, 92%). Rf 0.19 (10% MeOH-DCM). m.p >250 ºC. δH (500 MHz, 
DMSO) 12.10 (s, 1H, NH), 10.14 (s, 1H, NH), 8.74 (dd, 1H, J = 8.4, 0.8 Hz, 
3-H), 8.28-8.27 (m, 1H, 2’-H), 8.07 (dd, 1H, J = 8.2, 1.5 Hz, 6-H), 7.86-7.84 
(m, 1H, 4’H), 7.69-7.66 (m, 1H, 4-H), 7.61-7.59 (m, 1H, 6’-H), 7.51 (app t, 
1H, J = 7.9 Hz, 5’-H), 7.23-7.20 (m, 1H, 5-H), 2.36 (q, 2H, J = 7.6 Hz, propyl-
CH2), 1.11 (t, 3H, J = 7.6 Hz, propyl-CH3). δC (500 MHz, DMSO) 172.8 (C=O), 
170.5 (C=O), 165.1 (C=O), 141.6 (1-C), 140.5 (1’-C), 135.6 (4-C), 134.8 (3’-
C), 131.8 (6-C), 129.8 (5’-C), 123.4 (5-C), 122.9 (4’-C), 121.4 (6’-C), 120.4 
(3-C), 118.4 (2’-C), 116.8 (2-C), 30.0 (propyl-CH2), 10.0 (propyl-CH3) 
νmax/cm-1 (ATR); 3265, 1633, 1586, 1524, 1486, 1234 (ESI) (100%, M-H); 
(Found M-H, 307.1034. C17H16N2O4 requires M-H, 307.1037).  
Synthesis of 2-(3-aminobenzamido)benzoic acid (59) 
To a stirred solution of methyl 2-(3-
aminobenzamido)benzoate 55 (0.270 g, 1.00 mmol) 
in MeOH (2 mL) and H2O (2 mL) was added 
LiOH·H2O (0.168 g, 4.00 mmol) at RT. The resultant 
reaction mixture was then stirred at 64 ºC for 12 
hours. An additional amount of LiOH.H2O (0.042 g, 1.00 mmol) was then 
added and the reaction mixture was stirred at 64 ºC for a further 2 hours. The 
reaction mixture was then cooled to RT, concentrated in vacuuo and acidified 
with 2M HCl. The resultant precipitate was then collected by vacuum filtration 
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and washed with H2O (5 mL) and DCM (5 mL) to afford the title compound 
as a colourless solid (0.251 g, 98%). Rf 0.25 (10% MeOH-DCM). m.p >250 
ºC. δH (500 MHz, DMSO) 12.18 (s, 1H, amide NH), 8.69-8.68 (m, 1H, 3-H), 
8.06 (dd, 1H, J = 7.9 Hz and 1.6 Hz, 6-H), 7.81-7.80 (m, 2H, 2’-H and 4’-H), 
7.70-7.67 (m, 1H, 5-H), 7.63 (app t, 1H, J = 8.0 Hz, 5’-H), 7.51-7.50 (m, 1H, 
6’-H), 7.25-7.22 (m, 1H, 4-H). δC (500 MHz, DMSO) 170.4 (C=O), 164.3 
(C=O), 141.3 (1-C), 136.4 (1’-C), 134.9 (5-C), 131.7 (6-C), 130.9 (5’-C), 
125.6 (6’-C), 124.1 (4’-C), 123.7 (4-C), 121.2 (2’-C), 120.9 (3’-C), 120.6 (3-
C), 117.4 (2-C). vmax / cm-1 (solid): 3379, 2811, 2590, 1667, 1607, 1524, 
1257.  m/z (EI): (Found M-H, 255.0770 C14H12N2O3 requires M-H, 255.0775). 
HPLC (RT: 1.67 min(100 % relative area)). 
Synthesis of methyl 3-bromo-5-(2-{[(tert-
butoxy)carbonyl]amino}acetamido)benzoate (64) 
To a stirred solution of methyl 3-amino-5-
bromobenzoate (0.230 g, 1.00 mmol) in 
DCM (20 mL) was added; Boc-Gly-OH 
(0.193 g, 1.10 mmol), EDC.HCl (0.211 g, 
1.10 mmol) and DMAP (0.013 g, 0.10 mmol) at RT. The reaction mixture was 
them stirred at RT for 12 hours and then diluted with DCM (20 mL). The 
resultant solution was then washed with water (2 x 20 mL) and brine (2 x 
20mL). The organic layer was then dried over MgSO4, filtered and the solvent 
removed to afford the title compound as a colourless oil (0.247 g, 64%). Rf 
0.64 (30% EtOAc-Petroleum ether). δH (500 MHz, DMSO) 10.34 (app s, 1H, 
amide NH), 8.17 (app s, 2H, 2-H and 4-H), 7.73 (app s, 1H, 6-H), 7.16-7.11 
(m, 1H, Gly-NH), 3.88 (s, 3H, OCH3), 3.74-3.68 (m, 2H, Gly-CH2), 1.44 (s, 
9H, Boc-CH3). δC (500 MHz, DMSO) 169.5 (C=O), 165.3 (C=O), 156.4 
(C=O), 141.3 (3-C), 132.5 (6-C), 126.3 (5-C), 125.9 (2-C), 122.2 (1-C), 118.9 
(4-C), 78.6 (Boc-C), 53.1 (OCH3), 43.3 (Gly-CH2), 28.7 (3 x Boc-CH3) vmax / 
cm-1 (solid): 2956, 1678, 1586, 1524, 1438, 1264. m/z (ESI) (100%, MNa+); 





Synthesis of 3-bromo-5-{[(tert-butoxy)carbonyl]amino}benzoic acid 
(67) 
To a solution of 3-amino-5-bromobenzoic acid (2.16 g, 
10 mmol) in dioxane (50 mL) and water (25 mL) was 
added triethylamine (2 mL, 15 mmol) and di-tert-butyl 
dicarbonate (3.27 g, 15 mmol). The reaction mixture was 
then stirred at RT for 12 hours. A further amount of di-tert-butyl dicarbonate 
(0.218 g, 1.00 mmol) was added and the reaction mixture was stirred at RT 
for a further 2 hours. The reaction mixture was then then concentred and 
cooled to 0 ºC. 2M HCl was then added dropwise and the resultant 
precipitate was collected by vacuum filtration. The solid was then washed 
with water (5 mL) to afford the title compound as a colourless solid (3.06 g, 
97%). Rf 0.42 (5% MeOH-DCM).  δH (500 MHz, DMSO) 9.78 (s, 1H, amide 
NH), 8.07 (app s, 1H, 4-H), 7.92 (app s, 1H, 2-H), 7.62 (app s, 1H, 6-H), 1.49 
(s, 9H, Boc-CH3). δC (500 MHz, DMSO) 166.9 (C=O), 153.0 (C=O), 141.9 (3-
C), 133.7 (5-C), 125.4 (6-C), 124.4 (1-C), 122.0 (2-C), 118.1 (4-C), 80.4 
(Boc-C), 28.9 (Boc-CH3). νmax/cm-1 (ATR); 3341, 1691, 1455, 1404, 1249, 
1156. m/z (ESI) (100%, M-H); (Found M-H, 314.0028. C12H14BrNO4 requires 
M-H, 314.0031). 
Synthesis of methyl 2-(3-bromo-5-{[(tert-
butoxy)carbonyl]amino}benzamido)benzoate (68) 
To a stirred solution of 3-bromo-5-{[(tert-
butoxy)carbonyl]amino}benzoic acid 67 (0.315 
g, 1.00 mmol) in DCM (20 mL) was added; 
methyl 4-aminobenzoate (0.166 g, 1.10 mmol), 
EDC.HCl (0.211 g, 1.10 mmol) and DMAP 
(0.012 g, 0.10 mmol) at RT. The reaction mixture was them stirred at RT for 
12 hours. The reaction mixture was then diluted with DCM (20 mL). The 
resultant solution was then washed with water (2 x 20 mL) and brine (2 x 
20mL). The organic layer was then dried over MgSO4, filtered and the solvent 
removed to give a crude colourless solid. The crude solid was then purified 
by column chromatography (2% MeOH in DCM) to give the title compound 
as a colourless oil (0.311 g, 69%). Rf 0.68 (2% MeOH-DCM). δH (500 MHz, 
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DMSO) 11.42 (s, 1H, amide NH), 9.86 (s, 1H, amide NH), 8.40-8.38 (m, 1H, 
3-H), 8.04-8.03 (m, 1H, 4’-H), 8.00-7.98 (m, 2H, 6-H and 2’-H), 7.70-7.67 (m, 
2H, 6’-H and 4-H), 7.29-7.26 (m, 1H, 5-H), 3.88 (s, 3H, CH3), 1.5 (s, 9H, Boc-
CH3). δC (500 MHz, DMSO), 168.2 (C=O), 164.0 (C=O). 153.0 (C=O), 142.2 
(3’-C), 139.5 (1-C), 137.5 (5’-C), 134.6 (4-C), 131.1 (6-C), 124.3 (6’-C), 123.8 
(1’-C), 123.1 (5-C), 122.3 (2’-C), 122.0 (3-C), 118.7 (4’-C), 116.0 (2-C), 80.4 
(Boc-C), 46.0 (CH3), 28.1 (Boc-CH3). vmax / cm-1 (solid): 3318, 1677, 1587, 
1519, 1443, 1258 m/z (ESI) (100%, M+H); (Found M+H, 451.0680. 
C20H21BrN2O5 requires M+H, 451.0610). 
Synthesis of 3-bromo-5-{[2-
(methoxycarbonyl)phenyl]carbamoyl}anilinium chloride (69) 
To a RBF charged with methyl 2-(3-bromo-5- 
{[(tert-butoxy)carbonyl]amino}benzamido) 
benzoate 68 (0.675 g, 1.50 mmol) was added 
4M HCl in dioxane (5 mL) at RT. The reaction 
mixture was then stirred at RT for 2 hours. The 
resultant ppt was then collected by vacuum filtration and was washed with 
DCM (5 mL) to afford the title compound as a colourless solid (0.475 g, 91 
%), Rf 0.68 (20% EtOAc-Petroleum ether). δH (500 MHz, DMSO) 11.38 (s, 
1H, amide NH), 8.41 (app d, 1H, J = 8.3 Hz, 3-H), 7.99 (dd, 1H, J = 8.2 Hz 
and 1.5 Hz, 6-H), 7.70-7.67 (m, 1H, 4-H), 7.42 (app s, 1H, 6’-H), 7.33 (app 
s, 1H, 4’-H), 7.28-7.25 (m, 1H, 5-H), 7.22 (app s, 1H, 2’-H), 6.59 (bs, 2H, 
NH2), 3.89 (s, 3H, CH3) δC (500 MHz, DMSO) 168.3 (C=O), 164.2 (C=O), 
147.0 (3’-C), 140.1 (1-C), 137.8 (5’-C), 134.6 (4-C), 131.1 (6-C), 124.2 (5-C), 
122.8 (1’-C), 122.1 (2’-C), 121.9 (3-C), 119.9 (6’-C), 118.5 (2-C), 114.8 (4’-
C), 53.2 (CH3) vmax / cm-1 (solid): 2844, 1678, 1590, 1536, 1431, 1282. m/z 








Synthesis of methyl 2-[3-bromo-5-(2-{[(tert-
butoxy)carbonyl]amino}acetamido)benzamido]benzoate (70) 
To a stirred solution 3-bromo-5-{[2-
(methoxycarbonyl)phenyl]carbamoyl} 
anilinium chloride 69 (0.348 g, 1.00 
mmol) in DCM (20 mL) was added; Boc-
Gly-OH (0.193 g, 1.10 mmol), EDC.HCl 
(0.211 g, 1.10 mmol) and DMAP (0.012 
g, 0.10 mmol) at RT. The reaction mixture was them stirred at RT for 12 
hours. An additional amount of Boc-Gly-OH (0.045 g, 0.25 mmol) was then 
added and the reaction mixture was stirred at RT for an additional 3 hours. 
The reaction mixture was then diluted with DCM (20 mL). The resultant 
solution was then washed with water (2 x 20 mL) and brine (2 x 20mL). The 
organic layer was then dried over MgSO4, filtered and the solvent removed 
to give a crude colourless solid. The crude solid was then recrystallized from 
ethanol to give the title compound as a colourless solid (0.328 g, 65%).Rf 
0.53 (2% MeOH-DCM). m.p 145-149 ºC. δH (500 MHz, DMSO) 11.38 (s, 1H, 
amide NH), 10.40 (s, 1H, amide NH), 8.37 (app d, 1H, J = 8.0 Hz, 3-H), 8.20-
8.19 (m, 1H, 4’-H), 8.11-8.10 (m, 1H, 2’-H), 8.00 (dd, 1H, J = 8.0 and 1.5 Hz, 
6-H), 7.78-7.77 (m, 1H, 6’-H), 7.71 (m, 1H, 4-H), 7.30-7.25 (m, 1H, 5-H), 7.13 
(t, 1H, J = 6.1 Hz, Gly-NH), 3.89 (s, 3H, OCH3), 3.76 (d, 2H, J = 6.1 Hz, Gly-
CH2), 1.41 (s, 9H, Boc-CH3) δC (500 MHz, DMSO) 169.5 (C=O), 168.4 (C=O), 
163.8 (C=O), 156.4 (C=O), 141.2 (3’-C), 140.1 (1-C), 137.4 (5’-C), 134.5 (4-
C), 131.1 (6-C), 124.8 (6’-C), 124.5 (1’-C), 124.2 (5-C), 122.4 (2’-C), 122.2 
(3-C), 119.1 (4’-C), 117.6 (2-C), 78.6 (Boc-C), 45.4 (OCH3), 44.3 (Gly-CH2), 
28.7 (Boc-CH3) νmax/cm-1 (ATR); 3075, 1670, 1600, 1547, 1440, 1266 (ESI) 









[1,1’-biphenyl]-3-yl]carbamoyl}methanaminium dichloride (60) 
To a solution of methyl 2-[3-
bromo-5-(2-{[(tert-butoxy)                           
carbonyl]amino}acetamido)  
benzamido] enzoate 70 (0.505 g, 
1.00 mmol) in dioxane were 
added; Pd(PPh3)4 (0.058 g, 
0.05mmol), 4-(N-Boc-
aminomethyl phenylboronic acid (0.276 g, 1.10 mmol) and 2M Na2CO3 (1.5 
mL , 3.00 mmol). The reaction mixture was then heated at 80 ºC for 4 hours. 
An additional amount of Pd(PPh3) (0.029 g, 0.03 mmol)  was then added and 
the reaction mixture was heated at 80 ºC for a further 16 hours. The reaction 
mixture was then cooled and water was then added (20 mL). The resultant 
solution was then washed with DCM (3 x 15 mL) and chloroform (3 x 15 mL). 
The aqueous layer was then acidified to pH 1 and stirred at RT for 30 mins. 
The solvent was then removed to give a crude brown solid. The solid was 
then purified by reverse phase ACC (gradient 0-40% MeCN-H2O in 0.1 % 
formic acid) to give the title compound as an off-white solid (0.195 g, 40%). 
Rf 0.05 (10% Methanolic ammonia-DCM). m.p >250 ºC. δH (500 MHz, 
DMSO), 10.91 (s, 1H, amide NH), 8.72 (app d, 1H, J = 8.0 Hz, 3-H), 8.32-
8.27 (m, 7H, 2 x NH3+ and 2’-H), 8.11 (app s, 1H, 4’-H), 8.08 (app d, 1H, J = 
7.9 Hz, 6-H), 7.98 (app s, 1H, 6’-H), 7.75 (app d, 2H, J = 8.3 Hz, 2’’-H), 7.67-
7.61 (m, 3H, 3’’-H and 4-H), 7.22 (app t, 1H, J = 7.8 Hz, 5-H), 4.13 (s, 2H, 
CH2), 3.88 (s, 2H, Gly CH2) δC (500 MHz, DMSO), 170.6 (C=O), 165.8 (C=O), 
164.6 (C=O), 141.5 (4’’-C), 141.4 (5’-C), 140.0 (1-C), 139.8 (1’’-C) 137.0 (1’-
C), 134.6 (4-C), 134.3 (3’-C), 131.9 (6-C), 130.4 (3’’-C), 127.5 (2’’-C), 123.5 
(5-C), 121.0 (4’C), 120.8 (6’-C), 120.3 (3-C), 118.8 (2’-C), 116.5 (2-C), 42.5 
(CH2), 41.6 (Gly CH2). νmax/cm-1 (ATR) 2920, 1666, 1587, 1517, 1450, 1130. 
m/z  (ESI) (100%, M-H); (Found M-H, 417.1600 C23H22N5O3 requires M-H, 




6.3.3 Synthesis of Sulfamide Fragments 
Synthesis of methyl 4-[(phenylsulfamoyl)amino]benzoate (77) 
Method 1: To a stirred solution of sodium N-
phenylsulfamate (0.200 g, 0.79 mmol) in CHCl3 
(10 mL) was added PCl5 (0.340 g, 1.60 mmol) at 
RT. The reaction mixture was then refluxed for 4 
hours. The reaction mixture was then cooled to 
RT, filtered and the solvent removed to give the 
crude sulfonyl chloride. The crude sulfonyl 
chloride was then dissolved in DCM (10 mL). This was followed by the 
addition of methyl 4-aminobenzoate (0.061g, 0.41 mmol) and trimethylamine 
(0.061 mL, 0.44 mmol) at RT. The reaction mixture was then stirred at RT 
for 1 hour. The reaction mixture was then diluted with DCM (10 mL). The 
resultant solution was then washed with water (2 x 20 mL) and brine (2 x 
20mL). The organic layer was then dried over MgSO4, filtered and the solvent 
removed to give a crude colourless solid. The crude solid was purified by 
column chromatography (2% MeOH-DCM) to afford the title compound as 
yellow solid (0.070 g, 29%). Method 2: To a round-bottom flask charged with 
methyl 4-(sulfamoylamino)benzoate 86 (0.230 g, 1.00 mmol), Cs2CO3 (0.456 
g, 1.4 mmol), XPhos (0.036 g, 0.075 mmol) and Pd2(dba)3 was added 
dioxane (5 mL) and bromobenzene (0.105 mL, 1.00 mmol) at RT. The 
reaction mixture was then refluxed for 12 hours. The reaction mixture was 
the cooled to RT and the solvent removed to give a crude solid. The crude 
solid was then purified by reverse phase ACC (gradient 0-40% MeCN-H2O 
in 0.1 % formic acid) to afford the title compound as a colourless solid (0.230 
g, 75%). Rf 0.45 (2% MeOH-DCM) δH (500 MHz, DMSO), 10.76 (s, 1H, 
sulfamide N-H), 10.46 (s, 1H, sulfamide N-H), 7.85 (app d, 2H, J = 8.7 Hz, 
3-H), 7.27-7.21 (m, 4H, 2’H and 3’-H) 7.10 (app d, 2H, J = 8.7 Hz, 2-H), 7.00 
(app t, 1H, J = 7.38 Hz, 4’-H), 3.80 (s, 3H, CH3) δC (500 MHz, DMSO), 166.2 
(C=O), 143.2 (1-C), 138.1 (1’-C), 130.9 (3-C), 129.5 (3’-C), 123.7 (4-C), 
123.6 (4’-C), 119.1 (2’-C), 117.0 (2-C), 52.3 (CH3) νmax/cm-1 (ATR); 3242, 
1693, 1605, 1429, 1315, 1158. m/z (ESI) (100%, M-H); (Found M-H, 
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305.0594. C14H14N2O4S requires M-H, 305.0596) HPLC (RT: 1.72 min(100 
% relative area)). 
Synthesis of 4-[(phenylsulfamoyl)amino]benzoic acid (71) 
To a stirred solution of methyl 4-
[(phenylsulfamoyl)amino]benzoate 77 
(0.306 g, 1.00 mmol) in MeOH (2 mL) and 
H2O (2 mL) was added LiOH·H2O (0.168 g, 
4.00 mmol) at RT. The resultant reaction mixture was then stirred at RT for 
12 hours. The reaction mixture was then concentrated in vacuuo and 
acidified with 2M HCl. The resultant precipitate was then collected by 
vacuum filtration and washed with H2O (5 mL) and DCM (5 mL) to afford the 
title compound as a colourless solid (0.289 g, 99%). Rf 0.22 (10% MeOH-
DCM). m.p >250 ºC  δH (500 MHz, DMSO) 10.28 (s, 1H, sulfamide NH), 
10.20 (s, 1H, sulfamide NH), 7.85-7.82 (app d, 2H, J = 8.8 Hz, 3-H), 7.27-
7.24 (m, 2H, 3’-H), 7.22 (app d, 2H, J = 8.8 Hz, 2-H), 7.13-7.10 (m, 2H, 2’-
H), 6.99 (app t, 1H, J = 7.4 Hz, 4’-H) δC (500 MHz, DMSO), 167.4 (C=O), 
143.2 (1-C), 138.1 (1’-C), 131.1 (3-C), 129.5 (3’-C), 124.8 (4-C), 123.7 (4’-
C), 119.1 (2’-C), 117.0 (2-C). νmax/cm-1 (ATR); 3291, 2679, 1680, 1607, 1321, 
1151. m/z (ESI) (100%, M-H); (Found M-H, 291.0444. C13H12N2O4S requires 
M-H, 291.0445). HPLC (RT: 2.07 min(99 % relative area)). 
Synthesis of methyl 4-[({[(tert-
butoxy)carbonyl]amino}sulfonyl)amino]benzoate (90) 
To a solution of chlorosulfonyl isocyanate 
(0.61 mL, 7.07 mmol) in DCM (20 mL) was 
added di-tert-butyl dicarbonate (1.54 g, 7.07 
mmol) at 0 ºC. The reaction mixture was then 
stirred at 0 ºC for 15 mins, this was followed 
by the dropwise addition of a solution methyl 4-aminobenzoate (1.07 g, 7.07 
mmol) and triethylamine (1.47 mL, 10.61 mmol) in DCM (10 mL) at 0 ºC. The 
reaction mixture was then warmed to RT and stirred at that temperature for 
two hours. The reaction mixture was then diluted with DCM (10 mL). The 
resultant solution was then washed with 0.1 M HCl (20 mL), water (20 mL) 
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and brine (20 mL). The organic layer was dried over MgSO4, filtered and the 
solvent removed to afford the title compound as an off-white solid (1.98 g, 
85%). Rf 0.53 (2% MeOH-DCM). δH (500 MHz, DMSO) 11.56 (s, 1H, 
sulfamide NH),  10.90 (s. 1H, sulfamide NH), 7.93-7.91 (m, 2H, 3-H), 7.28-
7.25 (m, 2H, 2-H), 3.82 (s, 3H, OCH3), 1.32 (s, 9H, Boc-CH3) δC (500 MHz, 
DMSO) 166.3 (C=O), 154.0 (C=O), 142.7 (1-C), 130.9 (3-C), 124.5 (4-C), 
117.3 (2-C), 82.4 (Boc-C), 52.4 (ester CH3), 28.0 (Boc-CH3). νmax/cm-1 (ATR) 
3226, 1690, 1606, 1520, 1436, 1146. m/z (ESI) (100%, M-H); (Found M-H, 
329.0806. C13H18N2O6S requires M-H, 329.0813). 
Synthesis of methyl 4-(sulfamoylamino)benzoate (86) 
To a RBF charged with methyl 4-[({[(tert- 
butoxy)carbonyl]amino}sulfonyl)amino]  
benzoate 90 (0.500 g, 1.51 mmol) was added 4M 
HCl in dioxane (5 mL) at RT. The resultant 
solution was then stirred at RT for 2 hours. The solvent was then removed 
to give a crude solid, which was triturated with DCM to afford the title 
compound as a colourless solid (0.366 g, 95%). Rf 0.29 (2% MeOH-DCM). 
m.p 134-136 ºC. δH (500 MHz, DMSO) 10.14 (s, 1H, sulfamide NH), 7.89-
7.87 (m 2H, 3-H), 7.36 (bs, 2H, sulfamide NH2), 7.24-7.22 (m, 2H, 2-H), 3.82 
(s, 3H, OCH3) δC (500 MHz, DMSO), 166.4 (C=O), 142.7 (1-C), 130.8 (3-C), 
124.4 (4-C), 116.7 (2-C), 52.3 (CH3). νmax/cm-1 (ATR) 3256, 1697, 1607, 
1437, 1290, 1146. m/z (ESI) (100%, M-H); (Found M-H, 229.0284. 
C8H10N2O4S requires M-H, 229.0289).  
Synthesis of Methyl 4-[({[(tert-butoxy)carbonyl]amino}sulfonyl)amino]-
2-methoxybenzoate  
To a solution of chlorosulfonyl isocyanate 
(0.61 mL, 7.07 mmol) in DCM (20 mL) was 
added di-tert-butyl dicarbonate (1.54 g, 7.07 
mmol) at 0 ºC. The reaction mixture was then 
stirred at 0 ºC for 15 mins, this was followed 
by the dropwise addition of a solution methyl 4-amino-2-methoxybenzoate 
(1.27 g, 7.07 mmol) and triethylamine (1.47 mL, 10.61 mmol) in DCM (20 
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mL) at 0 ºC. The reaction mixture was then warmed to RT and stirred at that 
temperature for 2 hours. The reaction mixture was then diluted with DCM (20 
mL) and washed with 0.1 M HCl (20 mL), water (20 mL) and brine (20 mL). 
The organic layer was dried over MgSO4, filtered and the solvent removed 
to give the title compound as an off-white solid (2.27 g, 89%). Rf 0.63 (2% 
MeOH-DCM) δH (500 MHz, DMSO) 11.35 (s, 1H, sulfamide NH), 10.56 (s, 
1H, sulfamide NH), 7.47 (app d, 1H, J = 8.5 Hz, 5-H), 6.71-6.70 (m, 1H, 2-
H), 6.60-6.58 (m, 1H, 4-H). 3.59 (s, 3H, ester CH3), 3.53 (s, 3H, OMe), 1.13 
(s, 9H, Boc CH3) δC (500 MHz, DMSO) 165.9 (C=O), 160.0 (1-C), 150.4 
(C=O), 143.3 (3-C), 132.2 (5-C), 114.5 (6-C), 110.0 (4-C), 102.4 (2-C), 82.3 
(Boc C), 56.2 (OMe), 55.6 (ester CH3), 27.8 (Boc CH3) νmax/cm-1 (ATR) 3268, 
3086, 1702, 1609, 1330, 1140 m/z (ESI): (Found M-H, 359.0919 
C14H20N2O7S requires M-H, 359.0913). 
Synthesis of methyl 2‐methoxy‐4‐(sulfamoylamino)benzoate (94) 
To a RBF charged with Methyl 4-
[({[(tertbutoxy)carbonyl]amino}sulfonyl)amino]-2-
methoxy benzoate (0.500 g, 1.38 mmol) was 
added 4M HCl in dioxane (5 mL) at RT. The 
reaction mixture was then stirred at RT for 2 hours. The resultant ppt was 
collected by vacuum filtration and the solid was washed with water (5 mL) 
and DCM (5 mL) to afford the title compound as a colourless solid (0.327 g, 
91%). Rf 0.41 (2% MeOH-DCM). δH (500 MHz, DMSO) 9.91 (s, 1H, 
sulfamide NH), 7.55 (app d, 1H, J = 8.5 Hz, 5-H), 7.27 (bs, 2H, sulfamide 
NH2), 6.78 (app d, 1H, J = 1.9 Hz, 2-H), 6.66 (dd, 1H, J = 8.5 Hz and 1.9 Hz, 
4-H). 3.70 (s, 3H, ester CH3), 3.64 (s, 3H, OMe). δC (500 MHz, DMSO) 165.9 
(C=O), 160.0 (1-C), 145.3 (3-C), 132.8 (5-C), 112.5 (6-C), 108.9 (4-C), 101.1 
(2-C), 56.1 (OMe), 51.9 (ester CH3). νmax/cm-1 (ATR) 3346, 3239. 1676, 






Synthesis of methyl 2-methoxy-4-[(phenylsulfamoyl)amino]benzoate 
(99) 
To a round-bottom flask charged with  
methyl 2-methoxy-4-(sulfamoylamino) 
benzoate 94 (0.260 g, 1.00 mmol), Cs2CO3 
(0.456 g, 1.4 mmol), XPhos (0.036 g, 0.075 
mmol) and Pd2(dba)3 (0.029 g, 0.05 mmol) was added dioxane (5 mL) and 
bromobenzene (0.105 mL, 1.00 mmol). The reaction mixture was then 
refluxed for 12 hours. The reaction mixture was then cooled and the solvent 
removed to give a crude solid. The crude solid was then purified by reverse 
phase ACC (gradient 0-40% MeCN-H2O in 0.1 % formic acid) to give the title 
compound as a colourless solid (0.265 g, 79%). Rf 0.51 (2% MeOH-DCM)  
δH (500 MHz, DMSO) 10.64 (s, 1H, sulfamide NH), 10.48 (s, 1H, sulfamide 
NH), 7.60 (app d, 1H, J = 8.5 Hz, 5-H), 7.28-7.25 (m, 2H, 3’-H), 7.13-7.11 
(m, 2H, 2’-H), 7.03-7.00 (m, 1H, 4’-H), 6.82 (app d, 1H, J = 1.9 Hz, 2-H), 6.73 
(dd, 1H, J = 8.5 and 1.9 Hz, 4-H), 3.77 (s, 3H, ester CH3), 3.72 (s, 3H, OMe) 
(500 MHz, DMSO) 165.8 (C=O), 160.2 (1-C), 143.9 (3-C), 138.2 (1’-C), 132.8 
(5-C), 129.9 (3’-C), 123.7 (4’-C), 119.2 (2’-C), 113.5 (6-C), 109.2 (4-C), 101.6 
(2-C), 55.2 (OMe), 52.1 (ester CH3) νmax/cm-1 (ATR) 3276, 3167, 1699, 1331, 
1153 m/z (ESI): (Found M-H, 335.0706 C15H16N2O5S requires M-H, 
335.0706). 
Synthesis of 2-methoxy-4-[(phenylsulfamoyl)amino]benzoic acid (104) 
To a stirred solution of 2-methoxy-4-
[(phenylsulfamoyl)amino]benzoic acid 99 
(0.150 g, 0.45 mmol) in MeOH (2 mL) and 
H2O (2 mL) was added LiOH·H2O (0.076 g, 
1.80 mmol) at RT. The resultant reaction 
mixture was then stirred at reflux for 12 hours. The reaction mixture was then 
cooled to RT, concentrated in vacuuo and acidified with 2M HCl. The 
resultant precipitate was then collected by vacuum filtration and the solid was 
washed with H2O (5 mL) and DCM (5 mL) to afford the title compound as a 
colourless solid (0.101 g, 70%). Rf 0.25 (2% MeOH-DCM). m.p >250 ºC. δH 
(500 MHz, DMSO)10.60 (s, 1H, sulfamide NH), 10.47 (s, 1H, sulfamide NH), 
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7.61 (app d, 1H, J = 8.6 Hz, 5-H), 7.28-7.25 (m, 2H, 3’-H), 7.13-7.11 (m, 2H, 
2’-H), 7.03-7.00 (m, 1H, 4’-H), 6.82 (app d, 1H, J = 2.0 Hz, 2-H), 6.73 (dd, 
1H, J = 2.0 and 8.6 Hz, 4-H), 3.76 (s, 3H, OMe) δC (500 MHz, DMSO) 166.8 
(C=O), 160.2 (1-C), 143.5 (3-C), 138.2 (1’-C), 132.9 (5-C), 129.5 (3’-C), 
123.7 (4’-C), 119.1 (2’-C), 114.6 (6-C), 109.2 (4-C), 101.6 (2-C), 56.2 (OMe) 
νmax/cm-1 (ATR) 3208, 1707, 1605, 1345, 1143 m/z (ESI): (Found M-H, 
321.0548 C14H14N2O5S requires M-H, 321.0551) HPLC (RT: 2.03 min(100 % 
relative area)). 
Synthesis of methyl 4-{[(4-nitrophenyl)sulfamoyl]amino}benzoate (100) 
To a round-bottom flask charged with 
methyl 4-(sulfamoylamino) benzoate 
86 (0.230 g, 1.00 mmol), Cs2CO3 
(0.456 g, 1.4 mmol), XPhos (0.036 g, 
0.075 mmol), 1-bromo-4-
nitrobenzene (0.202 g, 1.00 mmol)  and Pd2(dba)3 (0.029 g, 0.05 mmol) was 
added dioxane (5 mL). The reaction mixture was then refluxed for 12 hours 
A further amount of 1-bromo-4-nitrobenzene (0.101 g, 0.50 mmol) and 
Pd2(dba)3 (0.029 g, 0.05 mmol) was then added and the reaction mixture 
was refluxed for a further 5 hours. The reaction mixture was then cooled to 
RT and the solvent removed to give a crude solid. The crude solid was then 
purified by reverse phase ACC (gradient 0-40% MeCN-H2O in 0.1 % formic 
acid) to afford the title compound as a colourless solid (0.228 g, 65%). Rf 
0.31 (2% MeOH-DCM).  δH (500 MHz, DMSO) 11.47 (s, 1H, sulfamide NH), 
11.27 (s, 1H, sulfamide NH), 8.26-8.22 (m, 2H, 2’-H), 7.93-7.89 (m, 2H, 3-
H), 7.38-7.34 (m, 2H, 3’-H) 7.29-7.26 (m, 2H, 2-H), 3.85 (s, 3H, CH3) δC (500 
MHz, DMSO) 166.2 (C=O), 144.6 (4’-C), 142.7 (1-C), 142.4 (1’-C), 131.1 (3-
C), 125.8 (3’-C), 125.7 (4-C), 117.5 (2-C), 111.3 (2’-C), 52.4 (CH3) νmax/cm-1 
(ATR); 3126, 1699, 1609, 1439, 1289, 1144 m/z (EI): (Found M-H, 350.0450 






Synthesis of 4-{[(4-nitrophenyl)sulfamoyl]amino}benzoic acid (105) 
To a stirred solution of methyl 4-{[(4-
nitrophenyl)sulfamoyl]amino}benzoate 
100 (0.200 g, 0.57 mmol) in MeOH (2 
mL) and H2O (2 mL) was added 
LiOH·H2O (0.096 g, 2.28 mmol) at RT. 
The resultant reaction mixture was then stirred at RT for 12 hours. The 
reaction mixture was then concentrated and acidified with 2M HCl. The 
resultant precipitate was then collected by vacuum filtration and washed with 
H2O (5 mL) to afford the title compound as a colourless solid (0.125 g, 65%). 
Rf 0.16 (10% MeOH-DCM). m.p 234-238 ºC δH (500 MHz, DMSO) 11.38 (s, 
1H, sulfamide NH), 11.15 (s, 1H, sulfamide NH), 8.20-8.17 (m, 2H, 2’-H), 
7.88-7.83 (m, 2H, 3-H), 7.37-7.29 (m, 2H, 3’-H), 7.21-7.19 (m, 2H, 2-H). δC 
(500 MHz, DMSO) 167.3 (C=O), 144.6 (4’-C), 142.5 (1-C), 142.0 (1’-C), 
131.0 (3-C), 125.8 (3’-C), 125.2 (4-C), 117.5 (2-C), 117.2 (2’-C). νmax/cm-1 
(ATR); 3157, 1685, 1607, 1522, 1346, 1153 m/z (ESI): (Found M-H, 
336.0304 C13H11N3O6S requires M-H, 336.0296) HPLC (RT: 2.25 min(100 % 
relative area)). 
Synthesis of methyl 4-({[4-(methoxycarbonyl) phenyl] sulfamoyl} 
amino) benzoate (101) 
To a round-bottom flask charged 
with methyl 4-(sulfamoylamino) 
benzoate 86 (0.230 g, 1.00 mmol), 
Cs2CO3 (0.456 g, 1.4 mmol), XPhos 
(0.036 g, 0.075 mmol), methyl 4-
bromobenzoate (0.215 g, 1.00 mmol)  and Pd2(dba)3 (0.029 g, 0.05 mmol) 
was added dioxane (5 mL). The reaction mixture was then refluxed for 4 
hours. The reaction mixture was then cooled to RT and the solvent removed 
to give a crude solid. The crude solid was then purified by reverse phase 
ACC (gradient 0-40% MeCN-H2O in 0.1 % formic acid) to afford the title 
compound as a colourless solid (0.277 g, 76%). Rf 0.46 (2% MeOH-DCM). 
δH (500 MHz, DMSO) 11.08 (s, 2H, sulfamide NH), 7.85 (app d, 4H, J = 8.8 
Hz, 3-H), 7.23 (app d, 4H, J = 8.8 Hz, 2-H), 3.78 (s, 6H, 2 x OMe) δC (500 
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MHz, DMSO) 166.2 (C=O), 142.8 (1-C), 131.1 (3-C), 124.0 (4-C), 117.3 (2-
C), 52.4 (OMe). vmax / cm-1 (solid): 3292, 1605, 1679, 1294, 1115.  m/z 
(ESI): (Found M-H, 363.0670 C16H16N2O6S requires M-H, 363.0656). 
Synthesis of 4-{[(4-carboxyphenyl)sulfamoyl]amino}benzoic acid (106) 
To a stirred solution of methyl 4-({[4-
(methoxycarbonyl) phenyl] sulfamoyl} 
amino) benzoate 101 (0.250 g, 0.69 
mmol) in MeOH (2 mL) and H2O (2 
mL) was added LiOH·H2O (0.116 g, 
2.76 mmol) at RT. The resultant 
reaction mixture was then stirred at reflux for 12 hours. The reaction mixture 
was then cooled to RT, concentrated and acidified with 2M HCl. The resultant 
precipitate was then collected by vacuum filtration and washed with H2O (5 
mL) and DCM (5 mL) to give the title compound as a colourless solid (0.223 
g, 96%). m.p >250 ºC. δH (500 MHz, DMSO) 10.95 (s, 2H, 2 x sulfamide NH), 
7.83 (app d, 4H, J = 8.9 Hz, 3-H), 7.20 (app d, 4H, J = 8.9 Hz, 2-H) δC (500 
MHz, DMSO) 167.3 (C=O), 142.4 (1-C), 131.2 (3-C), 125.2 (4-C), 117.2 (2-
C). vmax / cm-1 (solid): 3210, 2948, 1688, 1606, 1291, 1151 m/z (ESI): 
(Found M-H, 335.0345 C14H12N2O6S requires M-H, 335.0343). HPLC (RT: 
1.79 min(100 % relative area)). 
Synthesis of methyl 4‐{[(3‐nitrophenyl)sulfamoyl]amino}benzoate 102 
To a round-bottom flask charged with 
methyl 4-(sulfamoylamino)benzoate 86 
(0.230 g, 1.00 mmol), Cs2CO3 (0.456 g, 1.4 
mmol), XPhos (0.036 g, 0.075 mmol), 1-
bromo-3-nitrobenzene (0.202 g, 1.00 
mmol) and Pd2(dba)3 (0.029 g, 0.05 mmol) 
was added dioxane (5 mL). The reaction mixture was then refluxed for 12 
hours. A further amount of 1-bromo-3-nitrobenzene (0.101 g, 0.50 mmol) and 
Pd2(dba)3 (0.029 g, 0.05 mmol)  was then added and the reaction mixture 
was refluxed for a further 6 hours. The reaction mixture was then cooled to 
RT. The reaction mixture was then filtered through a pad of Celite and the 
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solvent was then removed to give a crude solid. The crude solid was then 
purified by reverse phase ACC (gradient 0-40% MeCN-H2O in 0.1 % formic 
acid) to afford the title compound as a colourless solid (0.242 g, 69%). Rf 
0.32 (2% MeOH-DCM). δH (500 MHz, DMSO) 11.18 (bs, 1H, sulfamide N-
H), 11.13 (bs, 1H, sulfamide N-H), 7.98-7.97 (m, 1H, 2’-H), 7.87-7.85 (m, 3H, 
3-H and 6’-H), 7.56 (app t, 1H, J = 8.1 Hz, 5’-H), 7.52-7.50 (m, 1H, 4’-H), 
7.23 (app d, 2H, J = 8.9 Hz, 2-H), 3.80 (s, 3H, OCH3). δC (500 MHz, DMSO), 
166.2 (C=0), 148.7 (3’-C), 142.7 (1-C), 140.0 (1’-C), 131.1 (5’-C), 131.0 (3-
C) 124.5 (6’-C), 124.1 (C-4), 118.1 (4’-C), 117.4 (2-C), 112.6 (2’-C), 54.1 
(OCH3). νmax/cm-1 (ATR); 3224, 1703, 1610, 1510, 1144. m/z (EI): (Found M-
H, 350.0459 C14H13N3O6S requires M-H, 350.0452). 
Synthesis of 4‐{[(3‐nitrophenyl)sulfamoyl]amino}benzoic acid 107 
To a stirred solution of methyl 4‐{[(3‐
nitrophenyl)sulfamoyl]amino}benzoate 102 
(0.120 g, 0.34 mmol) in MeOH (2 mL) and 
H2O (2 mL) was added LiOH·H2O (0.058 g, 
1.36 mmol) at RT. The resultant reaction 
mixture was then stirred at RT for 12 hours. A further amount of LiOH·H2O 
(0.042 g, 1.00 mmol) was then added and the reaction mixture was stirred at 
RT for a further 3 hours.  The reaction mixture was then concentrated in 
vacuuo and acidified with 2M HCl. The resultant precipitate was then 
collected by vacuum filtration and washed with H2O (5 mL) and DCM (5 mL) 
to afford the title compound as a colourless solid (0.103 g, 90%). Rf 0.14 
(10% MeOH-DCM). m.p >250 ºC. δH (500 MHz, DMSO) 11.11 (s, 1H, 
sulfamide N-H), 11.05 (s, 1H, sulfamide NH), 7.98-7.97 (m, 1H, 2’-H), 7.87-
7.83 (m, 3H, 3-H and 6’-H), 7.57 (app t, 1H, J = 8.2 Hz, 5’-H), 7.51-7.49 (m, 
1H, 4’-H), 7.20 (app d, 2H, J = 8.9 Hz, 2-H) δC (500 MHz, DMSO) 167.2 
(C=O), 148.7 (3’-C), 142.3 (1-C), 139.6 (1’-C), 131.2 (5’-C), 131.1 (3-C), 
125.4 (6’-C), 124.4 (4-C), 118.0 (4’-C), 117.9 (2-C), 112.0 (2’-C) νmax/cm-1 
(ATR); 3157, 1685, 1607, 1522, 1346, 1102 m/z (ESI): (Found M-H, 





Synthesis of methyl 4‐{[(3‐aminophenyl)sulfamoyl]amino}benzoate 
(103) 
To a solution of 4‐{[(3‐
nitrophenyl)sulfamoyl]amino}benzoate 102 
(0.176 g, 0.5 mmol) in MeOH (20 mL) was 
added 10% Pd/C (0.125 g). The resultant 
slurry was then stirred at RT under an 
atmosphere of hydrogen (1 atmosphere) for 2 hours. The reaction mixture 
was then filtered through a bed of Celite and the solvent was then removed 
to give a crude purple solid. The crude solid was then purified by reverse 
phase ACC (gradient 0-40% MeCN-H2O in 0.1 % formic acid) to give the title 
compound as a colourless solid (0.135 g, 84%). Rf 0.41 (2% MeOH-DCM) 
δH (500 MHz, DMSO) 7.84 (app d, 2H, J = 8.7 Hz, 3-H), 7.23 (app d, 2H, J = 
8.7 Hz, 2-H), 6.85 (app t, 1H, J = 7.9 Hz, 5’-H), 6.32-6.29 (m, 2H, 2’-H and 
6’-H), 6.22 (app d, 1H, J = 7.9 Hz, 4’-H), 5.04 (bs, 2H, NH2), 3.80 (s, 3H, CH3) 
δC (500 MHz, DMSO) 166.7 (C=O), 149.7 (3’-C), 143.7 (1-C), 138.7 (1’-C), 
130.8 (3-C), 129.7 (5’-C), 123.2 (4-C), 116.9 (2-C), 110.1 (4’-C), 107.2 (6’-
C), 105.3 (2’-C), 52.3 (CH3). νmax/cm-1 (ATR); 3229, 1693, 1606, 1489, 1283, 
1145 m/z (ESI): (Found M-H, 320.0715 C14H15N3O4S requires 320.0709) 
Synthesis of 4‐{[(3‐aminophenyl)sulfamoyl]amino}benzoic acid (108) 
To a stirred solution of methyl 4‐{[(3‐
aminophenyl)sulfamoyl]amino}benzoate 
103 (0.100 g, 0.31 mmol) in MeOH (2 mL) 
and H2O (2 mL) was added LiOH·H2O 
(0.052 g, 1.24 mmol) at RT. The resultant 
reaction mixture was then stirred at reflux for 12 hours. The reaction mixture 
was then cooled to RT and the resultant solution was concentrated and 
acidified with 2M HCl. The resultant precipitate was then collected by 
vacuum filtration and washed with H2O (5 mL) and DCM (5 mL) to afford the 
title compound as a colourless solid (0.080 g, 84%). 0.22 (10% MeOH-DCM). 
m.p >250 ºC. δH (400 MHz, DMSO) 7.80 (app d, 2H, J = 8.7 Hz, 3-H), 7.18 
(app d, 2H, J = 8.7 Hz, 2-H), 6.85 (app t, 1H, J = 7.8 Hz, 5’-H), 6.36-6.32 (m, 
2H, 2’-H and 6’-H), 6.21 (app d, 1H, J = 7.8 Hz, 4’-H) δC (400 MHz, DMSO) 
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168.5 (C=O), 149.7 (3’-C), 142.3 (1-C), 139.0 (1’-C), 130.7 (3-C), 129.6 (5’-
C), 128.0 (4-C) 117.0 (2-C), 109.8 (4’-C), 107.2 (6’-C), 105.2 (2’-C) νmax/cm-
1 (ATR); 3267, 3086, 1702, 1610, 1584, 1241, 1144 m/z (ESI): (Found M-H, 
306.0558 C13H11N3O4S requires M-H, 306.0549) HPLC (RT: 1.10 min(100 % 
relative area)). 
Synthesis of Methyl 4-({[4-({[(tert-butoxy)carbonyl]amino}methyl) 
phenyl]sulfamoyl}amino)benzoate (114) 
A round-bottom flask was charged 
with methyl 4-(sulfamoylamino) 
benzoate 86 (0.230 g, 1.00 mmol), 
Cs2CO3 (0.456 g, 1.4 mmol), 
XPhos (0.036 g, 0.075 mmol), tert-butyl 4-bromobenzylcarbamate (0.286 g, 
1.00 mmol)  and Pd2(dba)3 (0.029 g, 0.05 mmol) was added dioxane (5 mL). 
The reaction mixture was then refluxed for 6 hours. An additional amount of 
tert-butyl 4-bromobenzylcarbamate (0.143 g, 0.50 mmol) and Pd2(dba)3 
(0.029 g, 0.05 mmol) was then added and the reaction mixture was refluxed 
for an additional 12 hours. This was again followed by a further addition of 
tert-butyl 4-bromobenzylcarbamate (0.143 g, 0.50 mmol) and Pd2(dba)3 
(0.029 g, 0.05 mmol) and the reaction mixture was refluxed for an additional 
6 hours.  The reaction mixture was then cooled to RT and the solvent 
removed to give a crude solid. The crude solid was then purified by 
reversephase ACC (gradient 0-40% MeCN-H2O in 0.1 % formic acid) to 
afford the title compound as a colourless solid (0.265 g, 61%). Rf 0.28 (2% 
MeOH-DCM) .δH (500 MHz, DMSO) 10.71 (s, 1H, sulfamide N-H), 10.40 (s, 
1H, sulfamide N-H), 7.85 (app d, 2H, J = 8.7 Hz, 3-H), 7.30 (t, 1H, J = 6.1 
Hz, Boc N-H), 7.24 (app d, 2H, J = 8.4 Hz, 3’-H), 7.10 (app d, 2H, J = 8.7 Hz, 
2-H), 7.04 (app d, 2H, J = 8.4 Hz, 2’-H), 4.02 (d, 2H, J = 6.1 Hz, CH2), 3.80 
(s, 3H, OCH3), 1.37 (s, 9H, Boc-CH3) δC (500 MHz, DMSO) 166.2 (C=O), 
156.2 (C=O), 143.2 (1-C), 136.6 (1’-C), 135.7 (3-C), 130.9 (3’-C), 128.2 (4’-
C), 123.6 (4-C), 119.4 (2’-C), 117.0 (2-C), 78.2 (Boc-C), 52.3 (OCH3), 43.3 
(CH2), 28.7 (Boc-CH3)    νmax/cm-1 (ATR); 3258, 1682, 1636, 1607, 1421, 




Synthesis of (4‐{[(4‐carboxyphenyl)sulfamoyl]amino}phenyl)  
methanaminium chloride (112) 
To a solution of Methyl 4 -({[4-
({[(tert-butoxy)carbonyl]amino} 
methyl)phenyl]sulfamoyl}amino) 
benzoate 114 (0.100 g, 0.23 
mmol) in MeOH (10 mL) was added conc. HCl (4 mL) and the resultant 
mixture was refluxed for 12 hours. The reaction mixture was then cooled to 
RT and the solvent was then removed to give a crude colourless solid. The 
crude solid was purified by reverse phase ACC (gradient 0-30% MeCN-H2O 
in 0.1 % formic acid) to give the title compound as a colourless solid (0.061 
g, 75%). Rf 0.09 (10% Methanolic ammonia-DCM) m.p >250 ºC. δH (500 
MHz, DMSO) 10.84 (bs, 1H, sulfamide NH), 10.65 (bs, 1H, sulfamide NH), 
8.33 (bs, 3H, NH3+), 7.83 (app d, 2H, J = 8.7 Hz, 3-H), 7.38 (app d, 2H, J = 
8.4 Hz, 3’-H), 7.23 (app d, 2H, J = 8.7 Hz, 2-H), 7.16 (app d, 2H, J = 8.4 Hz, 
2’-H), 3.89 (s, 2H, CH2) δC (500 MHz, DMSO) 167.3 (C=O), 142.7 (1-C), 
138.4 (1’-C), 131.0 (3-C), 130.3 (3’-C), 128.9 (4’-C), 124.9 (4-C), 118.3 (2’-
C), 116.9 (2-C), 68.8 (CH2) νmax/cm-1 (ATR); 3242, 1694, 1606,1430, 1287, 
1114. m/z (ESI): (Found M-H, 320.0715 C14H15N3O4S requires M-H, 
320.0705) HPLC (RT: 1.12 min(100 % relative area)). 
6.3.4 Synthesis of Heterocylic Fragments 
Synthesis of methyl 5-phenylthiophene-2-carboxylate (129) [91] 
To a RBF charged with methyl 5-bromo-2-
thiophenecarboxylate (0.200 g, 0.90 mmol), 
phenylboronic acid (0.122 g, 1.00 mmol) and Pd(PPh3)4 
(0.070 g, 0.045 mmol) was added DMF (10 mL) and 2M 
Na2CO3 (1.35 mL, 2.70 mmol). The reaction mixture was then stirred at 80 
ºC for 18 hrs. The reaction mixture was then cooled to RT and diluted with 
EtOAc (30mL). The resultant solutions was then washed with; water (2 x 30 
mL), sat. Na2HCO3 (2 x 30 mL) and brine (30 mL). The organic layer was 
then dried over MgSO4, filtered and the solvent removed to give a crude 
orange solid. The crude solid was then purified column chromatography 
(Eluent; DCM/Petrol 25:75) to give the tile compound as a colourless 
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crystaline solid (0.070 g, 35%). Experimental data matched that reported in 
[91]. m.p: 97-98°C. Rf 0.95 (20% EtOAc-Petrol).  δH (500 MHz, DMSO) 7.82 
(d, 1H, J = 4.0 Hz, 3-H), 7.78-7.75 (m, 2H, 2’-H), 7.63 (d, 1H, J = 4.0 Hz, 4-
H), 7.49-7.47 (m, 2H, 3’-H), 7.43-7.40 (m, 1H, 4’-H), 3.85 (s, 3H, OCH3) δC 
(500 MHz, DMSO) 162.2 (C=O), 150.8 (5-C), 135,4 (3-C), 133.0 (1’-C), 131.7 
(2-C), 129.8 (3’-C), 129.6 (4’-C), 126.4 (2’-C), 125.2 (4-C), 52.8 (CH3) vmax 
/ cm-1 (solid): 2931, 1707, 1551, 1431, 1258, 1224. m/z (ESI) (100%, M+H); 
(Found M+H, 219.0472. C12H10O2S requires M+H, 219.0479).  
Synthesis of 5-phenylthiophene-2-carboxylic acid (122) [92] 
To a solution of methyl 5-phenylthiophene-2-
carboxylate 129 (0.050 g, 0.23 mmol) in MeOH (5 mL) 
and H2O (1 mL) was added LiOH·H2O (0.038 g, 0.92 
mmol). The reaction mixture was then stirred at RT for 
18 hrs. The reaction mixture was then concentrated and acidified with 2M 
HCl and the resultant ppt was collected by vacuum filtration to afford the title 
compound as a colourless solid (0.015 g, 32%). Rf 0.55 (5% MeOH-DCM). 
δH (500 MHz, DMSO) 7.75-7.72 (m, 3H, 3-H and 2’-H), 7.58 (d, 1H, J = 3.8 
Hz, 4-H), 7.46 (app t, 2H, J = 7.5 Hz, 3’-H), 7.40 (app t, 1H, J = 7.5 Hz, 4’-
H), δC (500 MHz, DMSO) 163.3 (C=O), 150.2 (5-C), 134.7 (3-C), 133.9 (1’-
C), 133.3 (2-C), 129.8 (3’-C), 129.6 (4’-C), 126.1 (2’-C), 125.2 (4-C) vmax / 
cm-1 (solid): 2914, 2552, 1647, 1517, 1448, 1293. m/z (ESI) (100%, M+H); 
(Found M+H, 205.0317. C11H8O2S requires M+H, 205.0323). HPLC (RT: 
2.81 min(100 % relative area)). 
Synthesis of ethyl 5-phenyl-1,3-thiazole-2-carboxylate (134) [82] 
To a stirred solution of 2-aminoacetophenone 
hydrochloride (1.00 g, 5.83 mmol) in DCM (20 mL) was 
added triethylamine (2.40 g, 17.49 mmol) and  ethyl 
oxalyl chloride (0.65 mL, 5.83 mmol) at 0°C. The 
reaction mixture was then warmed to RT and stirred 
for 18 hours. The reaction mixture was then quenched with water (45 mL) 
and the resultant solution was extracted with ethyl acetate (2 x 15 mL). The 
combined organic layers were then washed with water (3 x 30 mL) and brine 
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(30 mL). The organic layer was dried over MgSO4, filtered and the solvent 
removed to give a crude orange residue. The crude residue was dissolved 
in chloroform (6 mL) and phosphorus decasulfide (0.95 g, 4.16 mmol) was 
added. The reaction mixture was then heated at reflux for 18 hours. A further 
amount of phosphorus decasulfide (0.475 g, 2.08 mmol) was then added and 
the reaction mixture was refluxed for a further 3 hours. The reaction mixture 
was then cooled to RT and quenched with water (20 mL). The resultant 
solution was then extracted with chloroform (2 x 10 mL). The organic layers 
were then combined and washed with water (20 mL) and brine (20 mL). The 
organic layer was then dried over MgSO4, filtered and the solvent removed 
to give a crude orange residue. The crude residue was purified using column 
chromatography (15% EtOAC-Petrol) to give the title compound as a 
crystalline yellow solid (0.489 g, 36%). Rf 0.87 (15% EtOAc-Petrol). m.p: 
49.8-51.8°C δH (400 MHz, DMSO), 8.52 (s, 1H, 4-H), 7.81 (d, 2H, J = 7.0 Hz, 
2’-H), 7.51-7.43 (m, 3H, 3’-H and 4’-H), 4.40 (q, 2H, J = 7.1 Hz, O CH2), 1.34 
(t, 3H, J = 7.1 Hz, CH3) δC (400 MHz, DMSO), 159.8 (2-C), 156.1 (C=O), 
145.42 (4-C), 141.58 (1’-C), 130.2 (5-C), 130.1 (4’-C), 130.0 (3’-C), 127.5 
(2’-C), 62.7 (OCH2), 14.54 (CH3) vmax / cm-1 (solid): 3077, 2981, 1700, 1412, 
1291 m/z (ESI):(molecular ion not observed)  
Synthesis of 5-phenyl-1,3-thiazole-2-carboxylic acid (123) [82] 
To a stirred solution of Ethyl 5-phenyl-1,3-thiazole-2-
carboxylate 134 (0.170 g, 0.73 mmol) in methanol (5 mL) 
and water (2 mL) was added lithium hydroxide (0.120 g, 
2.92 mmol)). The reaction mixture was stirred at room 
temperature for 18 hours. A further amount of LiOH (0.120 
g, 2.92 mmol) was then added and the reaction mixture was heated to reflux 
and stirred at temperature for two hours. The reaction mixture was then 
cooled to RT and concentrated in vacuuo. The resultant residue was 
dissolved in water (3 mL) and 2M HCl was added dropwise. The resultant 
ppt was then collected by vacuum filtration and washed with water (5 mL) 
and DCM (5 mL) to give the title compound as a yellow solid. Rf 0.48 (2% 
MeOH-DCM) δH (400 MHz, DMSO), 8.44 (s, 1H, 4-H), 7.79 (d, 2H, J = 1.4 
Hz, 2’-H), 7.51-7.43 (m, 3H, 3’-H and 4’-H) δC (400 MHz, DMSO), 161.4 (2-
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C), 154.1 (C=O), 141.1 (4-C), 139.9 (1’-C), 130.6 (5-C), 129.9 (3’-C), 129.8 
(4’-C), 127.4 (2’-C) vmax / cm-1 (solid): 2379, 1707, 1629, 1362, 1259 1224. 
m/z (ESI) (100%, M+H); (Found M+H, 206.0267. C10H7NO2S requires M+H, 
206.0275). HPLC (RT: 2.40 min (100 % relative area)). 
Synthesis of methyl 2-phenyl-1,3-thiazole-5-carboxylate (130) [93] 
To a stirred suspension of methyl 2-bromothiazole-5-
carboxylate (0.500 g, 2.3 mmol), phenylboronic acid (410 
mg, 3.4 mmol) and Pd(PPh3)4 (260 mg, 0.23 mmol) in 
DMF (10 mL) was added an aqueous 2M solution of 
Na2CO3 (4.7 mL, 9.5 mmol) and the reaction mixture was 
stirred at 85 °C for 18 h. The reaction mixture was then cooled to RT and 
diluted with EtOAc (20 mL). The resultant solution was them filtered through 
Celite and washed with; H2O (20 mL) 1M NaOH (20 mL) and brine (20 mL). 
The organic layer was then dried over MgSO4, filtered and concentrated to 
give a crude black residue. The crude product was purified using column 
chromatography (eluent; 10% EtOAc in Petroleum ether) to afford the title 
compound as a white solid (0.450 g, 89%). Rf 0.87 (15% EtOAc-Petrol). δH 
(500 MHz, DMSO), 8.52 (s, 1H, 4-H), 8.05-8.02 (m, 2H, 2’-H), 7.63-7.59 (m, 
3H, 3’-H and 4’-H), 3.76 (s, 3H, OCH3). δC (500 MHz, DMSO) 172.9 (C=O), 
161.6 (2-C), 149.8 (4-C), 132.9 (5-C), 132.1 (1’-C), 129.9 (3’-C), 128.8 (4’-
C), 127.2 (2’-C), 53.1 (OCH3) vmax / cm-1 (solid): 2944, 1705, 1247, 1091. 
m/z (ESI) (100%, M+H); (Found M+H, 220.0423. C11H9NO2S requires M+H, 
220.0427) HPLC (RT: 3.18 min (100 % relative area)). 
Synthesis of 2-phenyl-1,3-thiazole-5-carboxylic acid (124) [94] 
To a stirred solution of ethyl 2-phenyl-1,3-oxazole-5-
carboxylate 130 (0.100 g, 0.46 mmol) in methanol (5 
mL) and water (1 mL) was added LiOH·H2O (0.08 g, 
1.84 mmol). The reaction mixture was then refluxed for 
18 hours. The reaction mixture was then cooled to RT 
and the solution was then concentrated in vacuo. The resultant residue was 
then taken up in water (3 mL) and 2M HCl was added. The resultant ppt was 
collected by vacuum filtration and the solid was then washed with water (5 
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mL) and DCM (5 mL) to afford the title compound as a colourless solid (0.057 
g, 61%). Rf 0.39 (10% MeOH-DCM) δH (400 MHz, DMSO) 8.30 (s, 1H, 4-H), 
7.98-7.97 (m, 2H, 2’-H), 7.50-7.56 (m, 3H, 3’-H and 4’-H). δC (400 MHz, 
DMSO) 172.7 (C=O), 163.4 (2-C), 147.6 (4-C), 132.9 (5-C), 132.6 (1’-C), 
130.9 (3’-C), 128.9 (4’-C), 126.4 (2’-C). νmax / cm-1 (ATR); 3037, 2872, 1653, 
1244, 1095. m/z (ESI) (100%, M+H); (Found M+H, 206.0221. C10H7NO2S 
requires M+H, 206.0197). HPLC (RT: 2.39 min(100 % relative area)). 
Synthesis of ethyl 5-phenyl-1,3-oxazole-2-carboxylate (135) [81] 
To a stirred solution of 2-aminoacetophenone 
hydrochloride (1.00 g, 5.83 mmol) in DCM (20 mL) was 
added triethylamine (2.40 g, 17.49 mmol) and  ethyl 
oxalyl chloride (0.65 mL, 5.83 mmol) in DCM (2 mL), 
at 0°C. The reaction mixture was then warmed to RT 
and stirred for 18 hours. The reaction mixture was then quenched with water 
(45 mL). The resultant solution was then extracted with ethyl acetate (2 x 15 
mL). The combined organic layers were then washed with water (3 x 30 mL) 
and brine (30 mL). The organic layer was dried over MgSO4, filtered and the 
solvent removed to give a crude orange residue. The crude residue was 
dissolved in toluene (10 mL) and POCl3 (0.95 g, 4.16 mmol) was added. The 
reaction mixture was heated at reflux for 18 hours. An additional amount of 
POCl3 (0.95 g, 4.16 mmol) was then added and the reaction mixture was 
refluxed for an additional 18 hours. The reaction mixture was then cooled to 
0 °C and water (20 mL) was slowly added. The resultant solution was then 
warmed to RT and stirred for 30 mins. The solution was then extracted using 
EtOAc (3 x 20 mL). The organic layers were then combined, washed with 
water (20 mL) and brine (20 mL). The organic layer was then dried over 
MgSO4, filtered and the solvent removed give a crude orange oil. The crude 
product was purified using column chromatography (10% EtOAc:Petrol) to 
afford the title compound as a white solid. (0.521 g, 41%). Rf 0.92 (20% 
EtOAc-Petrol) δH (500 MHz, DMSO) 8.00 (s, 1H, 4-H), 7.83-7.80 (m, 2H, 2’-
H), 7.56-7.52 (m, 2H, 3’-H), 7.49-7.46 (m, 1H, 4’-H), 4.40 (q, 2H, J = 6.8 Hz, 
OCH3CH2), 1.35 (t, 3H, J = 6.8 Hz, OCH3CH2) δC (500 MHz, DMSO) 155.6 
(C=O), 153.7 (2-C), 151.7 (5-C), 130.3 (1’-C), 129. 8 (4’-C), 126.8 (3’-C), 
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125.3 (5-C), 125.2 (2’-C), 62.6 (OCH2), 14.5 (CH3). vmax / cm-1 (solid): 
2928,1722, 1445, 1173 m/z (ESI) (100%, M+Na); (Found M+Na, 240.0639. 
C12H11NO3 requires M+Na, 240.0631). 
Synthesis of 5-phenyl-1,3-oxazole-2-carboxylic acid (125) [81] 
To a stirred solution of ethyl 2-phenyl-1,3-oxazole-5-
carboxylate 135 (0.100 g, 0.46 mmol) in methanol (5 
mL) and water (1 mL) was added LiOH·H2O (0.08 g, 
1.84 mmol). The reaction mixture was then refluxed for 
18 hours. The reaction mixture was then cooled to RT 
and concentrated in vacuo. The resultant reside was dissolved in water (3 
mL) and 2M HCl was added dropwise. The resultant ppt was collected by 
vacuum filtration and washed with water (5 mL) and DCM (5 mL) to afford 
the title compound as a white solid (0.075 g, 86%). δH (500 MHz, DMSO) 
7.87 (s, 1H, 4-H), 7.74-7.72 (m, 2H, 2’-H), 7.46-7.43 (m, 2H, 3’-H), 7.39-7.36 
(m, 1H, 4’-H), δC (500 MHz, DMSO) 157.0 (C=O), 153.4 (2-C), 152.9 (5-C), 
130.1 (1’-C), 129. 8 (4’-C), 127.1 (3’-C), 125.2 (5-C), 125.1 (2’-C). vmax / cm-
1 (solid): 3130, 2335,1753, 1450, 1164 m/z (ESI) (100%, M-H); (Found M-H, 
188.0345. C10H7NO3 requires M-H, 188.0348). HPLC (RT: 2.63 min(100 % 
relative area)). 
Synthesis of ethyl (2Z)-3-(phenylformamido)prop-2-enoate (140) [84] 
To a stirred solution of benzamide (1.20 g, 10.00 
mmol) in toluene (50 mL) was added 
benzoquinone (1.80 g, 16.60 mmol), p-
Toluenesulfonic acid (1.00 g, 5.30 mmol) and palladium (II) acetate (0.200 
g, 0.90 mmol) at RT. The reaction mixture was then stirred for 5 minutes at 
RT before methyl acrylate (12.50 mL, 115.00 mmol) was added. The reaction 
mixture was then stirred at RT for 72 hours. The reaction mixture was then 
filtered through Celite and the filtrate was washed with water (30 mL) and 
brine (30 mL). The organic layer was dried over MgSO4, filtered and the 
solvent removed to give a crude yellow residue. The crude residue was 
purified using column chromatography (eluent 8:1 hexane: EtOAc) to afford 
the title compound as a colourless crystalline solid (0.635 g, 29%). m.p: 73-
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75 °C. Rf 0.71 (15% EtOAc-Petrol). δH (400 MHz, DMSO), 7.90 (app d, 2H, 
J = 7.8 Hz, 2’-H), 7.75-7.68 (m, 2H, 4’-H and 2-H), 7.62 (app t, 2H, J = 7.8 
Hz, 3’-H), 5.34 (d, 1H, J = 8.8 Hz, 3-H), 4.20 (q, 2H, J = 7.1 Hz, 5-H), 1.26 (t, 
3H, j = 7.1 Hz, 6-H) δC (400 MHz, DMSO), 169.3 (C=O), 164.1 (C=O), 139.3 
(2-C), 133.7 (1’-C), 132.3 (4’-C), 129.7 (3’-C), 127.8 (2’-C), 97.6 (3-C), 60.6 
(5-C), 14.6 (6-C) vmax / cm-1 (solid): 3293, 2967, 1655, 1595, 1457, 1362, 
1207 m/z (ESI) (100%, M+Na); (Found M+Na, 242.0786. C12H13NO3 
requires M+Na, 242.0793). 
Synthesis of ethyl 2-phenyl-1,3-oxazole-5-carboxylate (139) [84] 
To a stirred solution of ethyl (2Z)-3-
(phenylformamido)prop-2-enoate 140 (0.250 g, 1.25 
mmol) in TFE (15 mL) was added PIFA (0.590 g, 
1.35 mmol). The reaction mixture was stirred at room 
temperature for 18 hours. The solvent was then 
removed to give a crude residue. The crude residue was purified using 
column chromatography (10% EtOAc:Petrol) to afford the title compound as 
a crystalline colourless solid (0.210 g, 77%). m.p: 68-69°C. Rf 0.80 (10% 
EtOAc-Petrol).  δH (400 MHz, DMSO), 8.11 (s, 1H, 4-H), 8.10-8.05 (m, 2H, 
2’-H), 7.63-7.57 (m, 3H, 3’-H and 4’-H), 4.36 (q, 2H, J = 7.1 Hz, OCH2), 1.34 
(t, 3H, J = 7.1 Hz, CH3). δC (400 MHz, DMSO), 163.7 (2-C), 157.6 (C=O), 
142.4 (5-C), 136.0 (4-C), 132.4 (4’-C), 129.9 (3’-C), 127.2 (1’-C), 126.3 (2’-
C), 61.7 (OCH2), 14.6 (CH3) vmax / cm-1 (solid): 2966, 1707, 1569, 1517, 
1466, 1207, 1138. m/z (ESI) (100%, M+Na); (Found M+Na, 240.0627. 
C12H11NO3 requires M+Na, 240.0637). 
Synthesis of 2-phenyl-1,3-oxazole-5-carboxylic acid (126) [84] 
To a stirred solution of ethyl 2-phenyl-1,3-oxazole-5-
carboxylate 139 (0.100 g, 0.46 mmol) in methanol (5 
mL) was added a solution of lithium hydroxide (0.08 g, 
1.84 mmol) in water (1 mL). The reaction mixture was 
then refluxed for 18 hours. An additional amount of 
LiOH (0.080g, 1.84 mmol) was then added and the reaction mixture was 
refluxed for an additional 4 hours. The reaction mixture was then cooled to 
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RT and concentrated in vacuuo. The resultant reside was dissolved in water 
(3 mL) and 2M HCl was added. The resultant ppt was collected by vacuum 
filtration and the solid was washed with water (5 mL) and DCM (5 mL) to 
afford the title compound as a white solid (0.082 g, 93%). Rf 0.51 (10% 
MeOH-DCM) δH (400 MHz, DMSO), 8.06-8.04 (m, 2H, 2’-H), 8.02 (app s, 
1H, 4-H), 7.61-7.57 (m, 3H, 3’-H and 4’-H) δC (400 MHz, DMSO), 163.4 
(C=O), 158.9 (2-C), 143.4 (5-C), 135.5 (4-C), 132.3 (4’-C), 129.8 (3’-C), 
127.1 (1’-C), 126.5 (2’-C) vmax / cm-1 (solid): 2810, 2509, 1724, 1517, 1414, 
1293, 1138. m/z (ESI) (100%, 2M+H); (Found 2M+H, 383.0865. C10H7NO3 
requires 2M+H, 383.0865). HPLC (RT: 2.03 min(100 % relative area)). 
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Chapter 8 – Appendix;  NMR Spectra of Novel Final Compounds 
NMR Spectra of 3-{3-[7-(butylcarbamoyl)-1H-indole-1-carbonyl]phenyl} 







NMR Spectra of ({3-[7-butylcarbamoyl)-2,3-dihydro-1H-indole-1-






NMR Spectra of ({3-[(2-carbamoylphenyl)carbamoyl]phenyl} 





NMR Spectra of [(3-{[2-(methoxycarbonyl)phenyl]carbamoyl}phenyl) 





NMR Spectra of ({3-[(2-carboxyphenyl)carbamoyl]phenyl}carbamoyl) 

















NMR Spectra of {[4’-(azaniumylmethyl)-5-[(2-carboxyphenyl) 





















































NMR Spectra of (4-{[(4- carboxyphenyl)sulfamoyl]amino}phenyl) 
methaninium chloride (112) 
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